<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84315</article-id><article-id pub-id-type="doi">10.7554/eLife.84315</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>A meta-analysis of genome-wide association studies of childhood wheezing phenotypes identifies <italic>ANXA1</italic> as a susceptibility locus for persistent wheezing</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-296286"><name><surname>Granell</surname><given-names>Raquel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4890-4012</contrib-id><email>Raquel.Granell@bristol.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300365"><name><surname>Curtin</surname><given-names>John A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300366"><name><surname>Haider</surname><given-names>Sadia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300367"><name><surname>Kitaba</surname><given-names>Negusse Tadesse</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7518-9096</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300368"><name><surname>Mathie</surname><given-names>Sara A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300369"><name><surname>Gregory</surname><given-names>Lisa G</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300370"><name><surname>Yates</surname><given-names>Laura L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300371"><name><surname>Tutino</surname><given-names>Mauro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300372"><name><surname>Hankinson</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221146"><name><surname>Perretti</surname><given-names>Mauro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2068-3331</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300373"><name><surname>Vonk</surname><given-names>Judith M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300374"><name><surname>Arshad</surname><given-names>Hasan S</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300375"><name><surname>Cullinan</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300376"><name><surname>Fontanella</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300377"><name><surname>Roberts</surname><given-names>Graham C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300378"><name><surname>Koppelman</surname><given-names>Gerard H</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-107281"><name><surname>Simpson</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-300379"><name><surname>Turner</surname><given-names>Steve W</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300380"><name><surname>Murray</surname><given-names>Clare S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-166448"><name><surname>Lloyd</surname><given-names>Clare M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-241532"><name><surname>Holloway</surname><given-names>John W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9998-0464</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes" id="author-107282"><name><surname>Custovic</surname><given-names>Adnan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5218-7071</contrib-id><email>a.custovic@imperial.ac.uk</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf8"/></contrib><on-behalf-of>on behalf of UNICORN and Breathing Together investigators</on-behalf-of><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>MRC Integrative Epidemiology Unit, Department of Population Health Sciences, Bristol Medical School, University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00he80998</institution-id><institution>Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">Manchester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>National Heart and Lung Institute, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ryk1543</institution-id><institution>Human Development and Health, Faculty of Medicine, University of Southampton</institution></institution-wrap><addr-line><named-content content-type="city">Southampton</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>William Harvey Research Institute, Barts and The London School of Medicine Queen Mary University of London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012p63287</institution-id><institution>Department of Epidemiology, University of Groningen, University Medical Center Groningen\</institution></institution-wrap><addr-line><named-content content-type="city">Groningen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012p63287</institution-id><institution>University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)</institution></institution-wrap><addr-line><named-content content-type="city">Groningen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0485axj58</institution-id><institution>NIHR Southampton Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">Southampton</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03qcx4p52</institution-id><institution>David Hide Asthma and Allergy Research Centre</institution></institution-wrap><addr-line><named-content content-type="city">Isle of Wight</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ryk1543</institution-id><institution>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton</institution></institution-wrap><addr-line><named-content content-type="city">Southampton</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012p63287</institution-id><institution>Department of Pediatric Pulmonology and Pediatric Allergology, University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Groningen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016476m91</institution-id><institution>Child Health, University of Aberdeen</institution></institution-wrap><addr-line><named-content content-type="city">Aberdeen</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Agrawal</surname><given-names>Anurag</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j1xr113</institution-id><institution>Ashoka University</institution></institution-wrap><country>India</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Przeworski</surname><given-names>Molly</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj8s172</institution-id><institution>Columbia University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84315</elocation-id><history><date date-type="received" iso-8601-date="2022-10-19"><day>19</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-05-22"><day>22</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2023-03-05"><day>05</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.03.23284449"/></event></pub-history><permissions><copyright-statement>© 2023, Granell et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Granell et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84315-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84315-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Many genes associated with asthma explain only a fraction of its heritability. Most genome-wide association studies (GWASs) used a broad definition of ‘doctor-diagnosed asthma’, thereby diluting genetic signals by not considering asthma heterogeneity. The objective of our study was to identify genetic associates of childhood wheezing phenotypes.</p></sec><sec id="abs2"><title>Methods:</title><p>We conducted a novel multivariate GWAS meta-analysis of wheezing phenotypes jointly derived using unbiased analysis of data collected from birth to 18 years in 9568 individuals from five UK birth cohorts.</p></sec><sec id="abs3"><title>Results:</title><p>Forty-four independent SNPs were associated with early-onset persistent, 25 with pre-school remitting, 33 with mid-childhood remitting, and 32 with late-onset wheeze. We identified a novel locus on chr9q21.13 (close to annexin 1 [<italic>ANXA1</italic>], p&lt;6.7 × 10<sup>-9</sup>), associated exclusively with early-onset persistent wheeze. We identified rs75260654 as the most likely causative single nucleotide polymorphism (SNP) using Promoter Capture Hi-C loops, and then showed that the risk allele (T) confers a reduction in <italic>ANXA1</italic> expression. Finally, in a murine model of house dust mite (HDM)-induced allergic airway disease, we demonstrated that anxa1 protein expression increased and anxa1 mRNA was significantly induced in lung tissue following HDM exposure. Using anxa1<sup>-/-</sup> deficient mice, we showed that loss of anxa1 results in heightened airway hyperreactivity and Th2 inflammation upon allergen challenge.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Targeting this pathway in persistent disease may represent an exciting therapeutic prospect.</p></sec><sec id="abs5"><title>Funding:</title><p>UK Medical Research Council Programme Grant MR/S025340/1 and the Wellcome Trust Strategic Award (108818/15/Z) provided most of the funding for this study.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Three-quarters of children hospitalized for wheezing or asthma symptoms are preschool-aged. Some will continue to experience breathing difficulties through childhood and adulthood. Others will undergo a complete resolution of their symptoms by the time they reach elementary school. The varied trajectories of young children with wheezing suggest that it is not a single disease. There are likely different genetic or environmental causes.</p><p>Despite these differences, wheezing treatments for young children are ‘one size fits all.’ Studying the genetic underpinnings of wheezing may lead to more customized treatment options.</p><p>Granell et al. studied the genetic architecture of different patterns of wheezing from infancy to adolescence. To do so, they used machine learning technology to analyze the genomes of 9,568 individuals, who participated in five studies in the United Kingdom from birth to age 18. The experiments found a new genetic variation in the ANXA1 gene linked with persistent wheezing starting in early childhood. By comparing mice with and without this gene, Granell et al. showed that the protein encoded by ANXA1 controls inflammation in the lungs in response to allergens. Animals lacking the protein develop worse lung inflammation after exposure to dust mite allergens.</p><p>Identifying a new gene linked to a specific subtype of wheezing might help scientists develop better strategies to diagnose, treat, and prevent asthma. More studies are needed on the role of the protein encoded by ANXA1 in reducing allergen-triggered lung inflammation to determine if this protein or therapies that boost its production may offer relief for chronic lung inflammation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GWAS</kwd><kwd>ALSPAC</kwd><kwd>wheezing phenotypes</kwd><kwd>meta-analysis</kwd><kwd>MAAS</kwd><kwd>ANXA1</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>UK Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/S025340/1</award-id><principal-award-recipient><name><surname>Granell</surname><given-names>Raquel</given-names></name><name><surname>Custovic</surname><given-names>Adnan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>108818/15/Z</award-id><principal-award-recipient><name><surname>Granell</surname><given-names>Raquel</given-names></name><name><surname>Custovic</surname><given-names>Adnan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>107059/Z/15/Z</award-id><principal-award-recipient><name><surname>Lloyd</surname><given-names>Clare M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Using unique data from five longitudinal UK birth cohorts, four distinct subsets of genetic variants were identified as differentially associated across wheezing phenotypes from infancy to adolescence with little evidence of genetic associations spanning across different phenotypes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Asthma is a complex disorder caused by a variety of mechanisms which result in multiple clinical phenotypes (<xref ref-type="bibr" rid="bib60">Pavord et al., 2018</xref>). It has a strong genetic component, and twin studies estimate its heritability to be ~60–70% (<xref ref-type="bibr" rid="bib23">Duffy et al., 1990</xref>). ‘Asthma genes’ have been identified through a range of approaches, from candidate gene association studies (<xref ref-type="bibr" rid="bib70">Simpson et al., 2012</xref>) and family-based genome-wide linkage analyses (<xref ref-type="bibr" rid="bib19">Daniels et al., 1996</xref>) to genome-wide association studies (GWASs) (<xref ref-type="bibr" rid="bib52">Moffatt et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Moffatt et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Demenais et al., 2018</xref>). The first asthma GWAS (2007) identified multiple markers on chromosome 17q21 associated with childhood onset asthma (<xref ref-type="bibr" rid="bib52">Moffatt et al., 2007</xref>). A comprehensive review summarising the results of 42 GWASs of asthma and asthma-related traits has been published recently (<xref ref-type="bibr" rid="bib28">El-Husseini et al., 2020</xref>). The most widely replicated locus is 17q12-21, followed by 6p21 (<italic>HLA</italic> region), 2q12 (<italic>IL1RL1/IL18R1</italic>), 5q22 (<italic>TSLP</italic>), and 9p24 (<italic>IL33</italic>) (<xref ref-type="bibr" rid="bib38">Kim and Ober, 2019</xref>). Overall, the evidence suggests that multiple genes are underlying the association peaks (<xref ref-type="bibr" rid="bib38">Kim and Ober, 2019</xref>).</p><p>However, despite undeniable successes, genetic studies of asthma have produced relatively heterogeneous results, and only a small proportion of the heritability is accounted for (<xref ref-type="bibr" rid="bib56">Ober and Yao, 2011</xref>). One part of the explanation for the paucity of precise replication are numerous gene-environment interactions (<xref ref-type="bibr" rid="bib14">Custovic et al., 2012</xref>). Another important consideration is asthma heterogeneity, in that asthma diagnosis comprises several conditions with distinct pathophysiology (<xref ref-type="bibr" rid="bib17">Custovic, 2020</xref>; <xref ref-type="bibr" rid="bib33">Haider et al., 2022</xref>), each potentially underpinned by different genetic associations (<xref ref-type="bibr" rid="bib16">Custovic et al., 2019</xref>). However, in order to maximise sample size, most GWASs used a definition of ‘doctor-diagnosed asthma’ (<xref ref-type="bibr" rid="bib1">Aaron et al., 2017</xref>). Such aggregated outcome definitions are imprecise (<xref ref-type="bibr" rid="bib44">Looijmans-van den Akker et al., 2016</xref>) and phenotypically and mechanistically heterogeneous (<xref ref-type="bibr" rid="bib65">Robinson et al., 2021</xref>), and this heterogeneity may dilute important genetic signals (<xref ref-type="bibr" rid="bib16">Custovic et al., 2019</xref>).</p><p>One way of disaggregating asthma diagnosis is to use data-driven methods to derive subtypes in a hypothesis-neutral way (<xref ref-type="bibr" rid="bib36">Howard et al., 2015</xref>). For example, we jointly modelled data on wheezing from birth to adolescence in five UK population-based birth cohorts and identified five distinct phenotypes (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>). However, although latent modelling approaches have been instrumental in elucidating the heterogenous nature of childhood asthma diagnosis (<xref ref-type="bibr" rid="bib33">Haider et al., 2022</xref>), there has been little research into the genetic associations of phenotypes derived using data-driven methods. This is the first study to investigate the genetic architecture of wheezing phenotypes from infancy to adolescence, to identify genes specific to each phenotype and better understand the genetic heterogeneity between the disease class profiles.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Study design, setting, participants, and data sources/measurement</title><p>The Study Team for Early Life Asthma Research (STELAR) consortium (<xref ref-type="bibr" rid="bib15">Custovic et al., 2015</xref>) brings together five UK population-based birth cohorts: Avon Longitudinal Study of Parents and Children (ALSPAC) (<xref ref-type="bibr" rid="bib30">Golding et al., 2001</xref>), Ashford (<xref ref-type="bibr" rid="bib11">Cullinan et al., 2004</xref>) and Isle of Wight (IOW) (<xref ref-type="bibr" rid="bib3">Arshad et al., 2018</xref>) cohorts, Manchester Asthma and Allergy Study (MAAS) (<xref ref-type="bibr" rid="bib13">Custovic et al., 2002</xref>), and the Aberdeen Study of Eczema and Asthma to Observe the Effects of Nutrition (SEATON) (<xref ref-type="bibr" rid="bib47">Martindale et al., 2005</xref>). All studies were approved by research ethics committees. See Appendix 1: Description of cohorts for more details. Informed consent was obtained from parents, and study subjects gave their assent/consent when applicable.</p><p>Validated questionnaires were completed on multiple occasions from infancy to adolescence (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>). A list of variables, per cohort, is shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>, and the cohort-specific time points and sample sizes in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>. Data were harmonised and imported into Asthma eLab web-based knowledge management platform to facilitate joint analyses (<xref ref-type="bibr" rid="bib15">Custovic et al., 2015</xref>).</p></sec><sec id="s2-2"><title>Definition of primary outcome (wheeze phenotypes from infancy to adolescence)</title><p>In the pooled analysis among 15,941 subjects with at least two observations on current wheeze, we used latent class analysis (LCA) to derive wheeze phenotypes from birth to age 18 years (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>). A detailed description of the analysis is presented in <xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>, and in Appendix 1: Definition of variables. A five-class solution was selected as the optimal model (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>), and the classes (wheeze phenotypes) were labeled as: (1) <italic>never/infrequent wheeze</italic> (52.4%); (2) <italic>early-onset pre-school remitting wheeze</italic> (18.6%); (3) <italic>early-onset middle-childhood remitting wheeze</italic> (9.8%); (4) <italic>early-onset persistent wheeze</italic> (10.4%); and (5) <italic>late-onset wheeze</italic> (8.8%). These latent classes were used in the subsequent GWAS.</p></sec><sec id="s2-3"><title>Genotyping, imputation, and GWAS meta-analysis</title><p>Genotyping, quality control, imputation, and exclusions are described in Appendix 2: Genotyping and imputation. Analyses were performed independently in ALSPAC, MAAS, and the combined IOW-SEATON-Ashford (genotyped on the same platform, at the same time, and imputed together). We used SNPTEST v2.5.2 (<xref ref-type="bibr" rid="bib46">Marchini and Howie, 2010</xref>) with a frequentist additive multinomial logistic regression model (-method newml), using the never/infrequent wheeze as the reference and without including any covariates. A meta-analysis of the three GWASs was performed using METAL (<xref ref-type="bibr" rid="bib81">Willer et al., 2010</xref>) with a total of 8,057,852 SNPs. See Appendix 2: LD clumping, pre-selection, and gene annotation for more details.</p></sec><sec id="s2-4"><title>Post-GWASs</title><p>Our GWAS identified a novel locus in chr9q21 nearby <italic>Annexin A1</italic> (<italic>ANXA1</italic>), exclusively associated with early-onset persistent wheeze (see Results section). We therefore proceeded with studies to identify causal variants and explore the biological mechanisms underlying this locus (see Appendix 3: Post-GWAS: rs75260654 (<italic>ANXA1</italic>) for more details). To this end, we firstly identified the most likely causative SNP using Promoter Capture Hi-C (PCHi-C) loops. We then ascertained genotype effect on gene expression and assessed the potential biological function of <italic>ANXA1</italic> in asthma. Finally, we used a murine model of house dust mite (HDM)-induced allergic airway disease to investigate whether <italic>ANXA1</italic> was important in regulating immune responses to a clinically relevant aeroallergen and used knock-out mice to derive further in vivo functional data to support our GWAS finding.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Participants and descriptive data</title><p>We included a total of 9568 subjects with European ancestry: ALSPAC, n=6833; MAAS, n=887; SEATON, n=548; Ashford, n=348; and IOW, n=952. Demographic characteristics of the participants in STELAR cohorts included in this analysis and a flowchart are shown in <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref> and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>. Cohorts contain similar proportions of males (range 48–54%), maternal history of asthma (11–14%), maternal smoking (14–23%), (doctor-diagnosed) asthma ever during mid-childhood (16–24%) and adolescence (20–30%), current wheeze (12–20% mid-childhood, 9–25% adolescence), and current use of asthma medication (12–17% mid-childhood, 11–17% adolescence). Individuals with missing genetic data as well as related and non-European individuals were excluded. Comparison of included vs. excluded individuals across cohorts (per cohort and time point) is in Appendix 1 and <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>.</p></sec><sec id="s3-2"><title>GWAS meta-analysis</title><p>We conducted three GWASs (ALSPAC, MAAS, IOW-SEATON-Ashford) in parallel and results were meta-analysed. The distribution of the minor allele frequencies was consistent across genotyped datasets (mean SD 0.01). A circular Manhattan plot and a QQ plot are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Some observed p-values were clearly more significant than expected under the null hypothesis, particularly for early-onset persistent wheeze, without an early separation of the expected from the observed which indicates low evidence of population stratification. We observed slight deflation of the meta-analysis p-values in our summary statistics. Genomic inflation factor (λ) for early-onset pre-school remitting = 0.96, early-onset mid-childhood remitting = 0.94, late-onset = 0.96, and early-onset persistent wheezing = 0.97. A total of 589 SNPs were associated with at least one phenotype with p&lt;10<sup>–5</sup>. After clumping, we identified 134 independent SNPs uniquely associated with different phenotypes (p&lt;10<sup>–5</sup>): of these, 44 were exclusively associated with early-onset persistent, 25 with early-onset pre-school remitting, 33 with early-onset mid-childhood remitting, and 32 with late-onset wheeze (<xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>). Scatter plots in <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> show the heterogeneity in the genetic profile of the wheeze phenotypes. The plots show that all signals were phenotype-specific at p&lt;10<sup>–5</sup> and only nominal associations were shared across wheezing phenotypes. More details on how these plots were derived can be found in Appendix 2: Heterogeneity scatter plots. For example, chr17q21 was identified as a top locus for early-onset persistent wheeze (p=5.42 × 10<sup>–9</sup>), but some of the SNPs in this region were also associated with the early-onset mid-childhood remitting phenotype (p&lt;10<sup>–4</sup>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Circular Manhattan plot showing an overview of the genome-wide association study (GWAS) results by wheeze phenotype (from outside to inside: early-onset persistent, early-onset pre-school remitting, early-onset mid-childhood remitting, and late-onset wheeze).</title><p>The red line indicates the genome-wide significance threshold (p &lt; 5 × 10<sup>−8</sup>), while the blue line indicates the threshold for genetic variants that showed a suggestive significant association (p &lt; 10<sup>−5</sup>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>QQ plots for each wheezing phenotype.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig1-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Scatter plots illustrating the heterogeneity in the genetic profile of the wheezing phenotypes.</title><p>Top plots compare phenotype-specific beta effects for persistent and early-onset mid-childhood remitting wheezing. Shared nominal beta effects only found when relaxing p&lt;10<sup>–4</sup> for early-onset mid-childhood remitting wheezing. Bottom plots compare phenotype-specific beta effects for persistent and early-onset pre-school remitting. No shared beta effects (same or opposite direction) were found at p&lt;10<sup>–5</sup> for any of the comparisons. Abbreviations used: pw = persistent, er = early-onset pre-school remitting, and pe = early-onset mid-childhood remitting.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Scatter plots illustrating the heterogeneity in the genetic profile of wheezing phenotypes.</title><p>No shared beta effects (same or opposite direction) were found at p&lt;10<sup>–5</sup> for any of the comparisons. Abbreviations used: pw = persistent, er = early-onset pre-school remitting, pe = early-onset mid-childhood remitting, and lo = late-onset wheezing. Scatter plot for pw vs. lo (top left), er vs. pe (top right), er vs. lo (bottom left), pe vs lo (bottom right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To help identify functional elements located near the GWAS-associated variants (potential causal variants), we used locus zoom plots (LZPs) for the 134 independent SNPs (p&lt;10<sup>–5</sup>). Following close inspection of all plots, we short-listed 85 independent SNPs (<xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>) for which the LZPs potentially indicated more than one causal variant (<xref ref-type="fig" rid="app2fig1">Appendix 2—figures 1</xref>–<xref ref-type="fig" rid="app2fig4">4</xref>) and followed them up for further annotation. The results of GWAS meta-analysis for these 85 SNPs with main associations across the four wheeze phenotypes are presented in <xref ref-type="table" rid="table1">Table 1</xref>. Previously associated traits for each region/gene associated with the different wheeze phenotypes are shown in <xref ref-type="table" rid="app4table4 app4table3 app4table2 app4table1">Appendix 4—tables 1–4</xref> and results are summarised in Appendix 4: Results in context of literature. Briefly, one region (6q27) among the top hits for early-onset pre-school remitting wheeze was previously associated with asthma, but in the context of obesity with a nominal association with asthma and BMI (<xref ref-type="bibr" rid="bib51">Melén et al., 2010</xref>). Another region/gene (3q26.31/<italic>NAALADL2</italic>) identified as top hit for early-onset pre-school remitting wheeze was reported as an associate of severe asthma exacerbations, but only at nominal level (<xref ref-type="bibr" rid="bib35">Herrera‐Luis et al., 2021</xref>). No regions/genes identified as top hits for early-onset mid-childhood remitting wheeze were found to have previous associations with asthma. Several genes/loci identified as top hits for late-onset wheeze were previously associated with asthma: <italic>ACOXL</italic> chr2q13 (later onset asthma and obesity; <xref ref-type="bibr" rid="bib84">Zhu et al., 2020</xref>), <italic>PRKAA2</italic> chr1p32.2 (lymphocyte count and asthma susceptibility; <xref ref-type="bibr" rid="bib12">Cusanovich et al., 2012</xref>), <italic>CD200</italic> 3q13.2 (adult onset non-allergic asthma; <xref ref-type="bibr" rid="bib71">Siroux et al., 2014</xref>), <italic>GIMAP</italic> family 7q36.1 (autoimmune diabetes, asthma, allergy; <xref ref-type="bibr" rid="bib34">Heinonen et al., 2015</xref>), 9p22.3 (asthma in &lt;16 years of age; <xref ref-type="bibr" rid="bib22">Denham et al., 2008</xref>), and <italic>16p12.1</italic> (asthma and rhino-conjunctivitis at 10–15 years; <xref ref-type="bibr" rid="bib72">Sottile et al., 2019</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Genome-wide association study (GWAS) meta-analysis: short-listed 85 top independent single nucleotide polymorphisms (SNPs) across the four wheezing phenotypes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="10">Early-onset persistent wheezing</th></tr><tr><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">Independent SNPs</th><th align="left" valign="bottom">Nearby genes (SNPnexus)</th><th align="left" valign="bottom">Effect allele(freq)/ other allele</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Effect direction (3 GWAS)</th><th align="left" valign="bottom">min_pval_other<xref ref-type="table-fn" rid="table1fn3">*</xref></th><th align="left" valign="bottom">Previous relevant associations<xref ref-type="table-fn" rid="table1fn4">†</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>1q43</italic></td><td align="left" valign="bottom">rs4620530</td><td align="left" valign="bottom"><italic>CHRM3</italic></td><td align="left" valign="bottom">g(0.56)/t</td><td align="char" char="." valign="bottom">0.25</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">2.45E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, asthma- high priority drug target</td></tr><tr><td align="left" valign="bottom"><italic>2p25.1</italic></td><td align="left" valign="bottom">rs13398488</td><td align="left" valign="bottom"><italic>RNF144A</italic></td><td align="left" valign="bottom">g(0.29)/a</td><td align="char" char="." valign="bottom">0.25</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">2.18E-06</td><td align="char" char="." valign="bottom">+--</td><td align="left" valign="bottom">0.13</td><td align="left" valign="bottom">Asthma, allergy, childhood onset asthma, allergic rhinitis</td></tr><tr><td align="left" valign="bottom"><italic>2q12.2</italic></td><td align="left" valign="bottom">rs6543291</td><td align="left" valign="bottom"><italic>FHL2</italic></td><td align="left" valign="bottom">c(0.4)/t</td><td align="char" char="." valign="bottom">0.23</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">6.97E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.10</td><td align="left" valign="bottom">Bronchial hyper-responsiveness, airway inflammation; novel gene associated with asthma severity in human</td></tr><tr><td align="left" valign="bottom"><italic>3q21.3</italic></td><td align="left" valign="bottom">rs77655717</td><td align="left" valign="bottom"><italic>EFCC1, RAB43, RAB7A</italic></td><td align="left" valign="bottom">c(0.05)/t</td><td align="char" char="." valign="bottom">0.47</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">6.40E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.39</td><td align="left" valign="bottom"><italic>RAB43</italic>: response to bronchodilator, FEV/FEC ratio; <italic>RAB7A</italic>: eosinophil count</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>4p16.3</italic></td><td align="left" valign="bottom">rs7680608<sup>eQTL</sup></td><td align="left" valign="bottom" rowspan="2"><italic>RNF212, IDUA, DGKQ, SLC26A1</italic></td><td align="left" valign="bottom">g(0.93)/c</td><td align="char" char="." valign="bottom">–0.42</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">1.31E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.15</td><td align="char" char="." valign="bottom" rowspan="2"><italic>4</italic>p16: asthma</td></tr><tr><td align="left" valign="bottom">rs77822621<sup>eQTL</sup></td><td align="left" valign="bottom">c(0.96)/t</td><td align="char" char="." valign="bottom">–0.50</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="hyphen" valign="bottom">7.16E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.01</td></tr><tr><td align="left" valign="bottom"><italic>4q31.21</italic></td><td align="left" valign="bottom">rs115228498</td><td align="left" valign="bottom"><italic>INPP4B</italic></td><td align="left" valign="bottom">c(0.02)/t</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">2.70E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.02</td><td align="left" valign="bottom">Atopic asthma</td></tr><tr><td align="left" valign="bottom"><italic>5p15.31</italic></td><td align="left" valign="bottom">rs116494115</td><td align="left" valign="bottom"><italic>ADCY2</italic></td><td align="left" valign="bottom">g(0.01)/a</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">6.49E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.09</td><td align="left" valign="bottom">Asthma×air pollution, childhood asthma</td></tr><tr><td align="left" valign="bottom"><italic>7q22.3</italic></td><td align="left" valign="bottom">rs76871421</td><td align="left" valign="bottom"><italic>CDHR3</italic></td><td align="left" valign="bottom">c(0.12)/t</td><td align="char" char="." valign="bottom">0.37</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">5.71E-07</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.22</td><td align="left" valign="bottom">Childhood asthma</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>9q21.13</italic></td><td align="left" valign="bottom">rs75260654</td><td align="left" valign="bottom" rowspan="2"><bold><italic>ANXA1</italic></bold><italic>, TMC1, LOC101927258, ALDH1A1</italic></td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.90</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom"><bold>6.66E-09</bold></td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.05</td><td align="left" valign="bottom" rowspan="2"><bold><italic>ANXA1</italic></bold>: FEV<sub>1</sub>/FVC, response to bronchodilators in smokers, with anti-inflammatory properties, strongly expressed in bronchial mast cells and potentially involved in epithelial airway repair</td></tr><tr><td align="left" valign="bottom">rs116849664</td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.89</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom"><bold>1.99E-08</bold></td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.06</td></tr><tr><td align="left" valign="bottom"><italic>10q24.2</italic></td><td align="left" valign="bottom">rs7088157</td><td align="left" valign="bottom"><italic>LOXL4, R3HCC1L</italic></td><td align="left" valign="bottom">g(0.5)/a</td><td align="char" char="." valign="bottom">–0.23</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">7.34E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.26</td><td align="left" valign="bottom"><italic>R3HCC1L</italic>: eosinophil count, atopic eczema, psoriasis, BMI</td></tr><tr><td align="left" valign="bottom"><italic>11p15.4</italic></td><td align="left" valign="bottom">rs112474574</td><td align="left" valign="bottom"><italic>TRIM5, TRIM6, TRIM22</italic></td><td align="left" valign="bottom">c(0.96)/t</td><td align="char" char="." valign="bottom">–0.55</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="hyphen" valign="bottom">2.29E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.14</td><td align="left" valign="bottom">Severe asthma and insulin resistance</td></tr><tr><td align="left" valign="bottom"><italic>11q23.3</italic></td><td align="left" valign="bottom">rs116861530<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>SIK3</italic></td><td align="left" valign="bottom">g(0.94)/a</td><td align="char" char="." valign="bottom">–0.42</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">9.07E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.01</td><td align="left" valign="bottom">Triglycerides, glucose metabolism, eosinophil count</td></tr><tr><td align="left" valign="bottom"><italic>14q22.1</italic></td><td align="left" valign="bottom">rs1105683</td><td align="left" valign="bottom"><italic>KTN1</italic></td><td align="left" valign="bottom">c(0.07)/t</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">9.15E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.24</td><td align="left" valign="bottom">Severe asthma</td></tr><tr><td align="left" valign="bottom"><italic>5q13.3</italic></td><td align="left" valign="bottom">rs2202714<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>FAM227B</italic></td><td align="left" valign="bottom">g(0.36)/a</td><td align="char" char="." valign="bottom">0.23</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">8.71E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.01</td><td align="left" valign="bottom">rs35251997 and FEV<sub>1</sub>; FEV<sub>1</sub>/FVC</td></tr><tr><td align="left" valign="bottom">15q25.2</td><td align="left" valign="bottom">rs117540214<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>ADAMTSL3</italic></td><td align="left" valign="bottom">g(0.06)/a</td><td align="char" char="." valign="bottom">0.42</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">9.82E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">3.91E-03</td><td align="left" valign="bottom">FEV<sub>1</sub>/FVC</td></tr><tr><td align="left" valign="bottom"><italic>17q12</italic></td><td align="left" valign="bottom">rs17676191</td><td align="left" valign="bottom" rowspan="2"><italic>IKZF3</italic></td><td align="left" valign="bottom">g(0.10)/a</td><td align="char" char="." valign="bottom">0.36</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">2.18E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">3.06E-03</td><td align="left" valign="bottom" rowspan="9">Early-onset asthma, persistent wheezing (chr17q12-q21)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">rs79026872</td><td align="left" valign="bottom">c(0.03)/t</td><td align="char" char="." valign="bottom">0.64</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="hyphen" valign="bottom">2.08E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">2.56E-03</td></tr><tr><td align="left" valign="bottom" rowspan="7"><italic>17q21</italic></td><td align="left" valign="bottom">rs4795400</td><td align="left" valign="bottom" rowspan="3"><italic>GSDMB</italic></td><td align="left" valign="bottom">c(0.53)/t</td><td align="char" char="." valign="bottom">0.30</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom"><bold>5.42E-09</bold></td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">1.96E-04</td></tr><tr><td align="left" valign="bottom">rs1031460</td><td align="left" valign="bottom">g(0.50)/t</td><td align="char" char="." valign="bottom">0.27</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">8.71E-08</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">1.87E-04</td></tr><tr><td align="left" valign="bottom">rs56199421</td><td align="left" valign="bottom">c(0.45)/t</td><td align="char" char="." valign="bottom">–0.23</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">4.50E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">9.61E-04</td></tr><tr><td align="left" valign="bottom">rs4795406</td><td align="left" valign="bottom"><italic>LRRC3C</italic></td><td align="left" valign="bottom">g(0.55)/c</td><td align="char" char="." valign="bottom">–0.24</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">9.91E-07</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">1.51E-03</td></tr><tr><td align="left" valign="bottom">rs72832972</td><td align="left" valign="bottom" rowspan="3"><italic>GSDMA</italic></td><td align="left" valign="bottom">c(0.92)/t</td><td align="char" char="." valign="bottom">–0.38</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">8.91E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.01</td></tr><tr><td align="left" valign="bottom">rs4794821</td><td align="left" valign="bottom">c(0.47)/t</td><td align="char" char="." valign="bottom">0.27</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">9.43E-08</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">1.07E-03</td></tr><tr><td align="left" valign="bottom">rs59843584</td><td align="left" valign="bottom">c(0.78)/a</td><td align="char" char="." valign="bottom">–0.31</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">6.38E-08</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">6.63E-03</td></tr><tr><td align="left" valign="bottom" rowspan="4"><italic>19p13.2</italic></td><td align="left" valign="bottom">rs4804311</td><td align="left" valign="bottom" rowspan="4"><italic>MARCH2, HNRNPM, MYO1F</italic></td><td align="left" valign="bottom">g(0.08)/a</td><td align="char" char="." valign="bottom">0.42</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">9.65E-07</td><td align="char" char="." valign="bottom">+-+</td><td align="left" valign="bottom">0.05</td><td align="left" valign="bottom" rowspan="4">Triglycerides, HDL cholesterol, metabolic syndrome; <italic>MYO1F</italic>: FEV<sub>1</sub> and FVC</td></tr><tr><td align="left" valign="bottom">rs2013694</td><td align="left" valign="bottom">c(0.89)/t</td><td align="char" char="." valign="bottom">–0.38</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">8.29E-07</td><td align="char" char="hyphen" valign="bottom">--+</td><td align="left" valign="bottom">0.39</td></tr><tr><td align="left" valign="bottom">rs73501545</td><td align="left" valign="bottom">g(0.16)/a</td><td align="char" char="." valign="bottom">0.31</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">8.39E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.29</td></tr><tr><td align="left" valign="bottom">rs111644945</td><td align="left" valign="bottom">g(0.9)/a</td><td align="char" char="." valign="bottom">–0.41</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">4.01E-07</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.02</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>22q11.1</italic></td><td align="left" valign="bottom">rs5994170</td><td align="left" valign="bottom" rowspan="2"><italic>CECR5</italic></td><td align="left" valign="bottom">g(0.4)/a</td><td align="char" char="." valign="bottom">0.23</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">4.95E-06</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom" rowspan="2">Triglycerides, eosinophil count, and body height</td></tr><tr><td align="left" valign="bottom">rs34902370</td><td align="left" valign="bottom">c(0.75)/t</td><td align="char" char="." valign="bottom">–0.25</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">6.80E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="left" valign="bottom">0.41</td></tr><tr><th align="left" valign="bottom" colspan="10">Early-onset pre-school remitting wheezing</th></tr><tr><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">SNP</th><th align="left" valign="bottom">Nearby genes (SNPnexus)</th><th align="left" valign="bottom">Coded(freq)/other allele</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Direction</th><th align="left" valign="bottom">min_pval_other</th><th align="left" valign="bottom">Previous relevant associations</th></tr><tr><td align="left" valign="bottom"><italic>1q32.3</italic></td><td align="left" valign="bottom">rs12730098<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>PPP2R5A</italic></td><td align="left" valign="bottom">c(0.79)/t</td><td align="char" char="." valign="bottom">–0.22</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">8.44E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.53</td><td align="left" valign="bottom">Waist circumference and obesity</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>2p24.2</italic></td><td align="left" valign="bottom">rs2880066</td><td align="left" valign="bottom" rowspan="2"><italic>FAM49A or CYRIA</italic></td><td align="left" valign="bottom">t(0.09)/a</td><td align="char" char="." valign="bottom">0.32</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">4.34E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.20</td><td align="left" valign="bottom" rowspan="2">Airway repair in non-atopic asthma</td></tr><tr><td align="left" valign="bottom">rs10180268</td><td align="left" valign="bottom">c(0.06)/t</td><td align="char" char="." valign="bottom">0.43</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">6.56E-07</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.19</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>3q26.31</italic></td><td align="left" valign="bottom">rs3861377</td><td align="left" valign="bottom"><italic>NLGN1</italic></td><td align="left" valign="bottom">g(0.89)/a</td><td align="char" char="." valign="bottom">–0.28</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">7.75E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.28</td><td align="left" valign="bottom">Smoking</td></tr><tr><td align="left" valign="bottom">rs10513743</td><td align="left" valign="bottom"><italic>NAALADL2</italic></td><td align="left" valign="bottom">c(0.84)/t</td><td align="char" char="." valign="bottom">–0.25</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">4.97E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.06</td><td align="left" valign="bottom">Exacerbations requiring hospitalisation in asthma-suggestive p-value</td></tr><tr><td align="left" valign="bottom"><italic>5q13.3</italic></td><td align="left" valign="bottom">rs10075253</td><td align="left" valign="bottom"><italic>SV2C</italic></td><td align="left" valign="bottom">c(0.85)/t</td><td align="char" char="." valign="bottom">–0.27</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">1.20E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.17</td><td align="left" valign="bottom">BMI</td></tr><tr><td align="left" valign="bottom"><italic>6q27</italic></td><td align="left" valign="bottom">rs2453395</td><td align="left" valign="bottom"><italic>PDE10A</italic></td><td align="left" valign="bottom">g(0.33)/a</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="hyphen" valign="bottom">9.51E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom">Birth weight; asthma and BMI</td></tr><tr><td align="left" valign="bottom" rowspan="3"><italic>7q21.11</italic></td><td align="left" valign="bottom">rs4730561</td><td align="left" valign="bottom" rowspan="3"><italic>MAGI2</italic></td><td align="left" valign="bottom">g(0.36)/a</td><td align="char" char="." valign="bottom">–0.20</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="hyphen" valign="bottom">6.78E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.13</td><td align="left" valign="bottom" rowspan="3">Allergic diseases and atopy, smoking, BMI, airway wall thickness</td></tr><tr><td align="left" valign="bottom">rs73144976</td><td align="left" valign="bottom">g(0.97)/a</td><td align="char" char="." valign="bottom">–0.47</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="hyphen" valign="bottom">9.41E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom">rs67259321</td><td align="left" valign="bottom">c(0.06)/t</td><td align="char" char="." valign="bottom">0.43</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">1.65E-07</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.76</td></tr><tr><td align="left" valign="bottom"><italic>9p13.3</italic></td><td align="left" valign="bottom">rs10758259<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>C9orf24</italic></td><td align="left" valign="bottom">g(0.17)/a</td><td align="char" char="." valign="bottom">–0.27</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">4.64E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom">Airway repair</td></tr><tr><td align="left" valign="bottom"><italic>11q22.3</italic></td><td align="left" valign="bottom">rs72994149</td><td align="left" valign="bottom"><italic>GUCY1A2</italic></td><td align="left" valign="bottom">c(0.84)/t</td><td align="char" char="." valign="bottom">–0.24</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="hyphen" valign="bottom">8.33E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.06</td><td align="left" valign="bottom">Systolic blood pressure</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>13q21.1</italic></td><td align="left" valign="bottom">rs2872948</td><td align="left" valign="bottom" rowspan="2"><italic>PRR20A/B/C/D/E</italic></td><td align="left" valign="bottom">t(0.96)/a</td><td align="char" char="." valign="bottom">–0.54</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">5.93E-08</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.27</td><td align="left" valign="bottom" rowspan="2">Systolic blood pressure</td></tr><tr><td align="left" valign="bottom">rs73527654</td><td align="left" valign="bottom">g(0.08)/a</td><td align="char" char="." valign="bottom">0.34</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">2.85E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.41</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>15q21.1</italic></td><td align="left" valign="bottom">rs116966886</td><td align="left" valign="bottom" rowspan="2"><italic>SEMA6D</italic></td><td align="left" valign="bottom">g(0.99)/a</td><td align="char" char="." valign="bottom">–0.82</td><td align="char" char="." valign="bottom">0.18</td><td align="char" char="hyphen" valign="bottom">7.55E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.57</td><td align="left" valign="bottom" rowspan="2">Smoking</td></tr><tr><td align="left" valign="bottom">rs117565527</td><td align="left" valign="bottom">g(0.99)/a</td><td align="char" char="." valign="bottom">–0.87</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">2.38E-07</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.43</td></tr><tr><th align="left" valign="bottom" colspan="10">Early-onset mid-childhood remitting wheezing</th></tr><tr><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">SNP</th><th align="left" valign="bottom">Nearby genes (SNPnexus)</th><th align="left" valign="bottom">Coded(freq)/ other allele</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Direction</th><th align="left" valign="bottom">min_pval_other</th><th align="left" valign="bottom">Previous relevant associations</th></tr><tr><td align="left" valign="bottom" rowspan="3"><italic>1q23.2</italic></td><td align="left" valign="bottom">rs35725789</td><td align="left" valign="bottom" rowspan="3"><italic>CADM3, FCER1A, MPTX1, OR10J1</italic></td><td align="left" valign="bottom">c(0.95)/a</td><td align="char" char="." valign="bottom">–0.56</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="hyphen" valign="bottom">5.42E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom" rowspan="3">Neutrophil count, CRP</td></tr><tr><td align="left" valign="bottom">rs146141555</td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.89</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">2.04E-07</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.08</td></tr><tr><td align="left" valign="bottom">rs146575092</td><td align="left" valign="bottom">g(0.98)/a</td><td align="char" char="." valign="bottom">–0.85</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">8.73E-07</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.07</td></tr><tr><td align="left" valign="bottom"><italic>2p22.3</italic></td><td align="left" valign="bottom">rs7595553</td><td align="left" valign="bottom"><italic>MRPL50P1</italic></td><td align="left" valign="bottom">g(0.16)/c</td><td align="char" char="." valign="bottom">–0.46</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">3.26E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.12</td><td align="left" valign="bottom">PM 2.5 exposure level and global DNA methylation level</td></tr><tr><td align="left" valign="bottom"><italic>3p25.3</italic></td><td align="left" valign="bottom">rs34315999<sup>eQTL</sup></td><td align="left" valign="bottom"><italic>RAD18</italic></td><td align="left" valign="bottom">c(0.03)/t</td><td align="char" char="." valign="bottom">0.69</td><td align="char" char="." valign="bottom">0.14</td><td align="char" char="hyphen" valign="bottom">1.11E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.14</td><td align="left" valign="bottom">Atopy/SPT</td></tr><tr><td align="left" valign="bottom"><italic>3q29</italic></td><td align="left" valign="bottom">rs146961758</td><td align="left" valign="bottom"><italic>MRPL50P1, LSG1, TMEM44-AS1, TMEM44, ATP13A3</italic></td><td align="left" valign="bottom">t(0.05)/a</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="hyphen" valign="bottom">6.01E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.11</td><td align="left" valign="bottom"><italic>3q29:</italic> BMI<break/><italic>TMEM44-AS1, TMEM44, ATP13A3</italic>: diastolic blood pressure; <italic>LSG1</italic>: BMI, eosinophil count</td></tr><tr><td align="left" valign="bottom"><italic>4q24</italic></td><td align="left" valign="bottom">rs138794367</td><td align="left" valign="bottom"><italic>SLC9B1</italic></td><td align="left" valign="bottom">c(0.99)/t</td><td align="char" char="." valign="bottom">–1.02</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="hyphen" valign="bottom">5.47E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.13</td><td align="left" valign="bottom">Eosinophil count, allergic rhinitis</td></tr><tr><td align="left" valign="bottom"><italic>5q14.1</italic></td><td align="left" valign="bottom">rs115719402</td><td align="left" valign="bottom"><italic>AP3B1</italic></td><td align="left" valign="bottom">g(0.96)/a</td><td align="char" char="." valign="bottom">–0.60</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="hyphen" valign="bottom">7.20E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.06</td><td align="left" valign="bottom">Vital capacity, BMI</td></tr><tr><td align="left" valign="bottom" rowspan="5"><italic>13q31.1</italic></td><td align="left" valign="bottom">rs9602218</td><td align="left" valign="bottom" rowspan="3"><italic>RNU6-67P, SLITRK1</italic></td><td align="left" valign="bottom">c(0.06)/a</td><td align="char" char="." valign="bottom">0.58</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="hyphen" valign="bottom">1.74E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.05</td><td align="left" valign="bottom" rowspan="5">RNU6-67P/ rs976078: food allergy</td></tr><tr><td align="left" valign="bottom">rs61960366</td><td align="left" valign="bottom">g(0.97)/a</td><td align="char" char="." valign="bottom">–0.79</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="hyphen" valign="bottom">7.09E-08</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.12</td></tr><tr><td align="left" valign="bottom">rs74589927</td><td align="left" valign="bottom">g(0.02)/a</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom">3.78E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.02</td></tr><tr><td align="left" valign="bottom">rs2210726</td><td align="left" valign="bottom" rowspan="2"><italic>VENTXP2, UBE2D3P4, MTND4P1</italic></td><td align="left" valign="bottom">c(0.91)/t</td><td align="char" char="." valign="bottom">–0.47</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">1.33E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.02</td></tr><tr><td align="left" valign="bottom">rs4390476</td><td align="left" valign="bottom">c(0.08)/a</td><td align="char" char="." valign="bottom">0.46</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">8.81E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.12</td></tr><tr><td align="left" valign="bottom"><italic>14q24.2</italic></td><td align="left" valign="bottom">rs117443464</td><td align="left" valign="bottom"><italic>ZFYVE1</italic></td><td align="left" valign="bottom">g(0.95)/a</td><td align="char" char="." valign="bottom">–0.57</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="hyphen" valign="bottom">4.68E-06</td><td align="char" char="hyphen" valign="bottom">--+</td><td align="char" char="." valign="bottom">0.19</td><td align="left" valign="bottom">LDL cholesterol and systolic blood pressure</td></tr><tr><td align="left" valign="bottom"><italic>20p12.3-p12.2</italic></td><td align="left" valign="bottom">rs6077514</td><td align="left" valign="bottom"><italic>PLCB4</italic></td><td align="left" valign="bottom">c(0.88)/t</td><td align="char" char="." valign="bottom">–0.39</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="hyphen" valign="bottom">4.03E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.43</td><td align="left" valign="bottom">Neutrophil count</td></tr><tr><th align="left" valign="bottom" colspan="8">Late-onset wheezing</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">SNP</th><th align="left" valign="bottom">Nearby genes (SNPnexus)</th><th align="left" valign="bottom">Coded(freq)/ other allele</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Direction</th><th align="left" valign="bottom">min_pval_other</th><th align="left" valign="bottom">Previous relevant associations</th></tr><tr><td align="left" valign="bottom"><italic>1p36.13</italic></td><td align="left" valign="bottom">rs9439669</td><td align="left" valign="bottom"><italic>KLHDC7A</italic></td><td align="left" valign="bottom">t(0.82)/a</td><td align="char" char="." valign="bottom">–0.34</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">5.15E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.31</td><td align="left" valign="bottom"><italic>1p36.13</italic>: metabolic syndrome</td></tr><tr><td align="left" valign="bottom"><italic>1p32.2</italic></td><td align="left" valign="bottom">rs2051039</td><td align="left" valign="bottom"><italic>PPAP2B, PRKAA2</italic></td><td align="left" valign="bottom">c(0.08)/t</td><td align="char" char="." valign="bottom">0.47</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">6.06E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.08</td><td align="left" valign="bottom"><italic>PRKAA2</italic>: lymphocyte count and asthma susceptibility</td></tr><tr><td align="left" valign="bottom"><italic>1p31.1</italic></td><td align="left" valign="bottom">rs72673642</td><td align="left" valign="bottom"><italic>HMGB1P18</italic></td><td align="left" valign="bottom">g(0.77)/a</td><td align="char" char="." valign="bottom">–0.31</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="hyphen" valign="bottom">6.25E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom">Smoking, BMI</td></tr><tr><td align="left" valign="bottom"><italic>2q13</italic></td><td align="left" valign="bottom">rs140983998</td><td align="left" valign="bottom"><italic>ACOXL, BUB1</italic></td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.88</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="hyphen" valign="bottom">4.71E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.40</td><td align="left" valign="bottom"><italic>ACOXL</italic>: later onset asthma and obesity</td></tr><tr><td align="left" valign="bottom"><italic>2q14.3</italic></td><td align="left" valign="bottom">rs148008098</td><td align="left" valign="bottom"><italic>AMMECR1L</italic></td><td align="left" valign="bottom">c(0.96)/t</td><td align="char" char="." valign="bottom">–0.69</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="hyphen" valign="bottom">3.41E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom">Body height, blood protein; growth, bone, and heart alterations</td></tr><tr><td align="left" valign="bottom"><italic>3p24.2</italic></td><td align="left" valign="bottom">rs4072729</td><td align="left" valign="bottom"><italic>RARB</italic></td><td align="left" valign="bottom">c(0.03)/t</td><td align="char" char="." valign="bottom">0.61</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="hyphen" valign="bottom">4.20E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.23</td><td align="left" valign="bottom">FEV1/FVC, adult lung function</td></tr><tr><td align="left" valign="bottom"><italic>3q13.2</italic></td><td align="left" valign="bottom">rs145629570</td><td align="left" valign="bottom"><italic>KIAA2018, NAA50, SIDT1, CD200</italic></td><td align="left" valign="bottom">c(0.02)/t</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">0.18</td><td align="char" char="hyphen" valign="bottom">6.83E-07</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.10</td><td align="left" valign="bottom"><italic>SIDT1</italic>: FEV1/FVC; <italic>CD200</italic>: adult-onset non-allergic asthma</td></tr><tr><td align="left" valign="bottom"><italic>3q23</italic></td><td align="left" valign="bottom">rs113643470</td><td align="left" valign="bottom"><italic>TFDP2, XRN1</italic></td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.91</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="hyphen" valign="bottom">1.68E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.03</td><td align="left" valign="bottom"><italic>XRN1</italic>: eosinophil count; 3q23: allergic disease and atopic sensitisation</td></tr><tr><td align="left" valign="bottom"><italic>4</italic>p11</td><td align="left" valign="bottom">rs17472015</td><td align="left" valign="bottom"><italic>SLAIN2, SLC10A4, FRYL</italic></td><td align="left" valign="bottom">c(0.01)/t</td><td align="char" char="." valign="bottom">1.00</td><td align="char" char="." valign="bottom">0.23</td><td align="char" char="hyphen" valign="bottom">9.49E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.46</td><td align="left" valign="bottom"><italic>FRYL</italic>: body height, age at menopause</td></tr><tr><td align="left" valign="bottom" rowspan="3"><italic>7q36.1</italic></td><td align="left" valign="bottom">rs117660982</td><td align="left" valign="bottom"><italic>KRBA1, ZNF467</italic></td><td align="left" valign="bottom">g(0.97)/a</td><td align="char" char="." valign="bottom">–0.74</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom">7.63E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.18</td><td align="left" valign="bottom">Systolic blood pressure</td></tr><tr><td align="left" valign="bottom">rs118027705</td><td align="left" valign="bottom"><italic>GIMAP family, AOC1</italic></td><td align="left" valign="bottom">c(0.97)/t</td><td align="char" char="." valign="bottom">–0.77</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="hyphen" valign="bottom">6.48E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom"><italic>AOC1</italic>: CV disease, smoking; <italic>GIMAP</italic> family: autoimmune diabetes, asthma, and allergy</td></tr><tr><td align="left" valign="bottom">rs139489493</td><td align="left" valign="bottom"><italic>LOC105375566</italic></td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.95</td><td align="char" char="." valign="bottom">0.20</td><td align="char" char="hyphen" valign="bottom">2.28E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>7q36.3</italic></td><td align="left" valign="bottom">rs144271668</td><td align="left" valign="bottom"><italic>PTPRN2</italic></td><td align="left" valign="bottom">c(0.01)/a</td><td align="char" char="." valign="bottom">0.88</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="hyphen" valign="bottom">2.91E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.28</td><td align="left" valign="bottom">Eczema</td></tr><tr><td align="left" valign="bottom"><italic>8q21.3</italic></td><td align="left" valign="bottom">rs990182</td><td align="left" valign="bottom"><italic>LOC105375631</italic></td><td align="left" valign="bottom">t(0.42)/a</td><td align="char" char="." valign="bottom">0.28</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">2.57E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.46</td><td align="left" valign="bottom"><italic>8q21.3</italic>: type 1 diabetes</td></tr><tr><td align="left" valign="bottom"><italic>9p22.3</italic></td><td align="left" valign="bottom">rs79110962</td><td align="left" valign="bottom"><italic>NFIB, ZDHHC21</italic></td><td align="left" valign="bottom">c(0.08)/t</td><td align="char" char="." valign="bottom">0.51</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="hyphen" valign="bottom">3.98E-07</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.05</td><td align="left" valign="bottom"><italic>9p22.3</italic>: asthma (mean age &lt;16 years)</td></tr><tr><td align="left" valign="bottom"><italic>10q23.31</italic></td><td align="left" valign="bottom">rs7896106</td><td align="left" valign="bottom"><italic>SLC16A12, IFIT family, PANK1</italic></td><td align="left" valign="bottom">g(0.35)/t</td><td align="char" char="." valign="bottom">0.30</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">1.35E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.05</td><td align="left" valign="bottom"><italic>SLC16A12</italic>: Body height; <italic>PANK1</italic>: insulin</td></tr><tr><td align="left" valign="bottom"><italic>11q23.3</italic></td><td align="left" valign="bottom">rs141958628</td><td align="left" valign="bottom"><italic>CBL, CCDC84, MCAM</italic></td><td align="left" valign="bottom">c(0.98)/t</td><td align="char" char="." valign="bottom">–0.98</td><td align="char" char="." valign="bottom">0.20</td><td align="char" char="hyphen" valign="bottom">1.33E-06</td><td align="char" char="." valign="bottom">-+-</td><td align="char" char="." valign="bottom">0.27</td><td align="left" valign="bottom"><italic>CCDC84</italic>: asthma, allergy</td></tr><tr><td align="left" valign="bottom"><italic>15q15.3-q21.1</italic></td><td align="left" valign="bottom">rs139134265</td><td align="left" valign="bottom"><italic>SPG11, CTDSPL2</italic></td><td align="left" valign="bottom">g(0.02)/c</td><td align="char" char="." valign="bottom">0.87</td><td align="char" char="." valign="bottom">0.20</td><td align="char" char="hyphen" valign="bottom">9.11E-06</td><td align="char" char="." valign="bottom">+-+</td><td align="char" char="." valign="bottom">0.13</td><td align="left" valign="bottom"><italic>CTDSPL2</italic>: alcohol drinking</td></tr><tr><td align="left" valign="bottom"><italic>15q25.2</italic></td><td align="left" valign="bottom">rs143862030</td><td align="left" valign="bottom"><italic>ADAMTSL3, GOLGA6L4, UBE2Q2P8</italic></td><td align="left" valign="bottom">c(0.04)/t</td><td align="char" char="." valign="bottom">0.64</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="hyphen" valign="bottom">1.65E-06</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">0.08</td><td align="left" valign="bottom"><italic>ADAMTSL3</italic>: FEV1/FVC; lean mass</td></tr><tr><td align="left" valign="bottom"><italic>16p13.3</italic></td><td align="left" valign="bottom">rs113390367</td><td align="left" valign="bottom"><italic>SSTR5-AS1, CACNA1H</italic></td><td align="left" valign="bottom">g(0.86)/a</td><td align="char" char="." valign="bottom">–0.40</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="hyphen" valign="bottom">1.04E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.16</td><td align="left" valign="bottom"><italic>CACNA1H</italic>: eosinophil count</td></tr><tr><td align="left" valign="bottom"><italic>16p12.1</italic></td><td align="left" valign="bottom">rs4788025</td><td align="left" valign="bottom"><italic>GSG1L</italic></td><td align="left" valign="bottom">g(0.46)/a</td><td align="char" char="." valign="bottom">–0.30</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="hyphen" valign="bottom">7.99E-07</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.19</td><td align="left" valign="bottom"><italic>16p12.1</italic>: current asthma and rhino-conjunctivitis at 10–15 years</td></tr><tr><td align="left" valign="bottom"><italic>22q13.32</italic></td><td align="left" valign="bottom">rs133498</td><td align="left" valign="bottom"><italic>FAM19A5 or TAFA5</italic></td><td align="left" valign="bottom">g(0.94)/a</td><td align="char" char="." valign="bottom">–0.48</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="hyphen" valign="bottom">5.35E-06</td><td align="char" char="hyphen" valign="bottom">---</td><td align="char" char="." valign="bottom">0.84</td><td align="left" valign="bottom">Obesity and metabolic dysfunction</td></tr></tbody></table><table-wrap-foot><fn><p>eQTL: identified in expression analyses of whole blood and/or lung tissues using Genotype-Tissue Expression database (<ext-link ext-link-type="uri" xlink:href="https://gtexportal.org">https://gtexportal.org</ext-link>) using the European reference panel.</p></fn><fn><p>Bold p-values are genome-wide significant (p &lt; 5 × 10<sup>−8</sup>).</p></fn><fn id="table1fn3"><label>*</label><p>Minimum p-value across associations with the other three wheezing phenotypes, using the never/infrequent wheeze as the baseline phenotype.</p></fn><fn id="table1fn4"><label>†</label><p>List of references or sources (GeneCards, GWAS Catalog, PhenoScanner) available in <xref ref-type="table" rid="app5table1 app5table2 app5table3 app5table4">Appendix 5—tables 1–4</xref>.</p></fn></table-wrap-foot></table-wrap><p>We identified two GWAS-significant loci for early-onset persistent wheeze: 17q21, p&lt;5.5 × 10<sup>–9</sup>, and a novel locus on 9q21.13 (<italic>ANXA1</italic>), p&lt;6.7 × 10<sup>–9</sup>. The <italic>ANXA1</italic> locus was the only GWAS-significant locus that had not previously been associated with asthma or atopic traits, with one previous study showing an association with FEV<sub>1</sub>/FVC and bronchodilator response in smokers (<xref ref-type="bibr" rid="bib45">Lutz et al., 2015</xref>). <italic>ANXA1</italic> is strongly expressed in bronchial mast cells and has anti-inflammatory properties (<xref ref-type="bibr" rid="bib77">Vieira Braga et al., 2019</xref>), and may be involved in epithelial airway repair (<xref ref-type="bibr" rid="bib42">Leoni et al., 2015</xref>; <xref ref-type="table" rid="app4table1">Appendix 4—table 1</xref>). We therefore followed up top SNPs from this locus.</p></sec><sec id="s3-3"><title><italic>ANXA1</italic> locus and persistent wheeze</title><p>Two SNPs (rs75260654, the lead SNP, and rs116849664 located downstream of <italic>ANXA1</italic>) were associated with early-onset persistent wheeze at genome-wide significance (GWS), with an additional SNP rs78320984 almost reaching GWS (<xref ref-type="table" rid="app5table1">Appendix 5—table 1</xref>). These SNPs are in linkage disequilibrium (LD) with each other (<xref ref-type="fig" rid="app5fig1">Appendix 5—figure 1</xref>), but not with any other SNPs.</p><sec id="s3-3-1"><title>Promoter Capture identifies rs75260654 as the most likely causative variant</title><p>To identify the most likely causative variant, we investigated the overlap of the SNPs with PCHi-C interactions involving the <italic>ANXA1</italic> promoter in CD4+ cells in MAAS cohort subjects. Of the three SNPs, only rs75260654 overlapped a region interacting with the <italic>ANXA1</italic> promoter (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Moreover, rs75260654 overlapped a <italic>POLR2A</italic> ChIP-seq peaks and an ATAC-seq peak and active enhancer in the type II pneumocyte-derived A549 cell line. This shows that rs75260654 is located in a region directly interacting with the <italic>ANXA1</italic> promoter and is transcriptionally active in relevant cell types.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Chromatin interactions between rs75260654 and the <italic>ANXA1</italic> promoter in CD4+ cells in Manchester Asthma and Allergy Study (MAAS) <italic>rs75260654</italic> physically interacts with <italic>ANXA1</italic> promoter in CD4+ T cells and overlaps a region of active (POLR2AphosphoS2 ChIP-seq) open (ATAC-seq) chromatin in A549 cell line (lung epithelial carcinoma).</title><p>The region is also predicted to be an active enhancer (ChromHMM 18-state model) in the A549 cell type. Only ChromHMM enhancer chromatin are displayed. Yellow shaded area indicates the Promoter Capture Hi-C (PCHi-C) fragment overlapping rs75260654 (red bar) and interacting with the <italic>ANXA1</italic> promoter.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig3-v2.tif"/></fig><p>Allele frequencies of rs75260654 (MAF = 0.02) across wheeze phenotypes are shown in <xref ref-type="table" rid="app5table2">Appendix 5—table 2</xref>. Two individuals (one in MAAS and one in ALSPAC) were homozygote for the minor allele (T), and both were in the early-onset persistent wheeze class. One subject reported current wheeze and asthma through childhood, with hospitalisations for lower respiratory tract infection in the first year of life confirmed in healthcare records. The second individual reported current wheezing at 1.5, 2.5, and 8–9 years and doctor-diagnosed asthma and the use of asthma medication at 8–9 years.</p></sec><sec id="s3-3-2"><title>Rs75260654: effect on genomic features</title><p>Variant Effect Predictor (VEP) prediction shows the SNP rs75260654 (C changed to T) to be located downstream of three protein-coding transcripts of <italic>AXNA1</italic> and overlapping the known regulatory region ID ENSR00000882742 on Chromosome 9: 73,173,001–73,173,200. This region is active in the GI tract, M2 macrophages, neural progenitor cells, and trophoblasts, but is repressed in T lymphocytes including CD4+ CD25+, Treg, and CD8+ cells.</p></sec><sec id="s3-3-3"><title>Rs75260654: effect on gene expression</title><p>The effect of rs75260654 on the expression of nearby genes was investigated by browsing the eQTL GTEX data available in Ensembl. Compared to C, the T allele was found to reduce the expression of <italic>ANXA1</italic> in naïve B cells (effect size = −2.36795, p=0.01) and to increase expression in lymphoblasoid cell lines (effect size = 0.848856, pe = 0.001) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This SNP affects expression of the neighbouring gene <italic>ALDH1A1</italic> (aldehyde dehydrogenase-1 family member A1) (effect size = −2.40446, p=0.0039 in macrophages infected with <italic>Salmonella</italic>). In the eQTL catalogue<italic>,</italic> rs75260654 is identified as an eQTL of <italic>ANXA1</italic> in various immune cells (at nominal significance) including T cells, monocytes, fibroblasts, whole blood, Th2 memory cells, naïve B cells. rs75260654 is also an eQTL of <italic>ANXA1</italic> in monocytes that were stimulated with R848 (agonist of TLRs 7 and 8) and a human seasonal influenza A virus (<xref ref-type="bibr" rid="bib63">Quach et al., 2016</xref>) (at nominal significance) (<xref ref-type="table" rid="app5table3">Appendix 5—table 3</xref>). In the lung rs116849664 and rs78320984 (both in LD with rs75260654) were eQTLs of <italic>ANXA1</italic> (<xref ref-type="table" rid="app5table4">Appendix 5—table 4</xref>) as well as LINC01474 at nominal significance levels.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>eQTL <italic>ANXA1</italic> and rs75260654 across different tissue types.</title><p>Point size is proportional to -log10 p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig4-v2.tif"/></fig><p>Additional supporting evidence regarding the significance of the T-allele on the expression of these genes was provided using eQTLGene Consortium meta-analysis of 24 cohorts and 24,331 samples (<xref ref-type="bibr" rid="bib79">Võsa et al., 2018</xref>). This method reproduced the previous modest results showing a cis-eQTL effect of rs75260654 on both the <italic>ANXA1</italic> (p=6.02 × 10<sup>–23</sup>) and <italic>ALDH1A1</italic> (p=1.11 × 10<sup>–19</sup>) at FDR = 0. No significant trans-eQTLs were observed.</p></sec><sec id="s3-3-4"><title>Potential biological function of ANXA1 in asthma</title><p>Protein-protein network analysis demonstrated that <italic>ANXA1</italic> interacts directly with genes enriched for asthma (including <italic>IL4</italic> and <italic>IL13</italic>) and inflammatory regulation (<italic>NR3C1</italic>, glucocorticoid receptor) showing its significance in dysregulation of the immune response (see <xref ref-type="fig" rid="app5fig2">Appendix 5—figure 2</xref> and <xref ref-type="table" rid="app5table5">Appendix 5—table 5</xref>).</p></sec></sec><sec id="s3-4"><title>Functional studies of <italic>anxa1</italic> in a murine model</title><sec id="s3-4-1"><title>Pulmonary expression of anxa1 is modulated by aeroallergen exposure</title><p>We first analysed expression of <italic>anxa1</italic> using a model of HDM-induced allergic airway disease (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="bibr" rid="bib32">Gregory et al., 2009</xref>). Consistently, immunohistochemistry analysis revealed anxa1 protein expression increased following HDM challenge (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Anxa1 mRNA was significantly induced in lung tissue following HDM exposure (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This increase suggests that the pro-resolving <italic>anxa1</italic> may play a role in regulating the pulmonary immune response to allergen.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Annexin A1 is induced following house dust mite (HDM) challenge and mice deficient in <italic>ANXA1</italic> have exacerbated airway hyper-reactivity.</title><p>(<bold>A</bold>) Schematic of HDM allergen dosing protocol, N=4–6 per group, data representative of two animal experiments. (<bold>B, C</bold>) Immunofluorescent staining of paraffin-embedded lung tissue sections incubated with anti-annexin A1, counterstained with DAPI (N=4 per group). (<bold>D</bold>) mRNA expression of annexin A1 in lung tissue following HDM exposure, expression normalised to housekeeping gene hprt. Mice receiving HDM were analysed for changes in airway hyper-reactivity following methacholine (MCh) challenge in tracheotomised restrained mice. (<bold>E</bold>) Airway resistance at top MCh dose 100 mg/ml. (<bold>F</bold>) Eosinophils quantified in BAL, (<bold>F</bold>) T1/ST2+ lymphocytes quantified in the BAL. (<bold>H</bold>) IL-4, (<bold>I</bold>) IL-5, and (<bold>J</bold>) IL-13 quantified in lung tissue by ELISA. *p&lt;0.05 and **p&lt;0.01 relative to PBS control group by Mann-Whitney test. +p &lt; 0.05 and ++p &lt; 0.01 comparing HDM annexin A1 knock-out (KO) mice relative to HDM wildtype (WT) group by Mann-Whitney test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-fig5-v2.tif"/></fig></sec><sec id="s3-4-2"><title>Anxa1 suppresses allergen-induced airway hyperresponsiveness and type 2 inflammation</title><p>To confirm a functional role for <italic>anxa1</italic> in allergic airway disease, we exposed <italic>anxa1<sup>-/-</sup></italic> mice to intranasal HDM. Wildtype (WT) mice given HDM over 3 weeks developed significant airway hyperresponsiveness (AHR) compared to PBS control mice. Mice deficient in <italic>anxa1</italic> had significantly worse lung function (greater airway resistance) compared to WT-treated mice (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). <italic>Anxa1<sup>-/-</sup></italic> mice exhibited significantly increased airway eosinophilia and elevated numbers of Th2 lymphocytes (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). Lung tissue cytokine levels reflected the exacerbated airway Th2 inflammation, with elevation in IL-4, and significant induction of IL-5 and IL-13 (<xref ref-type="fig" rid="fig5">Figure 5H and J</xref>). Thus, <italic>anxa1</italic> deficiency results in an alteration of the pulmonary immune response, with uncontrolled eosinophilia and an exacerbation of type 2 inflammation and AHR in response to allergen. More details in Appendix 6: Functional mouse experiments.</p></sec></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Herein, we present a comprehensive description of the genetic architecture of childhood wheezing disorders. Using a novel approach applied to a unique dataset from five UK birth cohorts, we identified subsets of SNPs differentially associated across four wheezing phenotypes: early-onset persistent (44 SNPs, 19 loci), early-onset pre-school remitting (25 SNPs, 10 loci), early-onset mid-childhood remitting (33 SNPs, 9 loci), and late-onset (32 SNPs, 20 loci). We found little evidence of genetic associations spanning across different phenotypes. This suggests that genetic architecture of different wheeze phenotypes comprises a limited number of variants likely underpinning mechanisms which are shared across phenotypes, but that each phenotype is also characterised by unique phenotype-specific genetic associations. Importantly, we identified a novel locus in chr9q21 nearby <italic>ANXA1</italic> exclusively associated with early-onset persistent wheeze (p&lt;6.7 × 10<sup>–9</sup>). To identify the most likely causative variant, we investigated the overlap of the associated SNPs with PCHi-C interactions to demonstrate that SNP rs75260654 overlapped a region interacting with the <italic>ANXA1</italic> promoter. Using eQTL data, we identified that the risk allele (T) of rs75260654 associated with early-onset persistent wheeze is also associated with <italic>ANXA1</italic> expression. Further investigation of the biological function of <italic>ANXA1</italic> revealed that it interacts with genes enriched for asthma (including <italic>IL4</italic> and <italic>IL13</italic>) and inflammatory regulation (<italic>NR3C1</italic>, glucocorticoid receptor). In functional mouse experiments, anxa1 protein expression increased and anxa1 mRNA was significantly induced in lung tissue following HDM exposure, suggesting that the pro-resolving anxa1 may play a role in regulating the pulmonary immune response to allergen. Concurrently, by utilising <italic>anxa1<sup>-/-</sup></italic> deficient mice we demonstrated that loss of anxa1 results in heightened AHR and Th2 inflammation upon allergen challenge, providing important in vivo functional data to support our GWAS finding.</p><p><italic>ANXA1</italic> is a 37 kDa glycoprotein with potent anti-inflammatory and pro-resolving properties that are mediated by interaction with a specific G protein-coupled receptor FPR2 (<xref ref-type="bibr" rid="bib61">Perretti et al., 2002</xref>). This axis represents an important resolution pathway in chronic inflammatory settings such as those of rheumatoid arthritis (<xref ref-type="bibr" rid="bib18">D’Acquisto et al., 2008</xref>) and ulcerative colitis (<xref ref-type="bibr" rid="bib78">Vong et al., 2012</xref>). <italic>ANXA1</italic> belongs to the annexin family of Ca<sup>2+</sup>-dependent phospholipid-binding proteins, and through inhibition of phospholipase A2, it reduces eicosanoid production, which also contributes to its anti-inflammatory activities. Modulation of M2 macrophage phenotype is also promoted by <italic>ANXA1</italic> to attenuate tissue inflammation (<xref ref-type="bibr" rid="bib48">McArthur et al., 2020</xref>). Corticosteroids (a mainstay of asthma treatment) increase the synthesis of <italic>ANXA1</italic> (<xref ref-type="bibr" rid="bib64">Rhen and Cidlowski, 2005</xref>). Plasma <italic>ANXA1</italic> levels are significantly lower in asthmatic patients with frequent exacerbations compared to those with stable disease, suggesting a link between this mediator and disease state (<xref ref-type="bibr" rid="bib41">Lee et al., 2018</xref>). Furthermore, children with wheeze have reduced airway levels of <italic>ANXA1</italic> ( <xref ref-type="bibr" rid="bib27">Eke Gungor et al., 2014</xref>).</p><p>Previous functional studies using <italic>anxa1<sup>-/-</sup></italic> deficient mice challenged with ovalbumin showed <italic>anxa1-</italic>deficient mice to have elevated AHR compared to WT mice (<xref ref-type="bibr" rid="bib55">Ng et al., 2011</xref>). Ng et al. demonstrated that untreated <italic>anxa1</italic>-deficient mice have spontaneous AHR that predisposes them to exacerbated response to allergen (<xref ref-type="bibr" rid="bib55">Ng et al., 2011</xref>). In the current study, we demonstrated in the murine lung the induction of Anxa1 in response to HDM exposure. In addition, genetic deletion of <italic>anxa1</italic> potentiated the development of AHR and enhanced eosinophilia and markers of Th2 inflammation in mice treated with HDM, which is consistent with and extends previous reports. Of interest, in mice, <italic>anxa1</italic> expression was recently found to be characteristic of a novel cell type called the Hillock cell, which may be involved in squamous barrier function and immunomodulation (<xref ref-type="bibr" rid="bib54">Montoro et al., 2018</xref>). These data identify the ANXA1/FPR2 signalling axis as an important regulator of allergic disease, that could be manipulated for therapeutic benefit.</p><p>Our study has several limitations. By GWAS standards, our study is comparatively small and may be considered to be underpowered. The sample size may be an issue when using an aggregated definition (such as ‘doctor-diagnosed asthma’) but is less likely to be an issue when primary outcome is determined by deep phenotyping. This is indirectly confirmed in our analyses. Our primary outcome was derived through careful phenotyping over a period of more than two decades in five independent birth cohorts, and although comparatively smaller than some asthma GWASs, our study proved to be powered enough to detect previously identified key associations (e.g., chr17q21 locus). Precise phenotyping has the potential to identify new risk loci. For example, a comparatively small GWAS (1173 cases and 2522 controls) which used a specific subtype of early-onset childhood asthma with recurrent severe exacerbations as an outcome identified a functional variant in a novel susceptibility gene <italic>CDHR3</italic> (SNP rs6967330) as an associate of this disease subtype, but not of doctor-diagnosed asthma (<xref ref-type="bibr" rid="bib5">Bønnelykke et al., 2014</xref>). This important discovery was made with a considerably smaller sample size but using a more precise asthma subtype. In contrast, the largest asthma GWAS to date had an ~40-fold higher sample size (<xref ref-type="bibr" rid="bib21">Demenais et al., 2018</xref>), but reported no significant association between <italic>CDHR3</italic> and aggregated asthma diagnosis. Therefore, with careful phenotyping, smaller sample sizes may be adequately powered to identify larger effect sizes than those in large GWASs with broader outcome definitions (<xref ref-type="bibr" rid="bib68">Schoettler et al., 2019</xref>).</p><p>The importance of the precise outcome definition was highlighted in our previous studies in ALSPAC which explored genetic associates of wheeze phenotypes derived by LCA (<xref ref-type="bibr" rid="bib31">Granell et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Spycher et al., 2012</xref>). Our current findings are consistent with our earlier report suggesting that 17q21 SNPs are associated with early-onset persistent, but not with early transient or late-onset wheeze (<xref ref-type="bibr" rid="bib31">Granell et al., 2013</xref>). Further analysis using genetic prediction scores based on 10–200,000 SNPs ranked according to their associations with physician-diagnosed asthma found that the 46 highest ranked SNPs predicted persistent wheeze more strongly than doctor-diagnosed asthma (<xref ref-type="bibr" rid="bib73">Spycher et al., 2012</xref>). Finally, a candidate gene study combining data from ALSPAC and PIAMA found different associations of IL33-IL1RL1 pathway polymorphisms with different phenotypes (<xref ref-type="bibr" rid="bib67">Savenije et al., 2014</xref>).</p><p>We are cognisant that there may be a perception of the lack of replication of our GWAS findings. We would argue that direct replication is almost certainly not possible in other cohorts, as phenotypes for replication studies should be homogenous (<xref ref-type="bibr" rid="bib10">Crawford et al., 2015</xref>). However, there is a considerable heterogeneity in LCA-derived wheeze phenotypes between studies, and although phenotypes in different studies are usually designated with the same names, they differ between studies in temporal trajectories, distributions within a population, and associated risk factors (<xref ref-type="bibr" rid="bib57">Oksel et al., 2018</xref>). This heterogeneity is in part consequent on the number and the non-uniformity of the time points used, and is likely one of the factors responsible for the lack of consistent associations of discovered phenotypes with risk factors reported in previous studies (<xref ref-type="bibr" rid="bib59">Oksel et al., 2019b</xref>). This will also adversely impact the ability to identify phenotype-specific genetic associates. For example, we have previously shown that less distinct wheeze phenotypes in PIAMA were identified compared to those derived in ALSPAC (<xref ref-type="bibr" rid="bib66">Savenije et al., 2011</xref>). Thus, phenotypes that are homogeneous to those in our study almost certainly cannot readily be derived in available populations. This is exemplified in our attempted replication of <italic>ANXA1</italic> findings in PIAMA cohort (see Appendix 5: Replication of <italic>ANXA1</italic> top hits in PIAMA cohort and <xref ref-type="table" rid="app5table6">Appendix 5—table 6</xref>). In this analysis, the number of individuals assigned to persistent wheezing in PIAMA was small (<xref ref-type="bibr" rid="bib79">Võsa et al., 2018</xref>), associates of this phenotype differed to those in STELAR cohorts, and the SNPs’ imputation scores were low (&lt;0.60), which meant the conditions for replication were not met.</p><p>Our study population is of European descent, and we cannot generalise the results to different ethnicities or environments. It is important to highlight the under-representation of ethnically diverse populations in most GWASs (<xref ref-type="bibr" rid="bib38">Kim and Ober, 2019</xref>). To mitigate against this, large consortia have been formed, which combine the results of multiple ethnically diverse GWASs to increase the overall power to identify asthma susceptibility loci. Examples include the GABRIEL (<xref ref-type="bibr" rid="bib53">Moffatt et al., 2010</xref>), EVE (<xref ref-type="bibr" rid="bib76">Torgerson et al., 2011</xref>), and TAGC (<xref ref-type="bibr" rid="bib21">Demenais et al., 2018</xref>) consortia, and the value of diverse, multiethnic participants in large-scale genomic studies has recently been shown (<xref ref-type="bibr" rid="bib83">Wojcik et al., 2019</xref>). However, such consortia do not have the depth of longitudinal data to allow the type of analyses which we carried out to derive a multivariable primary outcome. Finally, the manual and visual inspection of LZPs for the refinement of association signals and identification of functional elements was an objective approach which might have undermined the findings. One strength of our approach is that we used data from five birth cohorts with detailed and lifelong phenotyping, which were harmonised in a common knowledge management platform (<xref ref-type="bibr" rid="bib15">Custovic et al., 2015</xref>), allowing joint analyses. We performed three parallel GWASs that produced estimates with remarkably consistent directions of effects.</p><p>In conclusion, using unique data from five UK birth cohorts, we identified subsets of SNPs differentially associated across four wheezing phenotypes from infancy to adolescence. We found little evidence of genetic associations spanning across different phenotypes. We discovered a novel locus in chr9q21 uniquely associated with early-onset persistent wheeze (p&lt;6.7 × 10<sup>–9</sup>), identified SNP rs75260654 as the most likely causative variant, and demonstrated that the risk allele (T) confers a reduction in <italic>ANXA1</italic> expression. In mouse experiments, <italic>ANXA1</italic> expression increased in lung tissue following allergen exposure, suggesting that the pro-resolving ANXA1 may play a role in regulating the pulmonary immune response to allergen. Using <italic>ANXA1</italic>-deficient mice, we demonstrated that loss of <italic>ANXA1</italic> results in heightened AHR and Th2 inflammation upon allergen challenge, providing important in vivo functional data to support our GWAS finding. Targeting these pathways to promote the clearance of chronic inflammation in persistent disease may represent an exciting therapeutic prospect.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>MRC grant to my institution; President of the British Society of Allergy and Clinical Immunology</p></fn><fn fn-type="COI-statement" id="conf3"><p>Dutch Lung Foundation, Ubbo Emmius Foundation (Money to insititution); Dutch Lung Foundation, Vertex, TEVA the Netherlands, GSK, ZON-MW (VICI grant), European Union (Money to institution); Astra Zeneca, Pure IMS, GSK (Money to institution); Sanofi, Boehringer Ingelheim (Money to institution)</p></fn><fn fn-type="COI-statement" id="conf4"><p>Medical research council Research grant; JP Moulton Charitable Foundation Research grant; Asthma UK Research grant</p></fn><fn fn-type="COI-statement" id="conf5"><p>has received grants from Asthma Uk, the National Institute for Health Research, the Moulton Charitable Foundation and the North West Lung Centre Charity (to the Institution). They received lecture fees from GSK and Novartis, and received a travel grant from Sanofi. The authors has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf6"><p>Wellcome Trust 107059/Z/15/Z</p></fn><fn fn-type="COI-statement" id="conf7"><p>Medial Research Council grant MR/S025340/1 (to institution); American Academy of Allergy Asthma and Immunology (AAAI) (Support for speaker travel to AAAAI annual congress)</p></fn><fn fn-type="COI-statement" id="conf8"><p>MRC (research grants); EPSRC (research grant); Wellcome Trust (research grant); Worg Pharmaceoticals (Personal payment)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing, Contributed to interpretation of results, Post-gwas analyses</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing, Contributed to work related to mouse models</p></fn><fn fn-type="con" id="con6"><p>Writing – original draft, Writing – review and editing, Contributed to work related to mouse models</p></fn><fn fn-type="con" id="con7"><p>Writing – review and editing, Contributed to work related to mouse models</p></fn><fn fn-type="con" id="con8"><p>Visualization, Writing – review and editing, Contributed to interpretation of results post-gwas</p></fn><fn fn-type="con" id="con9"><p>Writing – review and editing, Designed and carried out the HiC work</p></fn><fn fn-type="con" id="con10"><p>Writing – review and editing, Contributed to work related to mouse models</p></fn><fn fn-type="con" id="con11"><p>Writing – review and editing, Replication in PIAMA</p></fn><fn fn-type="con" id="con12"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Writing – review and editing, Replication in PIAMA</p></fn><fn fn-type="con" id="con17"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Writing – review and editing, Contributed to work related to mouse models</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – original draft</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>ALSPAC: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. All self-completion questionnaire content is approved by the ALSPAC Ethics and Law Committee. Bristol and Weston Health Authority: E1808 Children of the Nineties: Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC). (28th November 1989); Southmead Health Authority: 49/89 Children of the Nineties -&quot;ALSPAC&quot;. (5th April 1990); Frenchay Health Authority: 90/8 Children of the Nineties. (28th June 1990).MAAS: The study was approved by the North West - Greater Manchester East Research Ethics Committee. ERP/94/032 Up to 5 yrs. Allergen avoidance, Primary Prevention, genetics, sRaw age 3 and 5; SOU/00/259 5 year; ERP/95/137 Exposure to pet allergens, atopy, genetics; ERP/97/023 IFWIN, genetics; 03/SM/400 8 year; 06/Q1403/142 10-12 years; 11/NW/0228 13-15 years; 14/NW/1309 18+ years.SEATON: The study was approved by the North of Scotland Research Ethics Committee. REC reference: 13/NS/0108; Protocol number: 2/048/13; Amendment number: AM03.Ashford: The Asthma in Ashford study was reviewed by the Imperial College Research Ethics Committee on 11/11/2014. On 08/01/2015 the Joint Research Compliance Office granted full approval of the study on the basis described in the revised documents. ICREC reference: 14|C2288.IOW: Ethics approval for the IoW cohort was originally given by the Isle of Wight local research ethics committee in 1989 and at each subsequent follow up (1,2 and 4 years) (this is pre &quot;numbers&quot;)Age 10 follow up (including DNA and genotyping): Isle of Wight Health Authority Local Research Ethics Committee 18/98. Age 18 Follow up(including DNA and genotyping): Isle of Wight, Portsmouth &amp; South East Hampshire Research Ethics Committee 06/Q1701/34.</p></fn><fn fn-type="other"><p>In accordance with the Animals (scientific procedures) act 1986, all animal experiments were conducted under the approved UK Home Office Project License No: PPL 70/7643, reviewed by Imperial College's Animal Welfare and Ethical Review body.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84315-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STROBE flowchart.</title></caption><media xlink:href="elife-84315-repstand1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The informed consent obtained from all included participants does not allow the data to be made freely available through any third party maintained public repository. However, data used for this submission can be made available on request to the corresponding cohort Executive. Researchers will need to submit a research proposal to each cohort Executive Committee. Data access will have a cost, for more details re. ALSPAC contact alspac-data@bristol.ac.uk, for any other cohort contact philip.couch@manchester.ac.uk.The ALSPAC website provides information on how to request and access its data (<ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/researchers/access/">http://www.bristol.ac.uk/alspac/researchers/access/</ext-link>). For queries regarding access of data from MAAS, IoW, SEATON or Ashford please contact Philip Couch (philip.couch@manchester.ac.uk). All code used to analyse the individual level data and all summary data and code used to plot the figures in our manuscript has been deposited in Dryad.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Granell</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>A meta-analysis of genome-wide association studies of childhood wheezing phenotypes identifies ANXA1 as a susceptibility locus for persistent wheezing (GWAS ANXA1)</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.3r2280gm3</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>STELAR/UNICORN investigators: Professor Graham Devereux, Dr Dimitrios Charalampopoulos. Breathing Together investigators: Prof Andrew Bush, Prof Sejal Saglani, Prof Benjamin Marsland, Prof Jonathan Grigg, Prof Jurgen Schwarze, Prof Mike Shields, Prof Peter Ghazal, Prof Ultan Power, Dr Ceyda Oksel.</p><p>Supported by the UK Medical Research Council (MRC) Programme Grant MR/S025340/1, the Wellcome Trust (WT) Strategic Award (108818/15/Z) and a WT Senior Fellowship to CML (107059/Z/15/Z). The MRC and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).</p><p>PIAMA was funded by the Netherlands Lung Foundation (grant 3.4.01.26, 3.2.06.022, 3.4.09.081 and 3.2.10.085CO), the ZON-MW Netherlands Organization for Health Research and Development (grant 912-03-031), the Stichting Astmabestrijding and the Ministry of the Environment. Genome-wide genotyping was funded by the European Commission as part of GABRIEL (grant number 018996) and a grant from BBMRI-NL (CP 29). GHK is supported by a ZON-MW VICI grant.</p><p>For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaron</surname><given-names>SD</given-names></name><name><surname>Vandemheen</surname><given-names>KL</given-names></name><name><surname>FitzGerald</surname><given-names>JM</given-names></name><name><surname>Ainslie</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Lemière</surname><given-names>C</given-names></name><name><surname>Field</surname><given-names>SK</given-names></name><name><surname>McIvor</surname><given-names>RA</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Mayers</surname><given-names>I</given-names></name><name><surname>Mulpuru</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>GG</given-names></name><name><surname>Pakhale</surname><given-names>S</given-names></name><name><surname>Mallick</surname><given-names>R</given-names></name><name><surname>Boulet</surname><given-names>L-P</given-names></name><collab>Canadian Respiratory Research Network</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Reevaluation of diagnosis in adults with physician-diagnosed asthma</article-title><source>JAMA</source><volume>317</volume><fpage>269</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.19627</pub-id><pub-id pub-id-type="pmid">28114551</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Adsera</surname><given-names>CB</given-names></name><name><surname>Park</surname><given-names>YP</given-names></name><name><surname>Meuleman</surname><given-names>W</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrative analysis of 10,000 epigenomic maps across 800 samples for regulatory genomics and disease dissection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/810291</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshad</surname><given-names>SH</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Karmaus</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ewart</surname><given-names>S</given-names></name><name><surname>Mansfield</surname><given-names>L</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Hodgekiss</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Kurukulaaratchy</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cohort profile: the Isle of Wight Whole Population Birth Cohort (IOWBC)</article-title><source>International Journal of Epidemiology</source><volume>47</volume><fpage>1043</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy023</pub-id><pub-id pub-id-type="pmid">29547889</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>W</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Mills</surname><given-names>P</given-names></name><name><surname>Moffat</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Lynch</surname><given-names>O</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Newman Taylor</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Domestic aeroallergen exposures among infants in an English town</article-title><source>The European Respiratory Journal</source><volume>13</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1183/09031936.99.13358599</pub-id><pub-id pub-id-type="pmid">10232430</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bønnelykke</surname><given-names>K</given-names></name><name><surname>Sleiman</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>K</given-names></name><name><surname>Kreiner-Møller</surname><given-names>E</given-names></name><name><surname>Mercader</surname><given-names>JM</given-names></name><name><surname>Belgrave</surname><given-names>D</given-names></name><name><surname>den Dekker</surname><given-names>HT</given-names></name><name><surname>Husby</surname><given-names>A</given-names></name><name><surname>Sevelsted</surname><given-names>A</given-names></name><name><surname>Faura-Tellez</surname><given-names>G</given-names></name><name><surname>Mortensen</surname><given-names>LJ</given-names></name><name><surname>Paternoster</surname><given-names>L</given-names></name><name><surname>Flaaten</surname><given-names>R</given-names></name><name><surname>Mølgaard</surname><given-names>A</given-names></name><name><surname>Smart</surname><given-names>DE</given-names></name><name><surname>Thomsen</surname><given-names>PF</given-names></name><name><surname>Rasmussen</surname><given-names>MA</given-names></name><name><surname>Bonàs-Guarch</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>C</given-names></name><name><surname>Nohr</surname><given-names>EA</given-names></name><name><surname>Yadav</surname><given-names>R</given-names></name><name><surname>March</surname><given-names>ME</given-names></name><name><surname>Blicher</surname><given-names>T</given-names></name><name><surname>Lackie</surname><given-names>PM</given-names></name><name><surname>Jaddoe</surname><given-names>VWV</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Duijts</surname><given-names>L</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>DE</given-names></name><name><surname>Torrents</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Hollegaard</surname><given-names>MV</given-names></name><name><surname>Hougaard</surname><given-names>DM</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Bisgaard</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A genome-wide association study identifies Cdhr3 as a susceptibility locus for early childhood asthma with severe exacerbations</article-title><source>Nature Genetics</source><volume>46</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/ng.2830</pub-id><pub-id pub-id-type="pmid">24241537</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Golding</surname><given-names>J</given-names></name><name><surname>Macleod</surname><given-names>J</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Fraser</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Molloy</surname><given-names>L</given-names></name><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cohort profile: the 'children of the 90S'--The index offspring of the Avon Longitudinal Study of Parents and Children</article-title><source>International Journal of Epidemiology</source><volume>42</volume><fpage>111</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/ije/dys064</pub-id><pub-id pub-id-type="pmid">22507743</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branchett</surname><given-names>WJ</given-names></name><name><surname>Walker</surname><given-names>SA</given-names></name><name><surname>Lloyd</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Experimental mouse models of asthma and analysis of Cd4 T cells</article-title><source>Methods in Molecular Biology</source><volume>2285</volume><fpage>329</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1311-5_25</pub-id><pub-id pub-id-type="pmid">33928563</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunekreef</surname><given-names>B</given-names></name><name><surname>Smit</surname><given-names>J</given-names></name><name><surname>de Jongste</surname><given-names>J</given-names></name><name><surname>Neijens</surname><given-names>H</given-names></name><name><surname>Gerritsen</surname><given-names>J</given-names></name><name><surname>Postma</surname><given-names>D</given-names></name><name><surname>Aalberse</surname><given-names>R</given-names></name><name><surname>Koopman</surname><given-names>L</given-names></name><name><surname>Kerkhof</surname><given-names>M</given-names></name><name><surname>Wilga</surname><given-names>A</given-names></name><name><surname>van Strien</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The prevention and incidence of asthma and mite allergy (PIAMA) birth cohort study: design and first results</article-title><source>Pediatric Allergy and Immunology</source><volume>13</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3038.13.s.15.1.x</pub-id><pub-id pub-id-type="pmid">12688626</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>J</given-names></name><name><surname>Freire-Pritchett</surname><given-names>P</given-names></name><name><surname>Wingett</surname><given-names>SW</given-names></name><name><surname>Varnai</surname><given-names>C</given-names></name><name><surname>Dimond</surname><given-names>A</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Zerbino</surname><given-names>D</given-names></name><name><surname>Schoenfelder</surname><given-names>S</given-names></name><name><surname>Javierre</surname><given-names>BM</given-names></name><name><surname>Osborne</surname><given-names>C</given-names></name><name><surname>Fraser</surname><given-names>P</given-names></name><name><surname>Spivakov</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>127</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0992-2</pub-id><pub-id pub-id-type="pmid">27306882</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Cezard</surname><given-names>G</given-names></name><name><surname>Chappell</surname><given-names>FM</given-names></name><name><surname>Murray</surname><given-names>GD</given-names></name><name><surname>Price</surname><given-names>JF</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>CR</given-names></name><name><surname>Stansby</surname><given-names>GP</given-names></name><name><surname>Young</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the International research collaboration for the prediction of diabetic foot ulcerations (PODUS)</article-title><source>Health Technology Assessment</source><volume>19</volume><fpage>1</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.3310/hta19570</pub-id><pub-id pub-id-type="pmid">26211920</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>MacNeill</surname><given-names>SJ</given-names></name><name><surname>Harris</surname><given-names>JM</given-names></name><name><surname>Moffat</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>P</given-names></name><name><surname>Newman Taylor</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study</article-title><source>Thorax</source><volume>59</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1136/thx.2003.019877</pub-id><pub-id pub-id-type="pmid">15454651</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusanovich</surname><given-names>DA</given-names></name><name><surname>Billstrand</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chavarria</surname><given-names>C</given-names></name><name><surname>De Leon</surname><given-names>S</given-names></name><name><surname>Michelini</surname><given-names>K</given-names></name><name><surname>Pai</surname><given-names>AA</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Gilad</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>2111</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds021</pub-id><pub-id pub-id-type="pmid">22286170</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>BM</given-names></name><name><surname>Murray</surname><given-names>CS</given-names></name><name><surname>Lowe</surname><given-names>L</given-names></name><name><surname>Woodcock</surname><given-names>A</given-names></name><name><surname>Asthma</surname><given-names>N</given-names></name><name><surname>Allergy Study</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The National Asthma Campaign Manchester Asthma and Allergy Study</article-title><source>Pediatric Allergy and Immunology</source><volume>13</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3038.13.s.15.3.x</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Marinho</surname><given-names>S</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gene-environment interactions in the development of asthma and atopy</article-title><source>Expert Review of Respiratory Medicine</source><volume>6</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1586/ers.12.24</pub-id><pub-id pub-id-type="pmid">22788944</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Ainsworth</surname><given-names>J</given-names></name><name><surname>Arshad</surname><given-names>H</given-names></name><name><surname>Bishop</surname><given-names>C</given-names></name><name><surname>Buchan</surname><given-names>I</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Devereux</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Holloway</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Turner</surname><given-names>S</given-names></name><name><surname>Woodcock</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together</article-title><source>Thorax</source><volume>70</volume><fpage>799</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-206781</pub-id><pub-id pub-id-type="pmid">25805205</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Does understanding endotypes translate to better asthma management options for all</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>144</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.05.016</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custovic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>“Asthma” or “Asthma Spectrum Disorder”?</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>8</volume><fpage>2628</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.06.005</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Acquisto</surname><given-names>F</given-names></name><name><surname>Paschalidis</surname><given-names>N</given-names></name><name><surname>Raza</surname><given-names>K</given-names></name><name><surname>Buckley</surname><given-names>CD</given-names></name><name><surname>Flower</surname><given-names>RJ</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Glucocorticoid treatment inhibits Annexin-1 expression in rheumatoid arthritis Cd4+ T cells</article-title><source>Rheumatology</source><volume>47</volume><fpage>636</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ken062</pub-id><pub-id pub-id-type="pmid">18390587</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>SE</given-names></name><name><surname>Bhattacharrya</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>A</given-names></name><name><surname>Leaves</surname><given-names>NI</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>MR</given-names></name><name><surname>Faux</surname><given-names>JA</given-names></name><name><surname>Ryan</surname><given-names>GF</given-names></name><name><surname>le Söuef</surname><given-names>PN</given-names></name><name><surname>Lathrop</surname><given-names>GM</given-names></name><name><surname>Musk</surname><given-names>AW</given-names></name><name><surname>Cookson</surname><given-names>WO</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A genome-wide search for quantitative trait loci underlying asthma</article-title><source>Nature</source><volume>383</volume><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/383247a0</pub-id><pub-id pub-id-type="pmid">8805698</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayem Ullah</surname><given-names>AZ</given-names></name><name><surname>Oscanoa</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nagano</surname><given-names>A</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Chelala</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Snpnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W109</fpage><lpage>W113</lpage><pub-id pub-id-type="doi">10.1093/nar/gky399</pub-id><pub-id pub-id-type="pmid">29757393</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demenais</surname><given-names>F</given-names></name><name><surname>Margaritte-Jeannin</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Cookson</surname><given-names>WOC</given-names></name><name><surname>Altmüller</surname><given-names>J</given-names></name><name><surname>Ang</surname><given-names>W</given-names></name><name><surname>Barr</surname><given-names>RG</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Becker</surname><given-names>AB</given-names></name><name><surname>Beilby</surname><given-names>J</given-names></name><name><surname>Bisgaard</surname><given-names>H</given-names></name><name><surname>Bjornsdottir</surname><given-names>US</given-names></name><name><surname>Bleecker</surname><given-names>E</given-names></name><name><surname>Bønnelykke</surname><given-names>K</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Bouzigon</surname><given-names>E</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Brossard</surname><given-names>M</given-names></name><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Burchard</surname><given-names>E</given-names></name><name><surname>Burkart</surname><given-names>KM</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Couto Alves</surname><given-names>A</given-names></name><name><surname>Curtin</surname><given-names>JA</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Daley</surname><given-names>D</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name><name><surname>Del-Rio-Navarro</surname><given-names>BE</given-names></name><name><surname>Donohue</surname><given-names>KM</given-names></name><name><surname>Duijts</surname><given-names>L</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Fedorova</surname><given-names>Y</given-names></name><name><surname>Feenstra</surname><given-names>B</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><collab>Australian Asthma Genetics Consortium (AAGC) collaborators</collab><name><surname>Freidin</surname><given-names>MB</given-names></name><name><surname>Gajdos</surname><given-names>Z</given-names></name><name><surname>Gauderman</surname><given-names>J</given-names></name><name><surname>Gehring</surname><given-names>U</given-names></name><name><surname>Geller</surname><given-names>F</given-names></name><name><surname>Genuneit</surname><given-names>J</given-names></name><name><surname>Gharib</surname><given-names>SA</given-names></name><name><surname>Gilliland</surname><given-names>F</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Graves</surname><given-names>PE</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Heederik</surname><given-names>D</given-names></name><name><surname>Heinrich</surname><given-names>J</given-names></name><name><surname>Heliövaara</surname><given-names>M</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Himes</surname><given-names>BE</given-names></name><name><surname>Hirose</surname><given-names>H</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Holt</surname><given-names>P</given-names></name><name><surname>Hottenga</surname><given-names>J</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Imboden</surname><given-names>M</given-names></name><name><surname>Ivanov</surname><given-names>V</given-names></name><name><surname>Jaddoe</surname><given-names>VWV</given-names></name><name><surname>James</surname><given-names>A</given-names></name><name><surname>Janson</surname><given-names>C</given-names></name><name><surname>Jarvelin</surname><given-names>M-R</given-names></name><name><surname>Jarvis</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Jonsdottir</surname><given-names>I</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><name><surname>Kähönen</surname><given-names>M</given-names></name><name><surname>Kantor</surname><given-names>DB</given-names></name><name><surname>Karunas</surname><given-names>AS</given-names></name><name><surname>Khusnutdinova</surname><given-names>E</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>Kozyrskyj</surname><given-names>AL</given-names></name><name><surname>Kreiner</surname><given-names>E</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kuokkanen</surname><given-names>M</given-names></name><name><surname>Lahousse</surname><given-names>L</given-names></name><name><surname>Laitinen</surname><given-names>T</given-names></name><name><surname>Laprise</surname><given-names>C</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>Y-A</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Letort</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Loehr</surname><given-names>LR</given-names></name><name><surname>London</surname><given-names>SJ</given-names></name><name><surname>Loth</surname><given-names>DW</given-names></name><name><surname>Manichaikul</surname><given-names>A</given-names></name><name><surname>Marenholz</surname><given-names>I</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Matheson</surname><given-names>MC</given-names></name><name><surname>Mathias</surname><given-names>RA</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Mbarek</surname><given-names>H</given-names></name><name><surname>McArdle</surname><given-names>WL</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Melén</surname><given-names>E</given-names></name><name><surname>Meyers</surname><given-names>D</given-names></name><name><surname>Michel</surname><given-names>S</given-names></name><name><surname>Mohamdi</surname><given-names>H</given-names></name><name><surname>Musk</surname><given-names>AW</given-names></name><name><surname>Myers</surname><given-names>RA</given-names></name><name><surname>Nieuwenhuis</surname><given-names>MAE</given-names></name><name><surname>Noguchi</surname><given-names>E</given-names></name><name><surname>O’Connor</surname><given-names>GT</given-names></name><name><surname>Ogorodova</surname><given-names>LM</given-names></name><name><surname>Palmer</surname><given-names>CD</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Pennell</surname><given-names>CE</given-names></name><name><surname>Pershagen</surname><given-names>G</given-names></name><name><surname>Polonikov</surname><given-names>A</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Probst-Hensch</surname><given-names>N</given-names></name><name><surname>Puzyrev</surname><given-names>VP</given-names></name><name><surname>Raby</surname><given-names>BA</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Salam</surname><given-names>MT</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Schlünssen</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Selivanova</surname><given-names>PA</given-names></name><name><surname>Sigsgaard</surname><given-names>T</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Siroux</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>LJ</given-names></name><name><surname>Solodilova</surname><given-names>M</given-names></name><name><surname>Standl</surname><given-names>M</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>PJ</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Tiesler</surname><given-names>CMT</given-names></name><name><surname>Torgerson</surname><given-names>DG</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>van der Valk</surname><given-names>RJP</given-names></name><name><surname>Vaysse</surname><given-names>A</given-names></name><name><surname>Vedantam</surname><given-names>S</given-names></name><name><surname>von Berg</surname><given-names>A</given-names></name><name><surname>von Mutius</surname><given-names>E</given-names></name><name><surname>Vonk</surname><given-names>JM</given-names></name><name><surname>Waage</surname><given-names>J</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Wickman</surname><given-names>M</given-names></name><name><surname>Widén</surname><given-names>E</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>LK</given-names></name><name><surname>Wouters</surname><given-names>IM</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Zhao</surname><given-names>JH</given-names></name><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks</article-title><source>Nature Genetics</source><volume>50</volume><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/s41588-017-0014-7</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denham</surname><given-names>S</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>Blakey</surname><given-names>J</given-names></name><name><surname>Wjst</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Hall</surname><given-names>IP</given-names></name><name><surname>Sayers</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Meta-analysis of genome-wide linkage studies of asthma and related traits</article-title><source>Respiratory Research</source><volume>9</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/1465-9921-9-38</pub-id><pub-id pub-id-type="pmid">18442398</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>DL</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Battistutta</surname><given-names>D</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Mathews</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Genetics of asthma and hay fever in Australian twins</article-title><source>The American Review of Respiratory Disease</source><volume>142</volume><fpage>1351</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/142.6_Pt_1.1351</pub-id><pub-id pub-id-type="pmid">2252253</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficient haplotype matching and storage using the positional Burrows-Wheeler transform (PBWT)</article-title><source>Bioinformatics</source><volume>30</volume><fpage>1266</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu014</pub-id><pub-id pub-id-type="pmid">24413527</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Biomart and Bioconductor: a powerful link between biological databases and Microarray data analysis</article-title><source>Bioinformatics</source><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti525</pub-id><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.97</pub-id><pub-id pub-id-type="pmid">19617889</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eke Gungor</surname><given-names>H</given-names></name><name><surname>Tahan</surname><given-names>F</given-names></name><name><surname>Gokahmetoglu</surname><given-names>S</given-names></name><name><surname>Saraymen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Decreased levels of Lipoxin A4 and Annexin A1 in wheezy infants</article-title><source>International Archives of Allergy and Immunology</source><volume>163</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1159/000358490</pub-id><pub-id pub-id-type="pmid">24525704</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Husseini</surname><given-names>ZW</given-names></name><name><surname>Gosens</surname><given-names>R</given-names></name><name><surname>Dekker</surname><given-names>F</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Genetics of asthma and the promise of genomics-guided drug target discovery</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>1045</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30363-5</pub-id><pub-id pub-id-type="pmid">32910899</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>A</given-names></name><name><surname>Macdonald-Wallis</surname><given-names>C</given-names></name><name><surname>Tilling</surname><given-names>K</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Golding</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Macleod</surname><given-names>J</given-names></name><name><surname>Molloy</surname><given-names>L</given-names></name><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>SM</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort</article-title><source>International Journal of Epidemiology</source><volume>42</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1093/ije/dys066</pub-id><pub-id pub-id-type="pmid">22507742</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golding</surname><given-names>J</given-names></name><name><surname>Pembrey</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><collab>ALSPAC Study Team</collab></person-group><year iso-8601-date="2001">2001</year><article-title>ALSPAC–The Avon Longitudinal Study of Parents and Children</article-title><source>Paediatric and Perinatal Epidemiology</source><volume>15</volume><fpage>74</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3016.2001.00325.x</pub-id><pub-id pub-id-type="pmid">11237119</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Henderson</surname><given-names>AJ</given-names></name><name><surname>Timpson</surname><given-names>N</given-names></name><name><surname>St. Pourcain</surname><given-names>B</given-names></name><name><surname>Kemp</surname><given-names>JP</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Montgomery</surname><given-names>SB</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Examination of the relationship between variation at 17Q21 and childhood wheeze phenotypes</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>131</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.09.021</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>LG</given-names></name><name><surname>Causton</surname><given-names>B</given-names></name><name><surname>Murdoch</surname><given-names>JR</given-names></name><name><surname>Mathie</surname><given-names>SA</given-names></name><name><surname>O’Donnell</surname><given-names>V</given-names></name><name><surname>Thomas</surname><given-names>CP</given-names></name><name><surname>Priest</surname><given-names>FM</given-names></name><name><surname>Quint</surname><given-names>DJ</given-names></name><name><surname>Lloyd</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhaled House dust mite induces pulmonary T helper 2 cytokine production</article-title><source>Clinical and Experimental Allergy</source><volume>39</volume><fpage>1597</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2009.03302.x</pub-id><pub-id pub-id-type="pmid">19545261</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Curtin</surname><given-names>J</given-names></name><name><surname>Fontanella</surname><given-names>S</given-names></name><name><surname>Cucco</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>S</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Murray</surname><given-names>CS</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Devereux</surname><given-names>G</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Arshad</surname><given-names>SH</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Modeling wheezing spells identifies phenotypes with different outcomes and genetic associates</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>205</volume><fpage>883</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1164/rccm.202108-1821OC</pub-id><pub-id pub-id-type="pmid">35050846</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinonen</surname><given-names>MT</given-names></name><name><surname>Laine</surname><given-names>A-P</given-names></name><name><surname>Söderhäll</surname><given-names>C</given-names></name><name><surname>Gruzieva</surname><given-names>O</given-names></name><name><surname>Rautio</surname><given-names>S</given-names></name><name><surname>Melén</surname><given-names>E</given-names></name><name><surname>Pershagen</surname><given-names>G</given-names></name><name><surname>Lähdesmäki</surname><given-names>HJ</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><name><surname>Henttinen</surname><given-names>TA</given-names></name><name><surname>Kere</surname><given-names>J</given-names></name><name><surname>Lahesmaa</surname><given-names>R</given-names></name><collab>Finnish Pediatric Diabetes Registry</collab></person-group><year iso-8601-date="2015">2015</year><article-title>GIMAP GTPase family genes: potential modifiers in autoimmune diabetes, asthma, and allergy</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>5885</fpage><lpage>5894</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500016</pub-id><pub-id pub-id-type="pmid">25964488</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera‐Luis</surname><given-names>E</given-names></name><name><surname>Espuela‐Ortiz</surname><given-names>A</given-names></name><name><surname>Lorenzo‐Diaz</surname><given-names>F</given-names></name><name><surname>Keys</surname><given-names>KL</given-names></name><name><surname>Mak</surname><given-names>ACY</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Huntsman</surname><given-names>S</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Rodriguez‐Santana</surname><given-names>JR</given-names></name><name><surname>Burchard</surname><given-names>EG</given-names></name><name><surname>Pino‐Yanes</surname><given-names>M</given-names></name><name><surname>Genuneit</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-wide association study reveals a novel locus for asthma with severe exacerbations in diverse populations</article-title><source>Pediatric Allergy and Immunology</source><volume>32</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/pai.13337</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Rattray</surname><given-names>M</given-names></name><name><surname>Prosperi</surname><given-names>M</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinguishing asthma phenotypes using machine learning approaches</article-title><source>Current Allergy and Asthma Reports</source><volume>15</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1007/s11882-015-0542-0</pub-id><pub-id pub-id-type="pmid">26143394</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihaka</surname><given-names>R</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>R: A language for data analysis and graphics</article-title><source>Journal of Computational and Graphical Statistics</source><volume>5</volume><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1080/10618600.1996.10474713</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lessons learned from GWAS of asthma</article-title><source>Allergy, Asthma &amp; Immunology Research</source><volume>11</volume><elocation-id>170</elocation-id><pub-id pub-id-type="doi">10.4168/aair.2019.11.2.170</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurukulaaratchy</surname><given-names>RJ</given-names></name><name><surname>Fenn</surname><given-names>M</given-names></name><name><surname>Twiselton</surname><given-names>R</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Arshad</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The prevalence of asthma and wheezing illnesses amongst 10-year-old schoolchildren</article-title><source>Respiratory Medicine</source><volume>96</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1053/rmed.2001.1236</pub-id><pub-id pub-id-type="pmid">11905550</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurukulaaratchy</surname><given-names>RJ</given-names></name><name><surname>Fenn</surname><given-names>MH</given-names></name><name><surname>Waterhouse</surname><given-names>LM</given-names></name><name><surname>Matthews</surname><given-names>SM</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Arshad</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Characterization of wheezing phenotypes in the first 10 years of life</article-title><source>Clinical and Experimental Allergy</source><volume>33</volume><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2003.01657.x</pub-id><pub-id pub-id-type="pmid">12752584</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Kim</surname><given-names>BG</given-names></name><name><surname>Seo</surname><given-names>HJ</given-names></name><name><surname>Baek</surname><given-names>AR</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Jang</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Annexin A1 in plasma from patients with bronchial asthma: its association with lung function</article-title><source>BMC Pulmonary Medicine</source><volume>18</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/s12890-017-0557-5</pub-id><pub-id pub-id-type="pmid">29301525</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leoni</surname><given-names>G</given-names></name><name><surname>Neumann</surname><given-names>PA</given-names></name><name><surname>Kamaly</surname><given-names>N</given-names></name><name><surname>Quiros</surname><given-names>M</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>HR</given-names></name><name><surname>Sumagin</surname><given-names>R</given-names></name><name><surname>Hilgarth</surname><given-names>RS</given-names></name><name><surname>Alam</surname><given-names>A</given-names></name><name><surname>Fredman</surname><given-names>G</given-names></name><name><surname>Argyris</surname><given-names>I</given-names></name><name><surname>Rijcken</surname><given-names>E</given-names></name><name><surname>Kusters</surname><given-names>D</given-names></name><name><surname>Reutelingsperger</surname><given-names>C</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Parkos</surname><given-names>CA</given-names></name><name><surname>Farokhzad</surname><given-names>OC</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>1215</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1172/JCI76693</pub-id><pub-id pub-id-type="pmid">25664854</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>P-R</given-names></name><name><surname>Danecek</surname><given-names>P</given-names></name><name><surname>Palamara</surname><given-names>PF</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name><name><surname>A Reshef</surname><given-names>Y</given-names></name><name><surname>K Finucane</surname><given-names>H</given-names></name><name><surname>Schoenherr</surname><given-names>S</given-names></name><name><surname>Forer</surname><given-names>L</given-names></name><name><surname>McCarthy</surname><given-names>S</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>L Price</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reference-based phasing using the haplotype reference consortium panel</article-title><source>Nature Genetics</source><volume>48</volume><fpage>1443</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1038/ng.3679</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looijmans-van den Akker</surname><given-names>I</given-names></name><name><surname>van Luijn</surname><given-names>K</given-names></name><name><surname>Verheij</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Overdiagnosis of asthma in children in primary care: a retrospective analysis</article-title><source>The British Journal of General Practice</source><volume>66</volume><fpage>e152</fpage><lpage>e157</lpage><pub-id pub-id-type="doi">10.3399/bjgp16X683965</pub-id><pub-id pub-id-type="pmid">26917656</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>SM</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Young</surname><given-names>K</given-names></name><name><surname>Hersh</surname><given-names>CP</given-names></name><name><surname>Castaldi</surname><given-names>PJ</given-names></name><name><surname>McDonald</surname><given-names>ML</given-names></name><name><surname>Regan</surname><given-names>E</given-names></name><name><surname>Mattheisen</surname><given-names>M</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>M</given-names></name><name><surname>Make</surname><given-names>BJ</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Lomas</surname><given-names>DA</given-names></name><name><surname>Bhatt</surname><given-names>SP</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name><name><surname>Crapo</surname><given-names>JD</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Laird</surname><given-names>NM</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Investigators</surname><given-names>E</given-names></name><name><surname>Investigators</surname><given-names>CO</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry</article-title><source>BMC Genetics</source><volume>16</volume><elocation-id>138</elocation-id><pub-id pub-id-type="doi">10.1186/s12863-015-0299-4</pub-id><pub-id pub-id-type="pmid">26634245</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchini</surname><given-names>J</given-names></name><name><surname>Howie</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genotype imputation for genome-wide association studies</article-title><source>Nature Reviews. Genetics</source><volume>11</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nrg2796</pub-id><pub-id pub-id-type="pmid">20517342</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martindale</surname><given-names>S</given-names></name><name><surname>McNeill</surname><given-names>G</given-names></name><name><surname>Devereux</surname><given-names>G</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Russell</surname><given-names>G</given-names></name><name><surname>Seaton</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>171</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1164/rccm.200402-220OC</pub-id><pub-id pub-id-type="pmid">15531754</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>S</given-names></name><name><surname>Juban</surname><given-names>G</given-names></name><name><surname>Gobbetti</surname><given-names>T</given-names></name><name><surname>Desgeorges</surname><given-names>T</given-names></name><name><surname>Theret</surname><given-names>M</given-names></name><name><surname>Gondin</surname><given-names>J</given-names></name><name><surname>Toller-Kawahisa</surname><given-names>JE</given-names></name><name><surname>Reutelingsperger</surname><given-names>CP</given-names></name><name><surname>Chazaud</surname><given-names>B</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Mounier</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Annexin A1 drives macrophage Skewing to accelerate muscle regeneration through AMPK activation</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>1156</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1172/JCI124635</pub-id><pub-id pub-id-type="pmid">32015229</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Kretzschmar</surname><given-names>W</given-names></name><name><surname>Delaneau</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>AR</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name><name><surname>Danecek</surname><given-names>P</given-names></name><name><surname>Sharp</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Sidore</surname><given-names>C</given-names></name><name><surname>Kwong</surname><given-names>A</given-names></name><name><surname>Timpson</surname><given-names>N</given-names></name><name><surname>Koskinen</surname><given-names>S</given-names></name><name><surname>Vrieze</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Veldink</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Pato</surname><given-names>C</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Gillies</surname><given-names>CE</given-names></name><name><surname>Gandin</surname><given-names>I</given-names></name><name><surname>Mezzavilla</surname><given-names>M</given-names></name><name><surname>Gilly</surname><given-names>A</given-names></name><name><surname>Cocca</surname><given-names>M</given-names></name><name><surname>Traglia</surname><given-names>M</given-names></name><name><surname>Angius</surname><given-names>A</given-names></name><name><surname>Barrett</surname><given-names>J</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Branham</surname><given-names>K</given-names></name><name><surname>Breen</surname><given-names>G</given-names></name><name><surname>Brummet</surname><given-names>C</given-names></name><name><surname>Busonero</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chew</surname><given-names>E</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Corbin</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Dedoussis</surname><given-names>G</given-names></name><name><surname>Dorr</surname><given-names>M</given-names></name><name><surname>Farmaki</surname><given-names>AE</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Forer</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>RM</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Harrison</surname><given-names>T</given-names></name><name><surname>Hattersley</surname><given-names>A</given-names></name><name><surname>Holmen</surname><given-names>OL</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Kretzler</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>McGue</surname><given-names>M</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Melzer</surname><given-names>D</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Nickerson</surname><given-names>D</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Pato</surname><given-names>M</given-names></name><name><surname>Pirastu</surname><given-names>N</given-names></name><name><surname>Mclnnis</surname><given-names>M</given-names></name><name><surname>Richards</surname><given-names>B</given-names></name><name><surname>Sala</surname><given-names>C</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Schlessinger</surname><given-names>D</given-names></name><name><surname>Schoenheer</surname><given-names>S</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Small</surname><given-names>K</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Stambolian</surname><given-names>D</given-names></name><name><surname>Tuke</surname><given-names>M</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Van Rheenen</surname><given-names>W</given-names></name><name><surname>Volker</surname><given-names>U</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Toniolo</surname><given-names>D</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Gasparini</surname><given-names>P</given-names></name><name><surname>Sampson</surname><given-names>MG</given-names></name><name><surname>Wilson</surname><given-names>JF</given-names></name><name><surname>Frayling</surname><given-names>T</given-names></name><name><surname>Bakker</surname><given-names>P de</given-names></name><name><surname>Swertz</surname><given-names>MA</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Dekker</surname><given-names>A</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Wilier</surname><given-names>C</given-names></name><name><surname>Iacono</surname><given-names>W</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Marchini</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A Reference Panel of 64,976 Haplotypes for genotype imputation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/035170</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaren</surname><given-names>W</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Riat</surname><given-names>HS</given-names></name><name><surname>Ritchie</surname><given-names>GRS</given-names></name><name><surname>Thormann</surname><given-names>A</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Ensembl Variant Effect Predictor</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melén</surname><given-names>E</given-names></name><name><surname>Himes</surname><given-names>BE</given-names></name><name><surname>Brehm</surname><given-names>JM</given-names></name><name><surname>Boutaoui</surname><given-names>N</given-names></name><name><surname>Klanderman</surname><given-names>BJ</given-names></name><name><surname>Sylvia</surname><given-names>JS</given-names></name><name><surname>Lasky-Su</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Analyses of shared genetic factors between asthma and obesity in children</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>126</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.030</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Dixon</surname><given-names>AL</given-names></name><name><surname>Strachan</surname><given-names>D</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Depner</surname><given-names>M</given-names></name><name><surname>von Berg</surname><given-names>A</given-names></name><name><surname>Bufe</surname><given-names>A</given-names></name><name><surname>Rietschel</surname><given-names>E</given-names></name><name><surname>Heinzmann</surname><given-names>A</given-names></name><name><surname>Simma</surname><given-names>B</given-names></name><name><surname>Frischer</surname><given-names>T</given-names></name><name><surname>Willis-Owen</surname><given-names>SAG</given-names></name><name><surname>Wong</surname><given-names>KCC</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Vogelberg</surname><given-names>C</given-names></name><name><surname>Weiland</surname><given-names>SK</given-names></name><name><surname>von Mutius</surname><given-names>E</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Gut</surname><given-names>IG</given-names></name><name><surname>Lathrop</surname><given-names>GM</given-names></name><name><surname>Cookson</surname><given-names>WOC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Genetic variants regulating Ormdl3 expression contribute to the risk of childhood asthma</article-title><source>Nature</source><volume>448</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/nature06014</pub-id><pub-id pub-id-type="pmid">17611496</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Gut</surname><given-names>IG</given-names></name><name><surname>Demenais</surname><given-names>F</given-names></name><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Bouzigon</surname><given-names>E</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>von Mutius</surname><given-names>E</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Cookson</surname><given-names>WOCM</given-names></name><collab>GABRIEL Consortium</collab></person-group><year iso-8601-date="2010">2010</year><article-title>A large-scale, consortium-based genomewide association study of asthma</article-title><source>The New England Journal of Medicine</source><volume>363</volume><fpage>1211</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906312</pub-id><pub-id pub-id-type="pmid">20860503</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Haber</surname><given-names>AL</given-names></name><name><surname>Biton</surname><given-names>M</given-names></name><name><surname>Vinarsky</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Birket</surname><given-names>SE</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>HM</given-names></name><name><surname>Villoria</surname><given-names>J</given-names></name><name><surname>Rogel</surname><given-names>N</given-names></name><name><surname>Burgin</surname><given-names>G</given-names></name><name><surname>Tsankov</surname><given-names>AM</given-names></name><name><surname>Waghray</surname><given-names>A</given-names></name><name><surname>Slyper</surname><given-names>M</given-names></name><name><surname>Waldman</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Shivaraju</surname><given-names>M</given-names></name><name><surname>Bihler</surname><given-names>H</given-names></name><name><surname>Mense</surname><given-names>M</given-names></name><name><surname>Tearney</surname><given-names>GJ</given-names></name><name><surname>Rowe</surname><given-names>SM</given-names></name><name><surname>Engelhardt</surname><given-names>JF</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Rajagopal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A revised airway epithelial hierarchy includes CFTR-expressing Ionocytes</article-title><source>Nature</source><volume>560</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0393-7</pub-id><pub-id pub-id-type="pmid">30069044</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>FSP</given-names></name><name><surname>Wong</surname><given-names>KY</given-names></name><name><surname>Guan</surname><given-names>SP</given-names></name><name><surname>Mustafa</surname><given-names>FB</given-names></name><name><surname>Kajiji</surname><given-names>TS</given-names></name><name><surname>Bist</surname><given-names>P</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Wong</surname><given-names>WSF</given-names></name><name><surname>Lim</surname><given-names>LHK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Annexin-1-deficient mice exhibit spontaneous airway hyperresponsiveness and exacerbated allergen-specific antibody responses in a mouse model of asthma</article-title><source>Clinical and Experimental Allergy</source><volume>41</volume><fpage>1793</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2011.03855.x</pub-id><pub-id pub-id-type="pmid">22092555</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The genetics of asthma and allergic disease: a 21st century perspective</article-title><source>Immunological Reviews</source><volume>242</volume><fpage>10</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01029.x</pub-id><pub-id pub-id-type="pmid">21682736</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oksel</surname><given-names>C</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Fontanella</surname><given-names>S</given-names></name><name><surname>Frainay</surname><given-names>C</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Classification of pediatric asthma: from phenotype discovery to clinical practice</article-title><source>Frontiers in Pediatrics</source><volume>6</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2018.00258</pub-id><pub-id pub-id-type="pmid">30298124</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oksel</surname><given-names>C</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Fontanella</surname><given-names>S</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>S</given-names></name><name><surname>Devereux</surname><given-names>G</given-names></name><name><surname>Arshad</surname><given-names>SH</given-names></name><name><surname>Murray</surname><given-names>CS</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><collab>STELAR investigators, breathing Together investigators</collab></person-group><year iso-8601-date="2019">2019a</year><article-title>Distinguishing wheezing phenotypes from infancy to adolescence. A pooled analysis of five birth cohorts</article-title><source>Annals of the American Thoracic Society</source><volume>16</volume><fpage>868</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201811-837OC</pub-id><pub-id pub-id-type="pmid">30888842</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oksel</surname><given-names>C</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Mahmoud</surname><given-names>O</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>AJ</given-names></name><collab>STELAR</collab><collab>Breathing Together investigators</collab></person-group><year iso-8601-date="2019">2019b</year><article-title>Breathing together I causes of variability in latent phenotypes of childhood wheeze</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>143</volume><fpage>1783</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.10.059</pub-id><pub-id pub-id-type="pmid">30528616</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>GP</given-names></name><name><surname>Bel</surname><given-names>E</given-names></name><name><surname>Brusselle</surname><given-names>G</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Ducharme</surname><given-names>FM</given-names></name><name><surname>Fahy</surname><given-names>JV</given-names></name><name><surname>Frey</surname><given-names>U</given-names></name><name><surname>Gibson</surname><given-names>P</given-names></name><name><surname>Heaney</surname><given-names>LG</given-names></name><name><surname>Holt</surname><given-names>PG</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>CM</given-names></name><name><surname>Marks</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>FD</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name><name><surname>von Mutius</surname><given-names>E</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Zar</surname><given-names>HJ</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>After asthma: redefining airways diseases</article-title><source>Lancet</source><volume>391</volume><fpage>350</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)30879-6</pub-id><pub-id pub-id-type="pmid">28911920</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>N</given-names></name><name><surname>La</surname><given-names>M</given-names></name><name><surname>Fierro</surname><given-names>IM</given-names></name><name><surname>Marullo</surname><given-names>S</given-names></name><name><surname>Getting</surname><given-names>SJ</given-names></name><name><surname>Solito</surname><given-names>E</given-names></name><name><surname>Serhan</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Endogenous Lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the Lipoxin A4 receptor</article-title><source>Nature Medicine</source><volume>8</volume><fpage>1296</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1038/nm786</pub-id><pub-id pub-id-type="pmid">12368905</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruim</surname><given-names>RJ</given-names></name><name><surname>Welch</surname><given-names>RP</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Teslovich</surname><given-names>TM</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Gliedt</surname><given-names>TP</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Locuszoom: regional visualization of genome-wide association scan results</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2336</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq419</pub-id><pub-id pub-id-type="pmid">20634204</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Rotival</surname><given-names>M</given-names></name><name><surname>Pothlichet</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>Y-HE</given-names></name><name><surname>Dannemann</surname><given-names>M</given-names></name><name><surname>Zidane</surname><given-names>N</given-names></name><name><surname>Laval</surname><given-names>G</given-names></name><name><surname>Patin</surname><given-names>E</given-names></name><name><surname>Harmant</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Deschamps</surname><given-names>M</given-names></name><name><surname>Naffakh</surname><given-names>N</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Coen</surname><given-names>A</given-names></name><name><surname>Leroux-Roels</surname><given-names>G</given-names></name><name><surname>Clément</surname><given-names>F</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Kelso</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name><name><surname>Quintana-Murci</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic adaptation and Neandertal admixture shaped the immune system of human populations</article-title><source>Cell</source><volume>167</volume><fpage>643</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.024</pub-id><pub-id pub-id-type="pmid">27768888</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhen</surname><given-names>T</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Antiinflammatory action of glucocorticoids--new mechanisms for old drugs</article-title><source>The New England Journal of Medicine</source><volume>353</volume><fpage>1711</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1056/NEJMra050541</pub-id><pub-id pub-id-type="pmid">16236742</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PFM</given-names></name><name><surname>Fontanella</surname><given-names>S</given-names></name><name><surname>Ananth</surname><given-names>S</given-names></name><name><surname>Martin Alonso</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Kaya-de Vries</surname><given-names>D</given-names></name><name><surname>Polo Silveira</surname><given-names>L</given-names></name><name><surname>Gregory</surname><given-names>L</given-names></name><name><surname>Lloyd</surname><given-names>C</given-names></name><name><surname>Fleming</surname><given-names>L</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Saglani</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Recurrent severe preschool wheeze: from prespecified diagnostic labels to underlying endotypes</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>204</volume><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1164/rccm.202009-3696OC</pub-id><pub-id pub-id-type="pmid">33961755</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savenije</surname><given-names>OE</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Caudri</surname><given-names>D</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>Smit</surname><given-names>HA</given-names></name><name><surname>Wijga</surname><given-names>A</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name><name><surname>Brunekreef</surname><given-names>B</given-names></name><name><surname>Sterne</surname><given-names>JA</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Kerkhof</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>127</volume><fpage>1505</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2011.02.002</pub-id><pub-id pub-id-type="pmid">21411131</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savenije</surname><given-names>OE</given-names></name><name><surname>Mahachie John</surname><given-names>JM</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Kerkhof</surname><given-names>M</given-names></name><name><surname>Dijk</surname><given-names>FN</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name><name><surname>Smit</surname><given-names>HA</given-names></name><name><surname>Brunekreef</surname><given-names>B</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Van Steen</surname><given-names>K</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Association of Il33-IL-1 receptor-like 1 (Il1Rl1) pathway polymorphisms with wheezing phenotypes and asthma in childhood</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>134</volume><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.12.1080</pub-id><pub-id pub-id-type="pmid">24568840</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoettler</surname><given-names>N</given-names></name><name><surname>Rodríguez</surname><given-names>E</given-names></name><name><surname>Weidinger</surname><given-names>S</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Advances in asthma and allergic disease genetics: is bigger always better</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>144</volume><fpage>1495</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.10.023</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Schwikowski</surname><given-names>B</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Research</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Tepper</surname><given-names>R</given-names></name><name><surname>Graves</surname><given-names>P</given-names></name><name><surname>Stern</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Curtin</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Blekic</surname><given-names>M</given-names></name><name><surname>Bukvic</surname><given-names>BK</given-names></name><name><surname>Aberle</surname><given-names>N</given-names></name><name><surname>Marinho</surname><given-names>S</given-names></name><name><surname>Belgrave</surname><given-names>D</given-names></name><name><surname>Morgan</surname><given-names>WJ</given-names></name><name><surname>Martinez</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic variation in vascular endothelial growth factor-A and lung function</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>185</volume><fpage>1197</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1164/rccm.201112-2191OC</pub-id><pub-id pub-id-type="pmid">22461367</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siroux</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>JR</given-names></name><name><surname>Bouzigon</surname><given-names>E</given-names></name><name><surname>Curjuric</surname><given-names>I</given-names></name><name><surname>Boudier</surname><given-names>A</given-names></name><name><surname>Imboden</surname><given-names>M</given-names></name><name><surname>Anto</surname><given-names>JM</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Jarvis</surname><given-names>D</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Omenaas</surname><given-names>ER</given-names></name><name><surname>Pin</surname><given-names>I</given-names></name><name><surname>Wjst</surname><given-names>M</given-names></name><name><surname>Demenais</surname><given-names>F</given-names></name><name><surname>Probst-Hensch</surname><given-names>N</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Kauffmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic heterogeneity of asthma phenotypes identified by a clustering approach</article-title><source>European Respiratory Journal</source><volume>43</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1183/09031936.00032713</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sottile</surname><given-names>G</given-names></name><name><surname>Ferrante</surname><given-names>G</given-names></name><name><surname>Torregrossa</surname><given-names>M</given-names></name><name><surname>Cibella</surname><given-names>F</given-names></name><name><surname>Cilluffo</surname><given-names>G</given-names></name><name><surname>Fasola</surname><given-names>S</given-names></name><name><surname>Alessandro</surname><given-names>R</given-names></name><name><surname>Seidita</surname><given-names>G</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>La Grutta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An association analysis to identify genetic variants linked to asthma and rhino-conjunctivitis in a cohort of Sicilian children</article-title><source>Italian Journal of Pediatrics</source><volume>45</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/s13052-019-0603-4</pub-id><pub-id pub-id-type="pmid">30646946</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spycher</surname><given-names>BD</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genome-wide prediction of childhood asthma and related phenotypes in a longitudinal birth cohort</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>130</volume><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.06.002</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stelzer</surname><given-names>G</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Plaschkes</surname><given-names>I</given-names></name><name><surname>Zimmerman</surname><given-names>S</given-names></name><name><surname>Twik</surname><given-names>M</given-names></name><name><surname>Fishilevich</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>TI</given-names></name><name><surname>Nudel</surname><given-names>R</given-names></name><name><surname>Lieder</surname><given-names>I</given-names></name><name><surname>Mazor</surname><given-names>Y</given-names></name><name><surname>Kaplan</surname><given-names>S</given-names></name><name><surname>Dahary</surname><given-names>D</given-names></name><name><surname>Warshawsky</surname><given-names>D</given-names></name><name><surname>Guan-Golan</surname><given-names>Y</given-names></name><name><surname>Kohn</surname><given-names>A</given-names></name><name><surname>Rappaport</surname><given-names>N</given-names></name><name><surname>Safran</surname><given-names>M</given-names></name><name><surname>Lancet</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Genecards suite: from gene data mining to disease genome sequence analyses</article-title><source>Current Protocols in Bioinformatics</source><volume>54</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1002/cpbi.5</pub-id><pub-id pub-id-type="pmid">27322403</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Junge</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING V11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torgerson</surname><given-names>DG</given-names></name><name><surname>Ampleford</surname><given-names>EJ</given-names></name><name><surname>Chiu</surname><given-names>GY</given-names></name><name><surname>Gauderman</surname><given-names>WJ</given-names></name><name><surname>Gignoux</surname><given-names>CR</given-names></name><name><surname>Graves</surname><given-names>PE</given-names></name><name><surname>Himes</surname><given-names>BE</given-names></name><name><surname>Levin</surname><given-names>AM</given-names></name><name><surname>Mathias</surname><given-names>RA</given-names></name><name><surname>Hancock</surname><given-names>DB</given-names></name><name><surname>Baurley</surname><given-names>JW</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Stern</surname><given-names>DA</given-names></name><name><surname>Celedón</surname><given-names>JC</given-names></name><name><surname>Rafaels</surname><given-names>N</given-names></name><name><surname>Capurso</surname><given-names>D</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Roth</surname><given-names>LA</given-names></name><name><surname>Soto-Quiros</surname><given-names>M</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Myers</surname><given-names>RA</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Hansel</surname><given-names>NN</given-names></name><name><surname>Hernandez</surname><given-names>RD</given-names></name><name><surname>Israel</surname><given-names>E</given-names></name><name><surname>Salam</surname><given-names>MT</given-names></name><name><surname>Galanter</surname><given-names>J</given-names></name><name><surname>Avila</surname><given-names>PC</given-names></name><name><surname>Avila</surname><given-names>L</given-names></name><name><surname>Rodriquez-Santana</surname><given-names>JR</given-names></name><name><surname>Chapela</surname><given-names>R</given-names></name><name><surname>Rodriguez-Cintron</surname><given-names>W</given-names></name><name><surname>Diette</surname><given-names>GB</given-names></name><name><surname>Adkinson</surname><given-names>NF</given-names></name><name><surname>Abel</surname><given-names>RA</given-names></name><name><surname>Ross</surname><given-names>KD</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Faruque</surname><given-names>MU</given-names></name><name><surname>Dunston</surname><given-names>GM</given-names></name><name><surname>Watson</surname><given-names>HR</given-names></name><name><surname>Mantese</surname><given-names>VJ</given-names></name><name><surname>Ezurum</surname><given-names>SC</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Ruczinski</surname><given-names>I</given-names></name><name><surname>Ford</surname><given-names>JG</given-names></name><name><surname>Huntsman</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Vora</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Calhoun</surname><given-names>WJ</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Sienra-Monge</surname><given-names>JJ</given-names></name><name><surname>del Rio-Navarro</surname><given-names>B</given-names></name><name><surname>Deichmann</surname><given-names>KA</given-names></name><name><surname>Heinzmann</surname><given-names>A</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Gern</surname><given-names>JE</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Raby</surname><given-names>BA</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>London</surname><given-names>SJ</given-names></name><name><surname>Gilliland</surname><given-names>FD</given-names></name><name><surname>Burchard</surname><given-names>EG</given-names></name><name><surname>Martinez</surname><given-names>FD</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Williams</surname><given-names>LK</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations</article-title><source>Nature Genetics</source><volume>43</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1038/ng.888</pub-id><pub-id pub-id-type="pmid">21804549</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira Braga</surname><given-names>FA</given-names></name><name><surname>Kar</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Carpaij</surname><given-names>OA</given-names></name><name><surname>Polanski</surname><given-names>K</given-names></name><name><surname>Simon</surname><given-names>LM</given-names></name><name><surname>Brouwer</surname><given-names>S</given-names></name><name><surname>Gomes</surname><given-names>T</given-names></name><name><surname>Hesse</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Fasouli</surname><given-names>ES</given-names></name><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name><name><surname>Talavera-López</surname><given-names>C</given-names></name><name><surname>Jonker</surname><given-names>MR</given-names></name><name><surname>Affleck</surname><given-names>K</given-names></name><name><surname>Palit</surname><given-names>S</given-names></name><name><surname>Strzelecka</surname><given-names>PM</given-names></name><name><surname>Firth</surname><given-names>HV</given-names></name><name><surname>Mahbubani</surname><given-names>KT</given-names></name><name><surname>Cvejic</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>KB</given-names></name><name><surname>Saeb-Parsy</surname><given-names>K</given-names></name><name><surname>Luinge</surname><given-names>M</given-names></name><name><surname>Brandsma</surname><given-names>C-A</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Angelidis</surname><given-names>I</given-names></name><name><surname>Strunz</surname><given-names>M</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>van Oosterhout</surname><given-names>AJ</given-names></name><name><surname>Schiller</surname><given-names>HB</given-names></name><name><surname>Theis</surname><given-names>FJ</given-names></name><name><surname>van den Berge</surname><given-names>M</given-names></name><name><surname>Nawijn</surname><given-names>MC</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A cellular census of human lungs identifies novel cell states in health and in asthma</article-title><source>Nature Medicine</source><volume>25</volume><fpage>1153</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0468-5</pub-id><pub-id pub-id-type="pmid">31209336</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vong</surname><given-names>L</given-names></name><name><surname>Ferraz</surname><given-names>JGP</given-names></name><name><surname>Dufton</surname><given-names>N</given-names></name><name><surname>Panaccione</surname><given-names>R</given-names></name><name><surname>Beck</surname><given-names>PL</given-names></name><name><surname>Sherman</surname><given-names>PM</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Up-regulation of Annexin-A1 and Lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e39244</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0039244</pub-id><pub-id pub-id-type="pmid">22723974</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Võsa</surname><given-names>U</given-names></name><name><surname>Claringbould</surname><given-names>A</given-names></name><name><surname>Westra</surname><given-names>HJ</given-names></name><name><surname>Bonder</surname><given-names>MJ</given-names></name><name><surname>Deelen</surname><given-names>P</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Kirsten</surname><given-names>H</given-names></name><name><surname>Saha</surname><given-names>A</given-names></name><name><surname>Kreuzhuber</surname><given-names>R</given-names></name><name><surname>Kasela</surname><given-names>S</given-names></name><name><surname>Pervjakova</surname><given-names>N</given-names></name><name><surname>Alvaes</surname><given-names>I</given-names></name><name><surname>Fave</surname><given-names>MJ</given-names></name><name><surname>Agbessi</surname><given-names>M</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>R</given-names></name><name><surname>Seppälä</surname><given-names>I</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Schramm</surname><given-names>K</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Verlouw</surname><given-names>J</given-names></name><name><surname>Yaghootkar</surname><given-names>H</given-names></name><name><surname>Sönmez</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Kukushkina</surname><given-names>V</given-names></name><name><surname>Kalnapenkis</surname><given-names>A</given-names></name><name><surname>Rüeger</surname><given-names>S</given-names></name><name><surname>Porcu</surname><given-names>E</given-names></name><name><surname>Kronberg-Guzman</surname><given-names>J</given-names></name><name><surname>Kettunen</surname><given-names>J</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Arindrarto</surname><given-names>W</given-names></name><name><surname>Beutner</surname><given-names>F</given-names></name><name><surname>Brugge</surname><given-names>H</given-names></name><name><surname>Dmitreva</surname><given-names>J</given-names></name><name><surname>Elansary</surname><given-names>M</given-names></name><name><surname>Fairfax</surname><given-names>BP</given-names></name><name><surname>Georges</surname><given-names>M</given-names></name><name><surname>Heijmans</surname><given-names>BT</given-names></name><name><surname>Kähönen</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Knight</surname><given-names>CY</given-names></name><name><surname>Kovacs</surname><given-names>P</given-names></name><name><surname>Krohn</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Marigorta</surname><given-names>UM</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Momozawa</surname><given-names>Y</given-names></name><name><surname>Müller-Nurasyid</surname><given-names>M</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Nivard</surname><given-names>M</given-names></name><name><surname>Penninx</surname><given-names>B</given-names></name><name><surname>Pritchard</surname><given-names>J</given-names></name><name><surname>Raitakari</surname><given-names>O</given-names></name><name><surname>Rotzchke</surname><given-names>O</given-names></name><name><surname>Slagboom</surname><given-names>EP</given-names></name><name><surname>Stehouwer</surname><given-names>CDA</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>P</given-names></name><name><surname>t Hoen</surname><given-names>PAC</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name><name><surname>Tönjes</surname><given-names>A</given-names></name><name><surname>van Dongen</surname><given-names>J</given-names></name><name><surname>van Iterson</surname><given-names>M</given-names></name><name><surname>Veldink</surname><given-names>J</given-names></name><name><surname>Völker</surname><given-names>U</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Swertz</surname><given-names>M</given-names></name><name><surname>Andiappan</surname><given-names>A</given-names></name><name><surname>Montgomery</surname><given-names>WG</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Kutalik</surname><given-names>Z</given-names></name><name><surname>Dermitzakis</surname><given-names>E</given-names></name><name><surname>Bergmann</surname><given-names>S</given-names></name><name><surname>Frayling</surname><given-names>T</given-names></name><name><surname>van Meurs</surname><given-names>J</given-names></name><name><surname>Prokisch</surname><given-names>H</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><name><surname>Pierce</surname><given-names>B</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Boomsma</surname><given-names>D</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Gharib</surname><given-names>SA</given-names></name><name><surname>Awadalla</surname><given-names>P</given-names></name><name><surname>Milani</surname><given-names>L</given-names></name><name><surname>Ouwehand</surname><given-names>W</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Battle</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name><name><surname>Scholz</surname><given-names>M</given-names></name><name><surname>Gibson</surname><given-names>G</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><collab>BIOS Consortium</collab><collab>i2QTL Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/447367</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijga</surname><given-names>AH</given-names></name><name><surname>Kerkhof</surname><given-names>M</given-names></name><name><surname>Gehring</surname><given-names>U</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Aalberse</surname><given-names>RC</given-names></name><name><surname>Wolse</surname><given-names>APH</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>van Rossem</surname><given-names>L</given-names></name><name><surname>Oldenwening</surname><given-names>M</given-names></name><name><surname>Brunekreef</surname><given-names>B</given-names></name><name><surname>Smit</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cohort profile: the prevention and incidence of asthma and mite allergy (PIAMA) birth cohort</article-title><source>International Journal of Epidemiology</source><volume>43</volume><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1093/ije/dys231</pub-id><pub-id pub-id-type="pmid">23315435</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>METAL: fast and efficient meta-analysis of genomewide association scans</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2190</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq340</pub-id><pub-id pub-id-type="pmid">20616382</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingett</surname><given-names>S</given-names></name><name><surname>Ewels</surname><given-names>P</given-names></name><name><surname>Furlan-Magaril</surname><given-names>M</given-names></name><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Schoenfelder</surname><given-names>S</given-names></name><name><surname>Fraser</surname><given-names>P</given-names></name><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Hicup: pipeline for mapping and processing Hi-C data</article-title><source>F1000Research</source><volume>4</volume><elocation-id>1310</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.7334.1</pub-id><pub-id pub-id-type="pmid">26835000</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcik</surname><given-names>GL</given-names></name><name><surname>Graff</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>KK</given-names></name><name><surname>Tao</surname><given-names>R</given-names></name><name><surname>Haessler</surname><given-names>J</given-names></name><name><surname>Gignoux</surname><given-names>CR</given-names></name><name><surname>Highland</surname><given-names>HM</given-names></name><name><surname>Patel</surname><given-names>YM</given-names></name><name><surname>Sorokin</surname><given-names>EP</given-names></name><name><surname>Avery</surname><given-names>CL</given-names></name><name><surname>Belbin</surname><given-names>GM</given-names></name><name><surname>Bien</surname><given-names>SA</given-names></name><name><surname>Cheng</surname><given-names>I</given-names></name><name><surname>Cullina</surname><given-names>S</given-names></name><name><surname>Hodonsky</surname><given-names>CJ</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Huckins</surname><given-names>LM</given-names></name><name><surname>Jeff</surname><given-names>J</given-names></name><name><surname>Justice</surname><given-names>AE</given-names></name><name><surname>Kocarnik</surname><given-names>JM</given-names></name><name><surname>Lim</surname><given-names>U</given-names></name><name><surname>Lin</surname><given-names>BM</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Nelson</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>S-SL</given-names></name><name><surname>Poisner</surname><given-names>H</given-names></name><name><surname>Preuss</surname><given-names>MH</given-names></name><name><surname>Richard</surname><given-names>MA</given-names></name><name><surname>Schurmann</surname><given-names>C</given-names></name><name><surname>Setiawan</surname><given-names>VW</given-names></name><name><surname>Sockell</surname><given-names>A</given-names></name><name><surname>Vahi</surname><given-names>K</given-names></name><name><surname>Verbanck</surname><given-names>M</given-names></name><name><surname>Vishnu</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>RW</given-names></name><name><surname>Young</surname><given-names>KL</given-names></name><name><surname>Zubair</surname><given-names>N</given-names></name><name><surname>Acuña-Alonso</surname><given-names>V</given-names></name><name><surname>Ambite</surname><given-names>JL</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><name><surname>Bustamante</surname><given-names>CD</given-names></name><name><surname>Caberto</surname><given-names>C</given-names></name><name><surname>Canizales-Quinteros</surname><given-names>S</given-names></name><name><surname>Conomos</surname><given-names>MP</given-names></name><name><surname>Deelman</surname><given-names>E</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Doheny</surname><given-names>K</given-names></name><name><surname>Fernández-Rhodes</surname><given-names>L</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Hailu</surname><given-names>B</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><name><surname>Henn</surname><given-names>BM</given-names></name><name><surname>Hindorff</surname><given-names>LA</given-names></name><name><surname>Jackson</surname><given-names>RD</given-names></name><name><surname>Laurie</surname><given-names>CA</given-names></name><name><surname>Laurie</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>D-Y</given-names></name><name><surname>Moreno-Estrada</surname><given-names>A</given-names></name><name><surname>Nadkarni</surname><given-names>G</given-names></name><name><surname>Norman</surname><given-names>PJ</given-names></name><name><surname>Pooler</surname><given-names>LC</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Romm</surname><given-names>J</given-names></name><name><surname>Sabatti</surname><given-names>C</given-names></name><name><surname>Sandoval</surname><given-names>K</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Stahl</surname><given-names>EA</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Thornton</surname><given-names>TA</given-names></name><name><surname>Wassel</surname><given-names>CL</given-names></name><name><surname>Wilkens</surname><given-names>LR</given-names></name><name><surname>Winkler</surname><given-names>CA</given-names></name><name><surname>Yoneyama</surname><given-names>S</given-names></name><name><surname>Buyske</surname><given-names>S</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Matise</surname><given-names>TC</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Kenny</surname><given-names>EE</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic analyses of diverse populations improves discovery for complex traits</article-title><source>Nature</source><volume>570</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1310-4</pub-id><pub-id pub-id-type="pmid">31217584</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Panganiban</surname><given-names>RA</given-names></name><name><surname>Chung</surname><given-names>W</given-names></name><name><surname>O’Connor</surname><given-names>LJ</given-names></name><name><surname>Himes</surname><given-names>BE</given-names></name><name><surname>Gazal</surname><given-names>S</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Cookson</surname><given-names>WOC</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>145</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.09.035</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Description of cohorts</title><p>The STELAR consortium (<xref ref-type="bibr" rid="bib15">Custovic et al., 2015</xref>) brings together five UK population-based birth cohorts as described below. Informed consent was obtained from parents, and study subjects gave their assent/consent when applicable. Data were harmonised and imported into Asthma eLab web-based knowledge management platform to facilitate joint analyses (<ext-link ext-link-type="uri" xlink:href="https://www.asthmaelab.org">https://www.asthmaelab.org</ext-link>) (<xref ref-type="bibr" rid="bib15">Custovic et al., 2015</xref>).</p><sec sec-type="appendix" id="s8-1"><title>ALSPAC</title><p>ALSPAC is a birth cohort study established in 1991 in Avon, UK (<xref ref-type="bibr" rid="bib6">Boyd et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Fraser et al., 2013</xref>). Pregnant women with expected dates of delivery 1 April 1991 to 31 December 1992 were invited to take part in the study. The initial number of pregnancies enrolled is 14,541. Of these initial pregnancies, there was a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age.</p><p>When the oldest children were approximately 7 years of age, an attempt was made to bolster the study with eligible cases who had failed to join originally. As a result, when considering variables collected from the age of 7 onwards (and potentially abstracted from obstetric notes) there are data available for more than the 14,541 pregnancies mentioned above. The number of new pregnancies not in the initial sample (known as Phase I enrolment) that are currently represented on the built files and reflecting enrolment status at the age of 24 is 913 (456, 262, and 195 recruited during Phases II, III, and IV, respectively), resulting in an additional 913 children being enrolled. The phases of enrolment are described in more detail in the cohort profile paper and its update. The total sample size for analyses using any data collected after the age of 7 is therefore 15,454 pregnancies, resulting in 15,589 foetuses. Of these 14,901 were alive at 1 year of age.</p><p>Ethical approval: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. All self-completion questionnaire content is approved by the ALSPAC Ethics and Law Committee. Ethics protocols’ numbers: Initial approval Bristol and Weston Health Authority: E1808 Children of the Nineties: Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC) (28 November 1989). Southmead Health Authority: 49/89 Children of the Nineties – ‘ALSPAC’ (5 April 1990). Frenchay Health Authority: 90/8 Children of the Nineties (28 June 1990).</p><p>Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Data dictionary: The study website contains details of available data through a fully searchable data dictionary: <ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/researchers/our-data/">http://www.bristol.ac.uk/alspac/researchers/our-data/</ext-link>.</p><p>We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.</p></sec><sec sec-type="appendix" id="s8-2"><title>MAAS</title><p>MAAS is an unselected birth cohort study established in 1995 in Manchester, UK (<xref ref-type="bibr" rid="bib13">Custovic et al., 2002</xref>). It consists of a mixed urban-rural population within 50 square miles of South Manchester and Cheshire, UK, located within the maternity catchment area of Wythenshawe and Stepping Hill Hospitals. All pregnant women were screened for eligibility at antenatal visits (8–10th week of pregnancy). Of the 1499 couples who met the inclusion criteria (≤10 weeks of pregnancy, maternal age ≥18 years, and questionnaire and skin prick data test available for both parents), 288 declined to take part in the study and 27 were lost to follow-up between recruitment and the birth of a child. A total of 1184 children were born into the study between February 1996 and April 1998. They were followed prospectively for 19 years to date and attended follow-up clinics for assessments, which included lung function measurements, skin prick testing, biological samples (serum, plasma, and urine), and questionnaire data collection. The study was approved by the North West – Greater Manchester East Research Ethics Committee. Ethics protocols’ numbers: ERP/94/032 Up to 5 years. Allergen avoidance, primary prevention, genetics, sRaw age 3 and 5; SOU/00/259 5 years; ERP/95/137 Exposure to pet allergens, atopy, genetics; ERP/97/023 IFWIN, genetics; 03/SM/400 8 years; 06/Q1403/142 10–12 years; 11/NW/0228 13–15 years; 14/NW/1309 18+ years.</p></sec><sec sec-type="appendix" id="s8-3"><title>SEATON</title><p>SEATON is an unselected birth cohort study established in 1997 in Aberdeen, UK, which was designed to explore the relationship between antenatal dietary exposures and asthma outcomes in childhood (<xref ref-type="bibr" rid="bib47">Martindale et al., 2005</xref>). Two-thousand healthy pregnant women attending an antenatal clinic, at median 12 weeks gestation, were recruited. An interviewer administered a questionnaire to the women and atopic status was ascertained by skin prick test (SPT). The cohort included 1924 children born between April 1998 and December 1999. Participants were recruited prenatally and followed up by self-completion questionnaire to 15 years of age using postal questionnaires to record the presence of asthma and allergic diseases. Lung function measurements and SPT to common allergens were performed at 5, 10, and 15 years. The study was approved by the North of Scotland Research Ethics Committee. Ethics protocol REC reference: 13/NS/0108; protocol number: 2/048/13; amendment number: AM03.</p></sec><sec sec-type="appendix" id="s8-4"><title>Ashford</title><p>The Ashford study is an unselected birth cohort study established in 1991 in Ashford, UK (<xref ref-type="bibr" rid="bib4">Atkinson et al., 1999</xref>). It included 642 children born between 1992 and 1993. Participants were recruited prenatally and followed to age 14 years. Detailed standardised questionnaires were administered at each follow-up to collect information on the natural history of asthma and other allergic diseases. Lung function measurements and SPT was carried out at 5, 8, and 14 years of age. In 2015, the study children aged 20 were sent a self-completion questionnaire, which was returned by 60% of the participants. The Asthma in Ashford study was reviewed by the Imperial College Research Ethics Committee on 11 November 2014. On 8 January 2015 the Joint Research Compliance Office granted full approval of the study on the basis described in the revised documents. ICREC reference: 14|C2288.</p></sec><sec sec-type="appendix" id="s8-5"><title>The IOW cohort</title><p>IOW is an unselected birth cohort study established in 1989 on the IOW, UK (<xref ref-type="bibr" rid="bib3">Arshad et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kurukulaaratchy et al., 2002</xref>; <xref ref-type="bibr" rid="bib40">Kurukulaaratchy et al., 2003</xref>). After the exclusion of adoptions, perinatal deaths, and refusal for follow-up, written informed consent was obtained from parents to enrol 1456 newborns born between 1 January 1989 and 28 February 1990. Follow-up-up assessments were conducted to 26 years of age to prospectively study the development of asthma and allergic diseases. At each follow-up, validated questionnaires were completed by the parents. Additionally, the SPT was performed on 980, 1036, and 853 participants at 4, 10, and 18 years of age to check allergic reactions to common allergens. At 10, 18, and 26 years, spirometry and methacholine challenge tests were performed to diagnose lung problems. Ethics protocols’ numbers: Ethics approval for the IoW cohort was originally given by the Isle of Wight Local Research Ethics Committee (now named the National Research Ethics Service, NRES Committee South Central – Southampton B) in 1989 and at each subsequent follow-up (1, 2, and 4 years) (this is pre ‘numbers’); age 10 follow-up (including DNA and genotyping): Isle of Wight Health Authority Local Research Ethics Committee 18/98; age 18 follow-up (including DNA and genotyping): Isle of Wight, Portsmouth &amp; South East Hampshire Research Ethics Committee 06/Q1701/34.</p></sec></sec><sec sec-type="appendix" id="s9"><title>Definition of variables</title><p>A list of all variables used in the current study, per cohort, is shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><sec sec-type="appendix" id="s9-1"><title>Demographic, exposures and outcomes</title><p>Postal questionnaires were used in ALSPAC and SEATON, while interviewer-administered questionnaires were employed in other cohorts.</p><p>Parental history of asthma, eczema, and hay fever was defined based on the responses given to the question ‘have you (and/or your partner) ever had asthma/eczema/hay fever’. Maternal and paternal smoking were defined based on the response given to the question ‘do you (or does your partner) smoke’, administered during pregnancy. Low birth weight was defined as birth weight less than 2500 g based on NHS birth records.</p><p>Asthma in MAAS was defined as a case if positive for two of the following criteria: doctor diagnosis of asthma in the past 12 months, current wheeze in the last 12 months, doctor prescription for asthma. Asthma in ALSPAC was defined as a mothers’ report of doctor ever diagnosis of asthma.</p><p>Current wheeze in MAAS was defined as a questionnaire report to the question ‘have you wheezed in the last 12 months’ upon attendance at a follow-up clinic. Current wheeze in ALSPAC was defined as a mothers’ report to the question ‘has your child had any wheezing or whistling in the last 12 months?’.</p><p>Asthma medication in ALSPAC was defined as a mothers’ report to the question ‘has your child taken any asthma medication in the last 12 months?’. Lower respiratory hospital admissions: Data on hospital admissions in MAAS were obtained by manually inspecting the general practice (GP) records for each individual.</p><p>Early-life risk factors were divided into four groups according to timing of exposure: maternal and child characteristics (gender, maternal smoking during pregnancy, and maternal history of asthma), perinatal (low birth weight adjusted for gestational age), environmental (pet ownership, smoke exposure after birth), and allergic sensitisation (defined based on positive SPT to cat, HDM, or grass) variables.</p></sec><sec sec-type="appendix" id="s9-2"><title>Primary outcome: joint wheeze phenotypes</title><p>We used LCA to identify longitudinal trajectories of wheeze (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>) based on pooled analysis among 15,941 children with at least two observations on wheezing at five time periods that were approximately shared across all cohorts: infancy (½–1 year); early childhood (2–3 years); pre-school/early school age (4–5 years); middle childhood (8–10 years); and adolescence (14–18 years). Cohort-specific definitions and other variables derived from the questionnaires are provided in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>.</p><p>To control for cohort-specific variation, cohort ID was included in the LCA model as an additional predictor by transforming the five-category variable into a set of four dummy variables and including them as covariates. The largest cohort, ALSPAC, was treated as the non-coded category to which all other cohorts were compared. The expectation maximisation algorithm was used to estimate relevant parameters, with 100,000 iterations and 500 replications.</p><p>To assess model fit, we used (1) the Bayesian information criterion (BIC), (2) the Akaike information criterion (AIC), (3) Lo-Mendell-Rubin likelihood ratio test, (4) bootstrapped likelihood ratio, and (4) quality of classification certainty (model entropy). The BIC is an index used in Bayesian statistics to choose among a set of competing models; the model with the lowest BIC is preferred. Using the lowest BIC as a selection criterion, the best fitting model was chosen as the five-class solution with a nominal covariate (BIC:31340). Analyses were carried out using Mplus 8, R (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>) and Stata 14 (StataCorp, College Station, TX, USA).</p><p>Based on the statistical fit, a five-class solution was selected as the optimal model (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>), and the classes (wheeze phenotypes) were labeled as: (1) <italic>never/infrequent wheeze</italic> (52.4%); (2) <italic>early-onset pre-school remitting wheeze</italic> (18.6%), with high prevalence of wheeze during infancy, decreasing to 20% around early-childhood and to less than 10% afterwards; (3) <italic>early-onset middle-childhood remitting wheeze</italic> (9.8%), with early-onset wheeze and peak prevalence in early-childhood (~70%), and diminishing by middle-childhood (&lt;5%); (4) <italic>early-onset persistent wheeze</italic> (10.4%) with 58% wheeze prevalence during infancy, and prevalence between 70–80% thereafter; (5) <italic>late-onset wheeze</italic> (8.8%) with very low prevalence until middle childhood, increasing rapidly to 55% in adolescence. These latent classes were used in the subsequent GWAS.</p></sec><sec sec-type="appendix" id="s9-3"><title>Minimising bias and missing data effects</title><p>Extracted from reference (<xref ref-type="bibr" rid="bib58">Oksel et al., 2019a</xref>): “One of the advantages of our multicohort approach is that individual studies that might not provide conclusive evidence to make inference about the general population because of cohort specific effects and biases can contribute to revealing a more accurate picture when integrated together. The integration of five cohorts and their pooled analysis enhanced the credibility and generalizability of the phenotyping results to the U.K. population. A further advantage is to minimize the study-specific biases (including cohort specific effects, attrition effects, different recruitment strategies, and geographic factors) affecting the certainty of allocation of individuals to each latent class, while maximizing the benefits of individual cohort studies (e.g., potentially important risk factors and outcomes are captured in some, but not all cohorts).”</p><p>“Another strength of pooling cohort data is that a multicohort design allowed us to analyze a large sample with complete data on wheeze from birth to adolescence, thus increasing statistical power to detect less prevalent phenotypes.” However, “The optimal solution in the model using 15,941 children (allowing for missing data) remained five classes (see Table E3, Figure E1), and was very similar to that derived from a complete data set.” We used results from the larger sample, that is individuals with at least two observations of wheezing, to assign individuals to their most likely wheezing phenotype and used this as our primary outcome in this study.</p></sec><sec sec-type="appendix" id="s9-4"><title>Included vs. excluded participants</title><p>Related and non-European individuals were excluded as well as those individuals with missing genetic data.</p><p>In ALSPAC, 11,176 individuals had data on wheezing phenotypes, of these 6833 were white unrelated and had genetic data. We found more children from mothers who smoked during pregnancy in the excluded sample compared to the included sample; no difference in gender, maternal history of asthma, current wheezing at 8 or 15 years, and small evidence for more asthma ever and current medication at 8 years in the excluded sample (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>).</p><p>In MAAS, 1150 individuals had data on wheezing phenotypes, of these 887 were white unrelated and had genetic data. We found no difference in children from mothers who smoked during pregnancy in the excluded sample compared to the included sample; no difference in gender, maternal history of asthma or current wheezing at both 8 and 16 years. There was small evidence for more asthma ever and current medication at 8 years in the excluded sample (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>).</p><p>In SEATON, 1535 individuals had data on joint wheezing phenotypes, of these 548 were white unrelated and had genetic data. We found evidence for more children from mothers who smoked during pregnancy in the excluded sample compared to the included sample; and more males in the excluded sample. There was no difference in maternal history of asthma or current wheezing, asthma ever or current medication at both 10 and 15 years in the excluded sample compared to the included sample (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>).</p><p>In Ashford 620 individuals had data on joint wheezing phenotypes, of these 348 were white unrelated and had genetic data. We found evidence for more children from mothers who smoked during pregnancy in the excluded sample compared to the included sample; no difference in gender, maternal history of asthma, or asthma ever. There was small evidence for less current wheezing at 8 years, or current medication at 8 years in the excluded sample compared to the included sample (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>).</p><p>In IOW, 1460 individuals had data on joint wheezing phenotypes, of these 952 were white unrelated and had genetic data. We found evidence for more children from mothers who smoked during pregnancy in the excluded sample compared to the included sample; no difference in gender, maternal history of asthma, asthma ever at 10 and 18 years in the excluded sample compared to the included sample. There was small evidence for more children with current wheeze and medication at 8 years in the included sample compared to the included sample (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>).</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Definition of variables in each of the five Study Team for Early Life Asthma Research (STELAR) birth cohorts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">Definition</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="2"><bold><italic>Cohort: ALSPAC</italic></bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother – asthma</italic></bold></td><td align="left" valign="bottom">Have you ever had asthma? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother smoking</italic></bold></td><td align="left" valign="bottom">Mother smoked when expecting (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Doctor-diagnosed asthma ever</italic></bold></td><td align="left" valign="bottom">Has a doctor ever said that your child has asthma? (years 8 and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current wheezing</italic></bold></td><td align="left" valign="bottom">Two questions combined: Occurrence of wheezing and/or wheezing with whistling on the chest in the last 12 months (year ½, 2½, 4¾, 8½, and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current asthma medication</italic></bold></td><td align="left" valign="bottom">Asthma medication in the last 12 months (years 8½ and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current rhinitis</italic></bold></td><td align="left" valign="bottom">Child had problem with sneezing/runny nose without cold/flu in last 12 months (years 7 and 16½)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current hay fever</italic></bold></td><td align="left" valign="bottom">Child had hay fever in last 12 months (years 10½ and 14)</td></tr><tr><td align="left" valign="bottom" colspan="2"><bold><italic>Cohort: MAAS</italic></bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother – asthma</italic></bold></td><td align="left" valign="bottom">Has a doctor ever told you that you had asthma? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother smoking</italic></bold></td><td align="left" valign="bottom">Do you smoke − mother (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Doctor-diagnosed asthma ever</italic></bold></td><td align="left" valign="bottom">Has your doctor ever told you that your child has or had asthma? (years 8 and 16)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Asthma ever</italic></bold></td><td align="left" valign="bottom">Has your child ever suffered from asthma (years 8 and 16)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current wheezing</italic></bold></td><td align="left" valign="bottom">Has your child had wheezing or whistling in the chest in the last 6/12 months (years 1, 3, 5, 8, and 16)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current asthma medication</italic></bold></td><td align="left" valign="bottom">Asthma medication in the last 12 months (years 8 and 16)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current rhinitis</italic></bold></td><td align="left" valign="bottom">Has your child ever had a problem with sneezing, or a runny nose, or a blocked nose when he /she did not have a cold or the flu? (years 8 and 16)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current hay fever</italic></bold></td><td align="left" valign="bottom">Does your child have hay fever now? (years 8 and 16)</td></tr><tr><td align="left" valign="bottom" colspan="2"><bold><italic>Cohort: SEATON</italic></bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother – asthma</italic></bold></td><td align="left" valign="bottom">Do you suffer from asthma? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother smoking</italic></bold></td><td align="left" valign="bottom">Which of the following best describes your smoking status? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Doctor-diagnosed asthma ever</italic></bold></td><td align="left" valign="bottom">Has your child ever suffered from asthma? If yes, has this been confirmed by a doctor? (years 10 and 15)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Asthma ever</italic></bold></td><td align="left" valign="bottom">Has your child ever suffered from asthma? (year 10); Have you ever suffered from asthma? (year 15)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current wheezing</italic></bold></td><td align="left" valign="bottom">Has your child had wheezing in the chest in the last 12 months (years 1, 2, 5, 10, and 15)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current asthma medication</italic></bold></td><td align="left" valign="bottom">Has your child been prescribed medicines/inhalers for asthma in the last 12 months? (year 10); Have you been prescribed medicines/inhalers for asthma in the last 12 months? (year 15)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current hay fever</italic></bold></td><td align="left" valign="bottom">Has your child suffered from hay fever last 12 months? (years 10 and 15)</td></tr><tr><td align="left" valign="bottom" colspan="2"><bold><italic>Cohort: Ashford</italic></bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother – asthma</italic></bold></td><td align="left" valign="bottom">Do you have or have you ever been told you have asthma? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother smoking</italic></bold></td><td align="left" valign="bottom">Do you smoke cigarettes? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Doctor-diagnosed asthma ever</italic></bold></td><td align="left" valign="bottom">Has your doctor ever told you that your child has or had asthma? (years 8 and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Asthma ever</italic></bold></td><td align="left" valign="bottom">In the past 12 months has your daughter suffered from asthma? (year 8); Has she/he ever suffered from asthma? (year 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current wheezing</italic></bold></td><td align="left" valign="bottom">Which one best describes your child’s wheeze in past 12 months? ‘Yes’ (B:1–6, C:7+), ‘No’ (A:0) (years 1, 2, 5, 8, and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current asthma medication</italic></bold></td><td align="left" valign="bottom">Over the last 12 months has your daughter taken any of the following treatments (preventer, reliever, nebuliser, steroids) for asthma? (years 8 and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current rhinitis</italic></bold></td><td align="left" valign="bottom">In the last 12 months has your child had a problem with sneezing or a runny or blocked nose? (years 8 and 14)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current hay fever</italic></bold></td><td align="left" valign="bottom">In your opinion does your child have hay fever now? (year 8)<break/>Has your child ever had hay fever? (year 14)</td></tr><tr><td align="left" valign="bottom" colspan="2"><bold><italic>Cohort: IOW</italic></bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother − asthma</italic></bold></td><td align="left" valign="bottom">Do you or have you suffered from asthma or wheezing (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Mother smoking</italic></bold></td><td align="left" valign="bottom">Do you smoke in the house? (recruitment)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Doctor-diagnosed asthma ever</italic></bold></td><td align="left" valign="bottom">Asthma cared for by hospital specialist/ GP or nurse (years 10, 18, and 26)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Asthma ever</italic></bold></td><td align="left" valign="bottom">Child ever had asthma (years 10 and 18)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current wheezing</italic></bold></td><td align="left" valign="bottom">Presence of wheeze since previous review (years 1, 2, 4, 10, and 18)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Asthma medication ever</italic></bold></td><td align="left" valign="bottom">Child ever had asthma treatment (year 18) combined with asthma treatment questions being asked at years 1, 2, 4, 10, and 18</td></tr><tr><td align="left" valign="bottom"><bold><italic>Current rhinitis</italic></bold></td><td align="left" valign="bottom">In the past 12 months have you had a problem with sneezing, or a runny or blocked nose when you did not have a cold or the flu? (years 10, 18, and 26)</td></tr></tbody></table></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>The cohort-specific time points and sample size used to ascertain wheeze phenotypes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Birth cohort:</th><th align="left" valign="bottom">IOW</th><th align="left" valign="bottom">MAAS</th><th align="left" valign="bottom">SEATON</th><th align="left" valign="bottom">Ashford</th><th align="left" valign="bottom">ALSPAC</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Year of birth</italic></td><td align="left" valign="bottom">1989</td><td align="left" valign="bottom">1995</td><td align="left" valign="bottom">1997</td><td align="left" valign="bottom">1992</td><td align="left" valign="bottom">1991</td></tr><tr><td align="left" valign="bottom"><italic>Questionnaire</italic></td><td align="left" valign="bottom">Interviewer-administered</td><td align="left" valign="bottom">Interviewer-administered</td><td align="left" valign="bottom">Postal</td><td align="left" valign="bottom">Interviewer-administered</td><td align="left" valign="bottom">Postal</td></tr><tr><td align="left" valign="bottom"><italic>Data collection age (years</italic>)</td><td align="left" valign="bottom">1, 2, 4, 10, 18</td><td align="left" valign="bottom">1, 3, 5, 8, 16</td><td align="left" valign="bottom">1, 2, 5, 10, 15</td><td align="left" valign="bottom">1, 2, 5, 8, 14</td><td align="left" valign="bottom">½, 2½, 4¾, 8½, 14</td></tr><tr><td align="left" valign="bottom"><italic>No. of children with <underline>≥</underline></italic>2 <italic>observations on wheezing at five selected time points</italic></td><td align="left" valign="bottom">1460</td><td align="left" valign="bottom">1150</td><td align="left" valign="bottom">1535</td><td align="left" valign="bottom">620</td><td align="left" valign="bottom">11,176</td></tr></tbody></table></table-wrap><table-wrap id="app1table3" position="float"><label>Appendix 1—table 3.</label><caption><title>Characteristics of the participants in Study Team for Early Life Asthma Research (STELAR) cohorts included in this analysis (restricted to individuals with genetic data).</title><p>Numbers are N (%) except for age, where we report mean (SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">ALSPAC</th><th align="left" valign="bottom">MAAS</th><th align="left" valign="bottom">SEATON</th><th align="left" valign="bottom">Ashford</th><th align="left" valign="bottom">IOW</th></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">N=6,833(71.4%)</th><th align="left" valign="bottom">N=887(9.3%)</th><th align="left" valign="bottom">N=548(5.7%)</th><th align="left" valign="bottom">N=348(3.6%)</th><th align="left" valign="bottom">N=952(9.9%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Males</td><td align="char" char="." valign="bottom">3492 (51.1)</td><td align="char" char="." valign="bottom">475 (53.6)</td><td align="char" char="." valign="bottom">260 (47.5)</td><td align="char" char="." valign="bottom">179 (51.4)</td><td align="char" char="." valign="bottom">466 (49.0)</td></tr><tr><td align="left" valign="bottom">Maternal history of asthma</td><td align="char" char="." valign="bottom">748 (11.5)</td><td align="char" char="." valign="bottom">120 (13.5)</td><td align="char" char="." valign="bottom">77 (14.1)</td><td align="char" char="." valign="bottom">49 (14.1)</td><td align="char" char="." valign="bottom">106 (11.2)</td></tr><tr><td align="left" valign="bottom">Maternal smoking</td><td align="char" char="." valign="bottom">1423 (22.1)</td><td align="char" char="." valign="bottom">122 (13.8)</td><td align="char" char="." valign="bottom">107 (19.5)</td><td align="char" char="." valign="bottom">52 (14.9)</td><td align="char" char="." valign="bottom">217 (23.1)</td></tr><tr><td align="left" valign="bottom" colspan="6"><bold>Wheeze phenotypes</bold></td></tr><tr><td align="left" valign="bottom"><italic>Never/infrequent</italic></td><td align="char" char="." valign="bottom">4331 (63.4)</td><td align="char" char="." valign="bottom">506 (57.1)</td><td align="char" char="." valign="bottom">332 (60.6)</td><td align="char" char="." valign="bottom">145 (41.7)</td><td align="char" char="." valign="bottom">573 (60.2)</td></tr><tr><td align="left" valign="bottom"><italic>Early-onset persistent</italic></td><td align="char" char="." valign="bottom">656 (9.6)</td><td align="char" char="." valign="bottom">133 (15.0)</td><td align="char" char="." valign="bottom">36 (6.6)</td><td align="char" char="." valign="bottom">41 (11.8)</td><td align="char" char="." valign="bottom">77 (8.1)</td></tr><tr><td align="left" valign="bottom"><italic>Early-onset pre-school remitting</italic></td><td align="char" char="." valign="bottom">1076 (15.8)</td><td align="char" char="." valign="bottom">145 (16.4)</td><td align="char" char="." valign="bottom">117 (21.4)</td><td align="char" char="." valign="bottom">145 (41.7)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>Early-onset mid-childhood remitting</italic></td><td align="char" char="." valign="bottom">474 (6.9)</td><td align="char" char="." valign="bottom">48 (5.4)</td><td align="char" char="." valign="bottom">13 (2.4)</td><td align="char" char="." valign="bottom">13 (3.7)</td><td align="char" char="." valign="bottom">55 (5.8)</td></tr><tr><td align="left" valign="bottom"><italic>Late-onset</italic></td><td align="char" char="." valign="bottom">296 (4.3)</td><td align="char" char="." valign="bottom">55 (6.2)</td><td align="char" char="." valign="bottom">50 (9.1)</td><td align="char" char="." valign="bottom">4 (1.2)</td><td align="char" char="." valign="bottom">247 (26.0)</td></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">7–8 years</th><th align="left" valign="bottom">14–15 years</th><th align="left" valign="bottom">8 years</th><th align="left" valign="bottom">16 years</th><th align="left" valign="bottom">10 years</th><th align="left" valign="bottom">15 years</th><th align="left" valign="bottom">8 years</th><th align="left" valign="bottom">14 years</th><th align="left" valign="bottom">10 years</th><th align="left" valign="bottom">18 years</th></tr><tr><td align="left" valign="bottom">Age mean (SD) in years</td><td align="left" valign="bottom">8.7 (0.3)</td><td align="left" valign="bottom">15.4 (0.3)</td><td align="left" valign="bottom">7.98 (0.16)</td><td align="left" valign="bottom">16.09 (0.62)</td><td align="left" valign="bottom">10.15 (0.18)</td><td align="left" valign="bottom">15.09 (0.28)</td><td align="left" valign="bottom">7.97 (NA)</td><td align="left" valign="bottom">13.95 (NA)</td><td align="left" valign="bottom">9.98 (0.27)</td><td align="left" valign="bottom">17.87 (0.59)</td></tr><tr><td align="left" valign="bottom">Doctor-diagnosed asthma ever<xref ref-type="table-fn" rid="app1table3fn1">*</xref></td><td align="left" valign="bottom">1060 (19.7)</td><td align="left" valign="bottom">796 (23.2)</td><td align="left" valign="bottom">198 (23.9)</td><td align="left" valign="bottom">198 (30.0)</td><td align="left" valign="bottom">86 (16.0)</td><td align="left" valign="bottom">80 (19.5)</td><td align="left" valign="bottom">75 (21.6)</td><td align="left" valign="bottom">83 (23.9)</td><td align="left" valign="bottom">350 (40.9)</td><td align="left" valign="bottom">255 (28.6)</td></tr><tr><td align="left" valign="bottom">Asthma ever</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">193 (22.8)</td><td align="left" valign="bottom">192 (29.5)</td><td align="left" valign="bottom">87 (16.2)</td><td align="left" valign="bottom">66 (21.9)</td><td align="left" valign="bottom">54 (15.6)</td><td align="left" valign="bottom">65 (18.7)</td><td align="left" valign="bottom">194 (20.9)</td><td align="left" valign="bottom">264 (29.3)</td></tr><tr><td align="left" valign="bottom">Current wheeze</td><td align="left" valign="bottom">683 (12.5)</td><td align="left" valign="bottom">306 (9.0)</td><td align="left" valign="bottom">150 (17.6)</td><td align="left" valign="bottom">112 (16.9)</td><td align="left" valign="bottom">67 (12.4)</td><td align="left" valign="bottom">63 (15.5)</td><td align="left" valign="bottom">54 (15.6)</td><td align="left" valign="bottom">54 (15.5)</td><td align="left" valign="bottom">190 (20.4)</td><td align="left" valign="bottom">227 (25.1)</td></tr><tr><td align="left" valign="bottom">Current asthma medication</td><td align="left" valign="bottom">695 (12.9)</td><td align="left" valign="bottom">361 (10.6)</td><td align="left" valign="bottom">141 (16.5)</td><td align="left" valign="bottom">114 (17.1)</td><td align="left" valign="bottom">68 (12.6)</td><td align="left" valign="bottom">58 (14.0)</td><td align="left" valign="bottom">50 (14.41)</td><td align="left" valign="bottom">49 (14.1)</td><td align="left" valign="bottom">41 (11.81)</td><td align="left" valign="bottom">38 (10.9)</td></tr></tbody></table><table-wrap-foot><fn id="app1table3fn1"><label>*</label><p>DDA ever not available in IOW, we used asthma cared for by hospital specialist/ GP or nurse as proxy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table4" position="float"><label>Appendix 1—table 4.</label><caption><title>Comparison of included vs. excluded participants in the five cohorts at different ages.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"><underline>ALSPAC</underline></th><th align="left" valign="bottom">N</th><th align="left" valign="bottom">Included</th><th align="left" valign="bottom">N</th><th align="left" valign="bottom">Excluded</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="left" valign="bottom">Males (%)</td><td align="left" valign="bottom">6833</td><td align="left" valign="bottom">3492 (51.1)</td><td align="char" char="." valign="bottom">4343</td><td align="left" valign="bottom">2269 (52.2)</td><td align="left" valign="bottom">0.24</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal history asthma (%)</td><td align="left" valign="bottom">6497</td><td align="left" valign="bottom">748 (11.5)</td><td align="char" char="." valign="bottom">4038</td><td align="left" valign="bottom">453 (11.2)</td><td align="left" valign="bottom">0.64</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal smoking-pregnancy (%)</td><td align="left" valign="bottom">6438</td><td align="left" valign="bottom">1423 (22.1)</td><td align="char" char="." valign="bottom">4019</td><td align="left" valign="bottom">1167 (29.0)</td><td align="left" valign="bottom">&lt;0.001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">At 7.5–8.5 years</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">At 14–15 years</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">ALSPAC</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">Included</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">Excluded</td><td align="left" valign="bottom">p-Value</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">Included</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">Excluded</td><td align="left" valign="bottom">p-Value</td></tr><tr><td align="left" valign="bottom">Age mean (SD) years</td><td align="left" valign="bottom">5139</td><td align="left" valign="bottom">8.7 (0.3)</td><td align="char" char="." valign="bottom">1872</td><td align="left" valign="bottom">8.7 (0.3)</td><td align="left" valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">3885</td><td align="char" char="." valign="bottom">15.4 (0.3)</td><td align="char" char="." valign="bottom">1237</td><td align="char" char="." valign="bottom">15.5 (0.4)</td><td align="char" char="." valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Current wheeze (%)</td><td align="left" valign="bottom">5453</td><td align="left" valign="bottom">683 (12.5)</td><td align="char" char="." valign="bottom">2579</td><td align="left" valign="bottom">344 (13.3)</td><td align="left" valign="bottom">0.308</td><td align="char" char="." valign="bottom">3419</td><td align="char" char="." valign="bottom">306 (9.0)</td><td align="char" char="." valign="bottom">1078</td><td align="char" char="." valign="bottom">105 (9.7)</td><td align="char" char="." valign="bottom">0.432</td></tr><tr><td align="left" valign="bottom">Asthma ever (%)</td><td align="left" valign="bottom">5377</td><td align="left" valign="bottom">1060 (19.7)</td><td align="char" char="." valign="bottom">2605</td><td align="left" valign="bottom">562 (21.6)</td><td align="left" valign="bottom">0.053</td><td align="char" char="." valign="bottom">3425</td><td align="char" char="." valign="bottom">796 (23.2)</td><td align="char" char="." valign="bottom">1079</td><td align="char" char="." valign="bottom">279 (25.9)</td><td align="char" char="." valign="bottom">0.079</td></tr><tr><td align="left" valign="bottom">Current asthma medication (%)</td><td align="left" valign="bottom">5379</td><td align="left" valign="bottom">695 (12.9)</td><td align="char" char="." valign="bottom">2529</td><td align="left" valign="bottom">368 (14.6)</td><td align="left" valign="bottom">0.047</td><td align="char" char="." valign="bottom">3400</td><td align="char" char="." valign="bottom">361 (10.6)</td><td align="char" char="." valign="bottom">1077</td><td align="char" char="." valign="bottom">134 (12.4)</td><td align="char" char="." valign="bottom">0.096</td></tr><tr><td align="left" valign="bottom"><bold><underline>MAAS</underline></bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Males (%)</td><td align="left" valign="bottom">887</td><td align="left" valign="bottom">475 (53.6)</td><td align="char" char="." valign="bottom">263</td><td align="left" valign="bottom">149 (56.7)</td><td align="char" char="." valign="bottom">0.38</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal history asthma (%)</td><td align="left" valign="bottom">886</td><td align="left" valign="bottom">120 (13.5)</td><td align="char" char="." valign="bottom">259</td><td align="left" valign="bottom">45 (17.4)</td><td align="char" char="." valign="bottom">0.12</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal smoking* (%)</td><td align="left" valign="bottom">884</td><td align="left" valign="bottom">122 (13.8)</td><td align="char" char="." valign="bottom">260</td><td align="left" valign="bottom">47 (18.1)</td><td align="char" char="." valign="bottom">0.09</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 8 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 16 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>MAAS</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td></tr><tr><td align="left" valign="bottom">Age mean (SD) years</td><td align="left" valign="bottom">827</td><td align="left" valign="bottom">7.98 (0.16)</td><td align="char" char="." valign="bottom">149</td><td align="left" valign="bottom">8.00 (0.21)</td><td align="char" char="." valign="bottom">0.31</td><td align="char" char="." valign="bottom">605</td><td align="char" char="." valign="bottom">16.09 (0.62)</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">15.98 (0.60)</td><td align="char" char="." valign="bottom">0.20</td></tr><tr><td align="left" valign="bottom">Current wheeze (%)</td><td align="left" valign="bottom">853</td><td align="left" valign="bottom">150 (17.6)</td><td align="char" char="." valign="bottom">172</td><td align="left" valign="bottom">35 (20.4)</td><td align="char" char="." valign="bottom">0.39</td><td align="char" char="." valign="bottom">664</td><td align="char" char="." valign="bottom">112 (16.9)</td><td align="char" char="." valign="bottom">82</td><td align="char" char="." valign="bottom">15 (18.3)</td><td align="char" char="." valign="bottom">0.11</td></tr><tr><td align="left" valign="bottom">Asthma ever (%)</td><td align="left" valign="bottom">845</td><td align="left" valign="bottom">193 (22.8)</td><td align="char" char="." valign="bottom">173</td><td align="left" valign="bottom">52 (30.1)</td><td align="char" char="." valign="bottom">0.043</td><td align="char" char="." valign="bottom">651</td><td align="char" char="." valign="bottom">192 (29.5)</td><td align="char" char="." valign="bottom">79</td><td align="char" char="." valign="bottom">28 (35.4)</td><td align="char" char="." valign="bottom">0.28</td></tr><tr><td align="left" valign="bottom">Current asthma medication (%)</td><td align="left" valign="bottom">855</td><td align="left" valign="bottom">141 (16.5)</td><td align="char" char="." valign="bottom">173</td><td align="left" valign="bottom">43 (24.9)</td><td align="char" char="." valign="bottom">0.009</td><td align="char" char="." valign="bottom">666</td><td align="char" char="." valign="bottom">114 (17.1)</td><td align="char" char="." valign="bottom">83</td><td align="char" char="." valign="bottom">14 (16.9)</td><td align="char" char="." valign="bottom">0.96</td></tr><tr><td align="left" valign="bottom"><bold><underline>SEATON</underline></bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Males (%)</td><td align="left" valign="bottom">548</td><td align="left" valign="bottom">260 (47.5)</td><td align="char" char="." valign="bottom">987</td><td align="left" valign="bottom">525 (53.2)</td><td align="left" valign="bottom">0.031</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal history asthma (%)</td><td align="left" valign="bottom">548</td><td align="left" valign="bottom">77 (14.1)</td><td align="char" char="." valign="bottom">985</td><td align="left" valign="bottom">161 (16.4)</td><td align="left" valign="bottom">0.24</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal smoking* (%)</td><td align="left" valign="bottom">548</td><td align="left" valign="bottom">107 (19.5)</td><td align="char" char="." valign="bottom">987</td><td align="left" valign="bottom">276 (28.0)</td><td align="left" valign="bottom">&lt;0.001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 10 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 15 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>SEATON</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td></tr><tr><td align="left" valign="bottom">Age mean (SD) years</td><td align="left" valign="bottom">548</td><td align="left" valign="bottom">10.15 (0.18)</td><td align="char" char="." valign="bottom">987</td><td align="left" valign="bottom">10.23 (0.16)</td><td align="left" valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">545</td><td align="char" char="." valign="bottom">15.09 (0.28)</td><td align="char" char="." valign="bottom">916</td><td align="char" char="." valign="bottom">15.11 (0.26)</td><td align="char" char="." valign="bottom">0.20</td></tr><tr><td align="left" valign="bottom">Current wheeze (%)</td><td align="left" valign="bottom">541</td><td align="left" valign="bottom">67 (12.4)</td><td align="char" char="." valign="bottom">376</td><td align="left" valign="bottom">42 (11.2)</td><td align="left" valign="bottom">0.58</td><td align="char" char="." valign="bottom">407</td><td align="char" char="." valign="bottom">63 (15.5)</td><td align="char" char="." valign="bottom">310</td><td align="char" char="." valign="bottom">48 (15.5)</td><td align="char" char="." valign="bottom">0.99</td></tr><tr><td align="left" valign="bottom">Asthma ever (%)</td><td align="left" valign="bottom">537</td><td align="left" valign="bottom">87 (16.2)</td><td align="char" char="." valign="bottom">374</td><td align="left" valign="bottom">53 (14.2)</td><td align="left" valign="bottom">0.40</td><td align="char" char="." valign="bottom">409</td><td align="char" char="." valign="bottom">66 (21.9)</td><td align="char" char="." valign="bottom">302</td><td align="char" char="." valign="bottom">85 (20.8)</td><td align="char" char="." valign="bottom">0.73</td></tr><tr><td align="left" valign="bottom">Current asthma medication (%)</td><td align="left" valign="bottom">542</td><td align="left" valign="bottom">68 (12.6)</td><td align="char" char="." valign="bottom">378</td><td align="left" valign="bottom">39 (10.3)</td><td align="left" valign="bottom">0.30</td><td align="char" char="." valign="bottom">414</td><td align="char" char="." valign="bottom">58 (14.0)</td><td align="char" char="." valign="bottom">309</td><td align="char" char="." valign="bottom">34 (11.0)</td><td align="char" char="." valign="bottom">0.23</td></tr><tr><td align="left" valign="bottom"><bold><underline>Ashford</underline></bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Males (%)</td><td align="left" valign="bottom">348</td><td align="left" valign="bottom">179 (51.4)</td><td align="char" char="." valign="bottom">272</td><td align="left" valign="bottom">153 (56.3)</td><td align="char" char="." valign="bottom">0.23</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal history asthma (%)</td><td align="left" valign="bottom">348</td><td align="left" valign="bottom">49 (14.1)</td><td align="char" char="." valign="bottom">272</td><td align="left" valign="bottom">38 (14.0)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal smoking* (%)</td><td align="left" valign="bottom">348</td><td align="left" valign="bottom">52 (14.9)</td><td align="char" char="." valign="bottom">270</td><td align="left" valign="bottom">61 (22.6)</td><td align="char" char="." valign="bottom">0.015</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 8 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 14 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Ashford</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td></tr><tr><td align="left" valign="bottom">Age mean (SD) years</td><td align="left" valign="bottom">348</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">272</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">348</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">272</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom">Current wheeze (%)</td><td align="left" valign="bottom">347</td><td align="left" valign="bottom">54 (15.6)</td><td align="char" char="." valign="bottom">246</td><td align="left" valign="bottom">25 (10.2)</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">348</td><td align="char" char="." valign="bottom">54 (15.5)</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">18 (12.00)</td><td align="char" char="." valign="bottom">0.31</td></tr><tr><td align="left" valign="bottom">Asthma ever (%)</td><td align="left" valign="bottom">347</td><td align="left" valign="bottom">54 (15.6)</td><td align="char" char="." valign="bottom">246</td><td align="left" valign="bottom">38 (15.5)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">348</td><td align="char" char="." valign="bottom">65 (18.7)</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">25 (16.7)</td><td align="char" char="." valign="bottom">0.59</td></tr><tr><td align="left" valign="bottom">Current asthma medication (%)</td><td align="left" valign="bottom">347</td><td align="left" valign="bottom">50 (14.41)</td><td align="char" char="." valign="bottom">246</td><td align="left" valign="bottom">22 (8.9)</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">348</td><td align="char" char="." valign="bottom">49 (14.1)</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">16 (10.7)</td><td align="char" char="." valign="bottom">0.30</td></tr><tr><td align="left" valign="bottom"><bold><underline>IOW</underline></bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Males (%)</td><td align="left" valign="bottom">952</td><td align="left" valign="bottom">466 (49.0)</td><td align="char" char="." valign="bottom">508</td><td align="left" valign="bottom">275 (54.1)</td><td align="left" valign="bottom">0.06</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal history asthma (%)</td><td align="left" valign="bottom">946</td><td align="left" valign="bottom">106 (11.2)</td><td align="char" char="." valign="bottom">505</td><td align="left" valign="bottom">52 (10.3)</td><td align="left" valign="bottom">0.60</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Maternal smoking* (%)</td><td align="left" valign="bottom">941</td><td align="left" valign="bottom">217 (23.1)</td><td align="char" char="." valign="bottom">502</td><td align="left" valign="bottom">147 (29.3)</td><td align="left" valign="bottom">0.01</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">At 10 years</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>At 18 years</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>IOW</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Included</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Excluded</bold></td><td align="left" valign="bottom"><bold>p-Value</bold></td></tr><tr><td align="left" valign="bottom">Age mean (SD) years</td><td align="left" valign="bottom">932</td><td align="left" valign="bottom">9.98 (0.27)</td><td align="char" char="." valign="bottom">426</td><td align="left" valign="bottom">10.04 (0.31)</td><td align="left" valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">914</td><td align="char" char="." valign="bottom">17.87 (0.59)</td><td align="char" char="." valign="bottom">389</td><td align="char" char="." valign="bottom">18.14 (0.67)</td><td align="char" char="." valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Current wheeze (%)</td><td align="left" valign="bottom">932</td><td align="left" valign="bottom">190 (20.4)</td><td align="char" char="." valign="bottom">426</td><td align="left" valign="bottom">69 (16.2)</td><td align="left" valign="bottom">0.07</td><td align="char" char="." valign="bottom">903</td><td align="char" char="." valign="bottom">227 (25.1)</td><td align="char" char="." valign="bottom">377</td><td align="char" char="." valign="bottom">58 (15.4)</td><td align="char" char="." valign="bottom">&lt;0.002</td></tr><tr><td align="left" valign="bottom">Asthma ever (%)</td><td align="left" valign="bottom">930</td><td align="left" valign="bottom">194 (20.9)</td><td align="char" char="." valign="bottom">425</td><td align="left" valign="bottom">80 (18.8)</td><td align="left" valign="bottom">0.39</td><td align="char" char="." valign="bottom">900</td><td align="char" char="." valign="bottom">264 (29.3)</td><td align="char" char="." valign="bottom">385</td><td align="char" char="." valign="bottom">108 (28.1)</td><td align="char" char="." valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom">Current asthma medication (%)</td><td align="left" valign="bottom">347</td><td align="left" valign="bottom">41 (11.81)</td><td align="char" char="." valign="bottom">246</td><td align="left" valign="bottom">15 (6.10)</td><td align="left" valign="bottom">0.02</td><td align="char" char="." valign="bottom">348</td><td align="char" char="." valign="bottom">38 (10.9)</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">13 (8.7)</td><td align="char" char="." valign="bottom">0.45</td></tr></tbody></table></table-wrap><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Flowchart of individuals included in the final meta-analysis.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app1-fig1-v2.tif"/></fig></sec></sec></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s10"><title>Genotyping and imputation</title><sec sec-type="appendix" id="s10-1"><title>ALSPAC</title><p>Participants were genotyped using the Illumina HumanHap550 quad genome-wide SNP genotyping platform (Illumina Inc, San Diego, CA, USA) by the Wellcome Trust Sanger Institute (WTSI; Cambridge, UK) and the Laboratory Corporation of America (LCA, Burlington, NC, USA), using support from 23andMe. Haplotypes were estimated using ShapeIT (v2.r644) which uses relationship information to improve phasing accuracy. The phased haplotypes were then imputed to the Haplotype Reference Consortium (HRCr1.1, 2016) panel (<xref ref-type="bibr" rid="bib43">Loh et al., 2016</xref>) of approximately 31,000 phased whole genomes. The HRC panel was phased using ShapeIt v2, and the imputation was performed using the Michigan imputation server.</p></sec><sec sec-type="appendix" id="s10-2"><title>MAAS</title><p>In MAAS, we used the Illumina 610 quad genome-wide SNP genotyping platform (Illumina Inc, San Diego, CA, USA). Prior to imputation samples were excluded on the basis of gender mismatches; minimal or excessive heterozygosity, genotyping call rates of &lt;97%. SNPS were excluded if they had call rates of &lt;95%, minor allele frequencies of &lt;0.5%, and HWE p&lt;3 × 10<sup>–8</sup>. Prior to imputation each chromosome was pre-phased using EAGLE2 (v2.0.5) (<xref ref-type="bibr" rid="bib43">Loh et al., 2016</xref>) as recommended by the Sanger imputation server (<xref ref-type="bibr" rid="bib49">McCarthy et al., 2016</xref>). We then imputed with PBWT (<xref ref-type="bibr" rid="bib24">Durbin, 2014</xref>) with the Haplotype Reference Consortium (release 1.1) of 32,470 reference genomes (<xref ref-type="bibr" rid="bib49">McCarthy et al., 2016</xref>) using the Sanger Imputation Server.</p></sec><sec sec-type="appendix" id="s10-3"><title>IOW, SEATON, and Ashford</title><p>IOW, SEATON, and Ashford were genotyped using the illumina Infinium Omni2.5–8 v1.3 BeadChip genotyping platform (Illumina Inc, San Diego, CA, USA). Genotype QC and imputation was carried out as described for MAAS.</p></sec><sec sec-type="appendix" id="s10-4"><title>Exclusions</title><p>Individuals were excluded on the basis of gender mismatches; minimal or excessive heterozygosity; disproportionate levels of individual missingness (&gt;3%), insufficient sample replication (IBD &lt;0.8), or evidence of cryptic relatedness (IBD &gt;0.1). Following imputation, SNPs with a minor allele frequency of &lt;1%, a call rate of &lt;95%, evidence for violations of Hardy-Weinberg equilibrium (p&lt;5E-7), or imputation quality measure (MaCH-Rsq or IMPUTE-info score)&lt;0.40 were excluded. All individuals with non-European ancestry and siblings were removed.</p></sec></sec><sec sec-type="appendix" id="s11"><title>GWAS meta-analysis</title><p>GWASs of the joint wheezing phenotypes were performed independently in ALSPAC, MAAS, and the combined IOW-SEATON-Ashford (combined as they were genotyped on the same platform, at the same time, and quality-controlled and imputed together). All genetic data were imputed to a new Haplotype Reference Consortium panel. This comprises around 31,000 sequenced individuals (mostly European), so the coverage of European haplotypes is much greater than in other panels. As a consequence, we expect to improve imputation accuracy, particularly at lower frequencies.</p><p>We used SNPTEST v2.5.2 (<xref ref-type="bibr" rid="bib46">Marchini and Howie, 2010</xref>) with a frequentist additive multinomial regression model (-method newml, never/infrequent wheeze as the reference) to investigate the association between SNPs and wheezing phenotypes. No covariates were included in the model and only individuals of European descent were included in this analysis. A meta-analysis of the three GWASs, including 5887 controls and 943 cases for early-onset persistent, 1482 cases for early-onset remitting, 603 cases for mid-childhood onset remitting, and 652 cases for late-onset wheeze, was performed using METAL (<xref ref-type="bibr" rid="bib81">Willer et al., 2010</xref>) with a total of 8,057,852 SNPs present. We used the option SCHEME STDERR in METAL to implement an effect size-based method weighted by each study-specific standard error in a fixed-effects model. We performed clumping to keep only one representative SNP per LD block and used LZPs to short-list independent SNPs for further annotation.</p></sec><sec sec-type="appendix" id="s12"><title>LD clumping, pre-selection, and gene annotation</title><p>LD clumping was performed for all SNPs with p-value &lt;10<sup>–5</sup> for at least one wheezing phenotype. In order to avoid redundancy between SNPs and to ensure associations are independent, we used significance thresholds of 0.05 for index and clumped SNPs (<monospace>--clump-p1</monospace> 0.05, <monospace>--clump-p2</monospace> 0.05), LD threshold of 0.80 (<monospace>--clump-r2</monospace> 0.80) and physical distance threshold of 250 kb (<monospace>--clump-kb</monospace> 250). European 1000 Genome data were used to infer LD structure.</p><p>LZPs (<ext-link ext-link-type="uri" xlink:href="http://locuszoom.org/">http://locuszoom.org/</ext-link>) (<xref ref-type="bibr" rid="bib62">Pruim et al., 2010</xref>) were used for close inspection of all independent signals. Loci showing a peak with different colour dots (possibly indicating more than one causal variant) were short-listed for further annotation. SNPnexus database (<ext-link ext-link-type="uri" xlink:href="https://www.snp-nexus.org/v4/">https://www.snp-nexus.org/v4/</ext-link>) (<xref ref-type="bibr" rid="bib20">Dayem Ullah et al., 2018</xref>) was used to annotate the overlapping, upstream and downstream genes; the GWAS Catalog (by SNP and then gene) (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/gwas/search">https://www.ebi.ac.uk/gwas/search</ext-link>), GeneCards (<ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link>) (<xref ref-type="bibr" rid="bib74">Stelzer et al., 2016</xref>), database, and phenoscanner (<ext-link ext-link-type="uri" xlink:href="http://www.phenoscanner.medschl.cam.ac.uk/">http://www.phenoscanner.medschl.cam.ac.uk/</ext-link>) were used to further explore previously associated relevant phenotypes and gene function. Lead SNPs were looked in <ext-link ext-link-type="uri" xlink:href="https://www.regulomedb.org/">https://www.regulomedb.org/</ext-link> to assess potential functionality.</p></sec><sec sec-type="appendix" id="s13"><title>Genetic control</title><p>The genomic inflation factor (λ) was calculated using the scipy.stats.chi2 module in Python. The chi-squared test statistics from the meta-analysis p-values were first obtained. Then, the observed median chi-squared statistic from the calculated chi-squared test statistics were calculated. Finally, the genomic inflation factor (λ) was derived by dividing the observed median chi-squared statistic by the expected median chi-squared statistic.</p></sec><sec sec-type="appendix" id="s14"><title>Heterogeneity scatter plots</title><p>Heterogeneity scatter plots were based on filtering signals for each pair of wheezing phenotypes. For example, for group1=persistent and group2=early-onset mid-childhood remitting wheezing.</p><p>If group1 has a p-value &lt;10<sup>–5</sup> and group2 has a p-value &gt;0.05, and group1 has a negative effect size (beta) while the lower bound of group2’s effect size (beta - CI) is greater than group1’s effect size, then we classified the result as group1 specific. If group1 has a p-value &lt;10<sup>–5</sup> and group2 has a p-value &gt;0.05, and group1 has a positive effect size (beta) while the upper bound of group2’s effect size (beta+CI) is less than group1’s effect size, then we classified the result as group1 specific.</p><p>If group2 has a p-value &lt;10<sup>–5</sup> and group1 has a p-value &gt;0.05, and group2 has a negative effect size (beta) while the lower bound of group1’s effect size (beta - CI) is greater than group2’s effect size, then we classified the result as group2 specific. If group2 has a p-value &lt;10<sup>–5</sup> and group1 has a p-value &gt;0.05, and group2 has a positive effect size (beta) while the upper bound of group1’s effect size (beta+CI) is less than group2’s effect size, then we classified the result as group2 specific.</p><p>If both group1 and group2 have p-values &lt;10<sup>–5</sup>, and their effect sizes (betas) have the same sign (i.e., both positive or both negative), then we classified the result as ‘Same direction’.</p><p>If both group1 and group2 have p-values &lt;10<sup>–5</sup>, and their effect sizes (betas) have opposite signs (i.e., one positive and one negative), then we classified the result as ‘Opposite direction’.</p></sec><sec sec-type="appendix" id="s15"><title>Gene expression in whole blood and lung tissues</title><p>The top independent SNPs associated with each of the wheeze phenotypes were assessed for their association with cis- and trans-acting gene expression (mRNA) in whole blood and lung tissues. We identified potential eQTL signals using Genotype-Tissue Expression database (<ext-link ext-link-type="uri" xlink:href="https://gtexportal.org">https://gtexportal.org</ext-link>) using the European reference panel.</p><table-wrap id="app2table1" position="float"><label>Appendix 2—table 1.</label><caption><title>List of 134 independent single nucleotide polymorphisms (SNPs) identified after clumping and associated with at least one wheezing phenotype (p&lt;10<sup>–5</sup>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">CHR</th><th align="left" valign="bottom">SNP</th><th align="left" valign="bottom">BP</th><th align="left" valign="bottom">Short-listed after inspection of locus zoom plot</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="4"><bold>Persistent wheezing</bold></td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs4620530</td><td align="char" char="." valign="bottom">240063821</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs13398488</td><td align="char" char="." valign="bottom">7142199</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs77062323</td><td align="char" char="." valign="bottom">53049017</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs6543291</td><td align="char" char="." valign="bottom">106011626</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs77655717</td><td align="char" char="." valign="bottom">128737320</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs77822621</td><td align="char" char="." valign="bottom">1008212</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs7680608</td><td align="char" char="." valign="bottom">1050437</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs115228498</td><td align="char" char="." valign="bottom">142969757</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs145937716</td><td align="char" char="." valign="bottom">143192224</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">rs116494115</td><td align="char" char="." valign="bottom">7736317</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">rs78701483</td><td align="char" char="." valign="bottom">95680422</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs138099941</td><td align="char" char="." valign="bottom">7654240</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs9346404</td><td align="char" char="." valign="bottom">71606613</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs143979498</td><td align="char" char="." valign="bottom">151040328</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs76871421</td><td align="char" char="." valign="bottom">105676144</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">rs59670576</td><td align="char" char="." valign="bottom">128555771</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs116933120</td><td align="char" char="." valign="bottom">27458652</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs75260654</td><td align="char" char="." valign="bottom">75788108</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs116849664</td><td align="char" char="." valign="bottom">75820902</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs143481506</td><td align="char" char="." valign="bottom">139515723</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">rs7088157</td><td align="char" char="." valign="bottom">100038964</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs112474574</td><td align="char" char="." valign="bottom">5885773</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs116861530</td><td align="char" char="." valign="bottom">116962661</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs7982350</td><td align="char" char="." valign="bottom">73106322</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs17461573</td><td align="char" char="." valign="bottom">106711373</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">14</td><td align="left" valign="bottom">rs1105683</td><td align="char" char="." valign="bottom">56213787</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs2202714</td><td align="char" char="." valign="bottom">49811991</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs117540214</td><td align="char" char="." valign="bottom">84338642</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs17676191</td><td align="char" char="." valign="bottom">37949924</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs79026872</td><td align="char" char="." valign="bottom">37965932</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs4795400</td><td align="char" char="." valign="bottom">38067020</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs1031460</td><td align="char" char="." valign="bottom">38072247</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs56199421</td><td align="char" char="." valign="bottom">38090808</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs4795406</td><td align="char" char="." valign="bottom">38100134</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs72832972</td><td align="char" char="." valign="bottom">38110575</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs4794821</td><td align="char" char="." valign="bottom">38124203</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs59843584</td><td align="char" char="." valign="bottom">38124892</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">rs111812993</td><td align="char" char="." valign="bottom">30353181</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">rs4804311</td><td align="char" char="." valign="bottom">8615589</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">rs2013694</td><td align="char" char="." valign="bottom">8616392</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">rs73501545</td><td align="char" char="." valign="bottom">8620823</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">rs111644945</td><td align="char" char="." valign="bottom">8625081</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">rs5994170</td><td align="char" char="." valign="bottom">17615213</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">rs34902370</td><td align="char" char="." valign="bottom">17632194</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Early-onset remitting wheezing</bold></td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs12730098</td><td align="char" char="." valign="bottom">212427488</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs75639566</td><td align="char" char="." valign="bottom">233019116</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs2880066</td><td align="char" char="." valign="bottom">17107219</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs10180268</td><td align="char" char="." valign="bottom">17126699</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs115031796</td><td align="char" char="." valign="bottom">86691640</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs3861377</td><td align="char" char="." valign="bottom">173317378</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs10513743</td><td align="char" char="." valign="bottom">176022304</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">rs10075253</td><td align="char" char="." valign="bottom">75548246</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">rs12520884</td><td align="char" char="." valign="bottom">84406634</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs117477297</td><td align="char" char="." valign="bottom">92565052</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs2453395</td><td align="char" char="." valign="bottom">166286532</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs56027869</td><td align="char" char="." valign="bottom">50072919</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs4730561</td><td align="char" char="." valign="bottom">78531705</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs73144976</td><td align="char" char="." valign="bottom">78586112</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs67259321</td><td align="char" char="." valign="bottom">78686582</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs146771277</td><td align="char" char="." valign="bottom">154438861</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs10758259</td><td align="char" char="." valign="bottom">34392908</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs7128994</td><td align="char" char="." valign="bottom">71242209</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs72994149</td><td align="char" char="." valign="bottom">106837223</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom">rs117367256</td><td align="char" char="." valign="bottom">93508478</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs2872948</td><td align="char" char="." valign="bottom">57442480</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs73527654</td><td align="char" char="." valign="bottom">57447994</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs2151504</td><td align="char" char="." valign="bottom">82291577</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs116966886</td><td align="char" char="." valign="bottom">47043587</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs117565527</td><td align="char" char="." valign="bottom">47342882</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Mid-childhood onset remitting wheezing</bold></td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs35725789</td><td align="char" char="." valign="bottom">159207367</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs146141555</td><td align="char" char="." valign="bottom">159227423</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs146575092</td><td align="char" char="." valign="bottom">159374228</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs140877050</td><td align="char" char="." valign="bottom">220848829</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs72745905</td><td align="char" char="." valign="bottom">223451086</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs7595553</td><td align="char" char="." valign="bottom">36127878</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs145007503</td><td align="char" char="." valign="bottom">50688324</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs6546068</td><td align="char" char="." valign="bottom">64583398</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs17387431</td><td align="char" char="." valign="bottom">206651315</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs144791928</td><td align="char" char="." valign="bottom">236963432</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs34315999</td><td align="char" char="." valign="bottom">8969653</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs115245770</td><td align="char" char="." valign="bottom">99209128</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs146961758</td><td align="char" char="." valign="bottom">194285978</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs138794367</td><td align="char" char="." valign="bottom">103859545</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">rs115719402</td><td align="char" char="." valign="bottom">77538102</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">rs76026399</td><td align="char" char="." valign="bottom">47531792</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs73172838</td><td align="char" char="." valign="bottom">154842348</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">rs112631708</td><td align="char" char="." valign="bottom">134500083</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs72752356</td><td align="char" char="." valign="bottom">98094970</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs113195384</td><td align="char" char="." valign="bottom">46333770</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs9602218</td><td align="char" char="." valign="bottom">84139813</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs61960366</td><td align="char" char="." valign="bottom">84144202</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs74589927</td><td align="char" char="." valign="bottom">84208697</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs2210726</td><td align="char" char="." valign="bottom">84492936</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom">rs4390476</td><td align="char" char="." valign="bottom">84598570</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">14</td><td align="left" valign="bottom">rs117443464</td><td align="char" char="." valign="bottom">73460284</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">rs72820814</td><td align="char" char="." valign="bottom">81916262</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">rs190526697</td><td align="char" char="." valign="bottom">12274299</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">rs75286534</td><td align="char" char="." valign="bottom">26206826</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">rs138888086</td><td align="char" char="." valign="bottom">63591085</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">rs76551535</td><td align="char" char="." valign="bottom">71879807</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">rs77496444</td><td align="char" char="." valign="bottom">19192132</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">20</td><td align="left" valign="bottom">rs6077514</td><td align="char" char="." valign="bottom">9302948</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Late-onset wheezing</bold></td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs9439669</td><td align="char" char="." valign="bottom">18859049</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs2051039</td><td align="char" char="." valign="bottom">57067560</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">rs72673642</td><td align="char" char="." valign="bottom">80727443</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs147557117</td><td align="char" char="." valign="bottom">19778063</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs140983998</td><td align="char" char="." valign="bottom">111402871</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs117617447</td><td align="char" char="." valign="bottom">123387601</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs13025116</td><td align="char" char="." valign="bottom">127505482</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">rs148008098</td><td align="char" char="." valign="bottom">128633620</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs4072729</td><td align="char" char="." valign="bottom">24780393</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs143960666</td><td align="char" char="." valign="bottom">31227943</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs4677102</td><td align="char" char="." valign="bottom">72193991</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs145629570</td><td align="char" char="." valign="bottom">113422516</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">rs113643470</td><td align="char" char="." valign="bottom">141728174</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">rs17472015</td><td align="char" char="." valign="bottom">48467594</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs117660982</td><td align="char" char="." valign="bottom">149438923</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs118027705</td><td align="char" char="." valign="bottom">150456728</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs139489493</td><td align="char" char="." valign="bottom">150481499</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">rs144271668</td><td align="char" char="." valign="bottom">157934780</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">rs990182</td><td align="char" char="." valign="bottom">89976447</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs79110962</td><td align="char" char="." valign="bottom">14432953</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">rs9325460</td><td align="char" char="." valign="bottom">82492323</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">rs7896106</td><td align="char" char="." valign="bottom">91196402</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">rs115465993</td><td align="char" char="." valign="bottom">109372900</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs16935643</td><td align="char" char="." valign="bottom">41395746</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">rs141958628</td><td align="char" char="." valign="bottom">119083284</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">14</td><td align="left" valign="bottom">rs113363660</td><td align="char" char="." valign="bottom">69410278</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs139134265</td><td align="char" char="." valign="bottom">44923960</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">rs143862030</td><td align="char" char="." valign="bottom">84922146</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">rs113390367</td><td align="char" char="." valign="bottom">1118849</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">rs4788025</td><td align="char" char="." valign="bottom">28003221</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">rs72918264</td><td align="char" char="." valign="bottom">51009510</td><td align="left" valign="bottom">No</td></tr><tr><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">rs133498</td><td align="char" char="." valign="bottom">48913809</td><td align="left" valign="bottom">Yes</td></tr></tbody></table></table-wrap><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Zoom locus plots for short-listed independent top hits for persistent wheezing.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app2-fig1-v2.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Zoom locus plots for short-listed independent top hits for early-onset pre-school remitting wheezing.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app2-fig2-v2.tif"/></fig><fig id="app2fig3" position="float"><label>Appendix 2—figure 3.</label><caption><title>Zoom locus plots for short-listed independent top hits for early-onset mid-childhood remitting wheezing.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app2-fig3-v2.tif"/></fig><fig id="app2fig4" position="float"><label>Appendix 2—figure 4.</label><caption><title>Zoom locus plots for short-listed independent top hits for late-onset wheezing.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app2-fig4-v2.tif"/></fig></sec></app><app id="appendix-3"><title>Appendix 3</title><sec sec-type="appendix" id="s16"><title>Post-GWAS: rs75260654 (<italic>ANXA1</italic>)</title><sec sec-type="appendix" id="s16-1"><title>Annotation and distribution</title><p>Information including chromosome, strand, clinical significance was retrieved from ENSEMBL using the R package biomaRt (<xref ref-type="bibr" rid="bib25">Durinck et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Durinck et al., 2009</xref>). The effects of rs75260654 on genomic features were predicted by querying the Ensembl VEP (<xref ref-type="bibr" rid="bib50">McLaren et al., 2016</xref>) web tool.</p><p>rs75260654 distribution in the GRCh38.p13 build of the human genome across African, Asian, and European populations of the 1000 Genomes Project Phase 3 were accessed by querying the Ensembl (<ext-link ext-link-type="uri" xlink:href="https://www.ensembl.org">https://www.ensembl.org</ext-link>) web browser on 24 May 2021.</p></sec><sec sec-type="appendix" id="s16-2"><title>Promoter Capture</title><p>The Hi-C libraries were prepared from CD4+ T cells isolated from seven healthy individuals (two libraries per individual) from the MAAS cohort using the Arima-HiC kit (Arima Genomics). PCHi-C libraries were generated by capturing the restriction fragments (RF) overlapping the TSS of 18,775 protein-coding genes using the Agilent SureSelectXT HS Target Enrichment System according to the manufacturer’s protocols. The final design included 305,419 probes covering 13.476 Mb and 18,630 protein-coding genes. The RF overlapping the TSS (±1 RF, 3 RF per promoter) were captured with custom-designed biotinylated RNA baits. Libraries were sequenced to ~300 M 2×150 bp reads each (~600 M reads/individual). The 3’-end of the reads was quality trimmed with Sickle. The sequencing data were processed with the HiCUP pipeline to map the sequencing reads and eliminate experimental artefacts and PCR duplicates (<xref ref-type="bibr" rid="bib82">Wingett et al., 2015</xref>). The BAM files from technical replicates were merged. Promoter interactions were called using the CHiCAGO pipeline (<xref ref-type="bibr" rid="bib9">Cairns et al., 2016</xref>), which calls statistically significant interactions in PCHi-C data while accounting for noise and PCHi-C-specific bias. A CHiCAGO score &gt;5 (soft-thresholded -log weighted p-value) was considered significant. To gain information from all the available data, the BAM files from all seven individuals were supplied as biological replicates in the analysis with CHiCAGO. Moreover, to increase power, RF were binned as follows: 10 consecutive RF that were not covered by the baits were binned together; the 3 baited fragments for each promoter were binned with 1 RF upstream and 1 downstream, totalling 5 fragments per promoter. If the bins for two consecutive promoters overlapped, these were binned together into a single larger bin. Publicly available ENCODE ATAC-seq (A549 cell line) and ChIP-seq (A549 cell line ENCFF900GVO) and POLR2A ChIP-seq (A549 cell line, ENCFF737ZKN) data and 18-state ChromHMM from the EpiMap Project (BSS00007) (<xref ref-type="bibr" rid="bib2">Adsera et al., 2019</xref>) for A549 cell line were downloaded. The PCHi-C interactions of interest and their overlap with ATAC-seq and ChIP-seq peaks, and putative enhancers from the 18-state ChromHMM model were visualised using the Sushi R package.</p></sec><sec sec-type="appendix" id="s16-3"><title>eQTL catalogue lookup</title><p>We queried the eQTL catalogue (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/eqtl/">https://www.ebi.ac.uk/eqtl/</ext-link>; accessed 6 May 2021) using tabix-0.2.6 to assess if <italic>rs75260654</italic>, <italic>rs116849664,</italic> or <italic>rs78320984</italic> are eQTLs in studies that utilised the following cell types: lung, T cells, blood, monocytes, neutrophils, NK cells, fibroblasts, B cells, CD4+ T cells, CD8+ T cells, Th17 cells, Th1 cells, Th2 cells, Treg naive, Treg memory, CD16+ monocytes, cultured fibroblasts, EBV-transformed lymphocytes. We defined nominal significance as p ≤ 0.05.</p></sec><sec sec-type="appendix" id="s16-4"><title>Variant effect</title><p>Variant effect on tissue-specific gene expression, which is based on GTEx eQTL, was retrieved on May 24 from eQTL Ensembl database (<ext-link ext-link-type="uri" xlink:href="https://www.ensembl.org/">https://www.ensembl.org/</ext-link>) and eQTLGene Consortium (<ext-link ext-link-type="uri" xlink:href="https://www.eqtlgen.org/cis-eqtls.html">https://www.eqtlgen.org/cis-eqtls.html</ext-link>). Using downloaded correlation of variant on tissue-specific gene expression from Ensembl, the relative effect of T allele on the <italic>ANXA1</italic> expression across 86 tissue types was presented in scatter plot using R version 3.6.1 (<xref ref-type="bibr" rid="bib37">Ihaka and Gentleman, 1996</xref>). To get information on the functional role of <italic>ANXA1</italic>, the top 30 interacting proteins and enrichment were retrieved from STRING database (<xref ref-type="bibr" rid="bib75">Szklarczyk et al., 2019</xref>) into cystoscape for visualisation (<xref ref-type="bibr" rid="bib69">Shannon et al., 2003</xref>).</p></sec></sec></app><app id="appendix-4"><title>Appendix 4</title><sec sec-type="appendix" id="s17"><title>Results in context of literature</title><p>Previously relevant associated traits for each region/gene now associated with different wheezing phenotypes are presented in <xref ref-type="table" rid="app5table1 app5table2 app5table3 app5table4">Appendix 5—tables 1–4</xref>.</p><sec sec-type="appendix" id="s17-1"><title>Persistent wheeze</title><p>We identified two GWAS-significant loci: 17q21, p&lt;5.5 × 10<sup>–9</sup>, and a novel locus on 9q21.13 (<italic>ANXA1</italic>), p&lt;6.7 × 10<sup>–9</sup>. The remaining 17 loci (4.0×10<sup>–7</sup> ≤ p-values ≤9.8 × 10<sup>–6</sup>) included regions previously associated with childhood asthma (1q43, 4p16.3, 4q31.21, 5p15.31, 7q22.3, 17q12), asthma and rhinitis (2p25.1), eosinophil count (3q21.3, 10q24.2, 11q23.3, 22q11.1), bronchial hyper-responsiveness (2q12.2), lung function (1q43, 3q21.3, 5q13.3, 15q25.2, 19p13.2), triglycerides measurement and/or glucose metabolism (11q23.3, 19p13.2, and 22q11.1), severe asthma (14q22.1), and severe asthma and insulin resistance (11p15.4). See <xref ref-type="table" rid="app5table1">Appendix 5—table 1</xref>.</p></sec><sec sec-type="appendix" id="s17-2"><title>Early-onset pre-school remitting wheeze</title><p>Among the regions associated with early-onset pre-school remitting wheeze, we identified loci previously associated with smoking (3q26.31, 7q21.11, and 15q21.1), waist circumference and obesity (1q32.3), asthma and/or BMI (5q13.3, 6q27, 7q21.11), allergic disease and atopy (7q21.11), and airway repair (2p24.2 and 9p13.3). See <xref ref-type="table" rid="app5table2">Appendix 5—table 2</xref>.</p></sec><sec sec-type="appendix" id="s17-3"><title>Early-onset mid-childhood remitting wheeze</title><p>Loci associated with this phenotype were previously associated with neutrophil counts (1q23.2, 3q29, 20p12.3-p12.2), eosinophil counts and allergic rhinitis (4q24), pollution and DNA methylation (2p22.3), atopy (3p25.3), food allergy (13q31.1), and BMI (3q29, 5q14.1). See <xref ref-type="table" rid="app5table3">Appendix 5—table 3</xref>.</p></sec><sec sec-type="appendix" id="s17-4"><title>Late-onset wheeze</title><p>Regions associated with late-onset wheeze were previously associated with adult-onset non-allergic asthma (3q13.2), asthma/allergic disease and allergy/atopic sensitisation (3q23, 7q36.1), asthma and/or allergy in adolescence (9p22.3, 16p12.1), late-onset asthma and obesity (2q13), lung function or body height (2q14.3, 3p24.2, 3q13.2, 15q25.2), lymphocyte count and asthma susceptibility (1p32.2), obesity and/or metabolic syndrome/dysfunction (1p36.13 and 22q13.32), eczema (7q36.3), insulin resistance (10q23.31), type 1 diabetes (8q21.3), alcohol drinking (15q15.3-q21.1), and sex hormone-binding globulin levels (11q23.3). See <xref ref-type="table" rid="app5table4">Appendix 5—table 4</xref>.</p><table-wrap id="app4table1" position="float"><label>Appendix 4—table 1.</label><caption><title>References to previous relevant associated traits for each region/gene identified in early-onset persistent wheezing.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="4">Early-onset persistent wheezing</th></tr><tr><th align="left" valign="bottom">Gene(s)</th><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">Previous associated trait</th><th align="left" valign="bottom">Reference or source</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>CHRM3</italic></td><td align="char" char="." valign="bottom">1q43</td><td align="left" valign="bottom"><bold>FEV<sub>1</sub>, FEV<sub>1</sub>/FVC</bold>, <bold>asthma</bold> – high priority drug target</td><td align="left" valign="bottom">Patel, K.R. et al<italic>.</italic> Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma. <italic>FASEB J</italic> <bold>31</bold>, 4335–4346 (2017).</td></tr><tr><td align="left" valign="bottom"><italic>RNF144A</italic></td><td align="char" char="." valign="bottom">2p25.1</td><td align="left" valign="bottom"><bold>Asthma</bold>, allergy, childhood onset <bold>asthma</bold>, <bold>allergic rhinitis</bold></td><td align="left" valign="bottom">Schoettler, N. et al<italic>.</italic> Advances in asthma and allergic disease genetics: Is bigger always better? <italic>J Allergy Clin Immunol</italic> <bold>144</bold>, 1495–1506 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>FHL2</italic></td><td align="char" char="." valign="bottom">2q12.2</td><td align="left" valign="bottom"><bold>Bronchial hyper-responsiveness</bold>, airway inflammation, novel gene associated with <bold>asthma</bold> severity in human</td><td align="left" valign="bottom">Kurakula, K. et al<italic>.</italic> Deficiency of FHL2 attenuates airway inflammation in mice and genetic variation associates with human bronchial hyper-responsiveness. <italic>Allergy</italic> <bold>70</bold>, 1531–44 (2015).</td></tr><tr><td align="left" valign="bottom"><italic>RAB7A</italic></td><td align="char" char="." valign="bottom">3q21.3</td><td align="left" valign="bottom"><bold>Eosinophil count</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>RAB43</italic></td><td align="char" char="." valign="bottom">3q21.3</td><td align="left" valign="bottom">Response to <bold>bronchodilator</bold>, <bold>FEV<sub>1</sub>/FEC ratio</bold></td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>RNF212, IDUA, DGKQ, SLC26A1</italic></td><td align="char" char="." valign="bottom">4p16.3</td><td align="left" valign="bottom"><bold>Asthma</bold></td><td align="left" valign="bottom">Gautam, Y. et al<italic>.</italic> Comprehensive functional annotation of susceptibility variants associated with asthma. <italic>Hum Genet</italic> <bold>139</bold>, 1037–1053 (2020).</td></tr><tr><td align="left" valign="bottom"><italic>INPP4B</italic></td><td align="char" char="." valign="bottom">4q31.21</td><td align="left" valign="bottom">Atopic <bold>asthma</bold></td><td align="left" valign="bottom">Sharma, M. et al<italic>.</italic> A genetic variation in inositol polyphosphate 4 phosphatase a enhances susceptibility to asthma. <italic>Am J Respir Crit Care Med</italic> <bold>177</bold>, 712–9 (2008).</td></tr><tr><td align="left" valign="bottom"><italic>ADCY2</italic></td><td align="char" char="." valign="bottom">5p15.31</td><td align="left" valign="bottom"><bold>Asthma</bold>×air pollution, childhood <bold>asthma</bold></td><td align="left" valign="bottom">Gref, A. et al<italic>.</italic> Genome-Wide Interaction Analysis of Air Pollution Exposure and Childhood Asthma with Functional Follow-up. <italic>Am J Respir Crit Care Med</italic> <bold>195</bold>, 1373–1383 (2017).</td></tr><tr><td align="left" valign="bottom"><italic>CDHR3</italic></td><td align="char" char="." valign="bottom">7q22.3</td><td align="left" valign="bottom">Childhood <bold>asthma</bold></td><td align="left" valign="bottom">Everman, J.L. et al<italic>.</italic> Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations. <italic>J Allergy Clin Immunol</italic> <bold>144</bold>, 962–971 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="char" char="." valign="bottom">9q21.13</td><td align="left" valign="bottom"><bold>FEV<sub>1</sub>/FVC</bold>, response to <bold>bronchodilators</bold> in smokers</td><td align="left" valign="bottom">Lutz, S.M. et al<italic>.</italic> A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. <italic>BMC Genet</italic> <bold>16</bold>, 138 (2015).</td></tr><tr><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="char" char="." valign="bottom">9q21.13</td><td align="left" valign="bottom">Anti-inflammatory properties, strongly expressed in <bold>bronchial mast cells</bold></td><td align="left" valign="bottom">Vieira Braga FA et al<italic>.</italic> A cellular census of human lungs identifies novel cell states in health and in asthma. (2019).</td></tr><tr><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="char" char="." valign="bottom">9q21.13</td><td align="left" valign="bottom">Potentially involved in epithelial <bold>airway repair</bold></td><td align="left" valign="bottom">Leoni, G. et al<italic>.</italic> Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. <italic>J Clin Invest</italic> <bold>125</bold>, 1215–27 (2015).</td></tr><tr><td align="left" valign="bottom"><italic>R3HCC1L</italic></td><td align="char" char="." valign="bottom">10q24.2</td><td align="left" valign="bottom">Atopic <bold>eczema</bold>, psoriasis</td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>R3HCC1L</italic></td><td align="char" char="." valign="bottom">10q24.2</td><td align="left" valign="bottom"><bold>Eosinophil count</bold>, BMI</td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>TRIM5, TRIM6, TRIM22</italic></td><td align="char" char="." valign="bottom">11p15.4</td><td align="left" valign="bottom">Severe <bold>asthma</bold> and insulin resistance</td><td align="left" valign="bottom">Kimura, T. et al. Precision autophagy directed by receptor regulators - emerging examples within the TRIM family. <italic>J Cell Sci</italic> <bold>129</bold>, 881–91 (2016).</td></tr><tr><td align="left" valign="bottom"><italic>SIK3</italic></td><td align="char" char="." valign="bottom">11q23.3</td><td align="left" valign="bottom">Triglycerides, glucose metabolism, <bold>eosinophil count</bold></td><td align="left" valign="bottom">Sun, Z. et al. The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Sig Transduct Target Ther <bold>5</bold> (2020).</td></tr><tr><td align="left" valign="bottom"><italic>KTN1</italic></td><td align="char" char="." valign="bottom">14q22.1</td><td align="left" valign="bottom">Severe <bold>asthma</bold></td><td align="left" valign="bottom">Bigler, J. et al. A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts. Am J Respir Crit Care Med <bold>195</bold>, 1311–1320 (2017).</td></tr><tr><td align="left" valign="bottom"><italic>FAM227B</italic></td><td align="char" char="." valign="bottom">5q13.3</td><td align="left" valign="bottom">rs35251997 and <bold>FEV<sub>1</sub>, FEV<sub>1</sub>/FVC</bold></td><td align="left" valign="bottom">Shrine, N. et al<italic>.</italic> New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. <italic>Nat Genet</italic> <bold>51</bold>, 481–493 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>ADAMTSL3</italic></td><td align="char" char="." valign="bottom">15q25.2</td><td align="left" valign="bottom"><bold>FEV1/FVC</bold></td><td align="left" valign="bottom">Sakornsakolpat, P. et al<italic>.</italic> Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <italic>Nat Genet</italic> <bold>51</bold>, 494–505 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>IKZF3, GSDMB, LRRC3C, GSDMA</italic></td><td align="char" char="." valign="bottom">17q12</td><td align="left" valign="bottom">Early-onset <bold>asthma</bold>, <bold>persistent wheezing</bold> (chr17q12-q21)</td><td align="left" valign="bottom">Granell R et al. Examination of the relationship between variation at 17q21 and childhood wheeze phenotypes. J Allergy Clin Immunol. 2013 Mar;131(3):685–94.</td></tr><tr><td align="left" valign="bottom"><italic>MARCH2, HNRNPM, MYO1F</italic></td><td align="char" char="." valign="bottom">19p13.2</td><td align="left" valign="bottom">Triglycerides, HDL cholesterol, metabolic syndrome</td><td align="left" valign="bottom">Sajuthi, S.P. et al<italic>.</italic> Genetic regulation of adipose tissue transcript expression is involved in modulating serum triglyceride and HDL-cholesterol. <italic>Gene</italic> <bold>632</bold>, 50–58 (2017).</td></tr><tr><td align="left" valign="bottom"><italic>MYO1F</italic></td><td align="char" char="." valign="bottom">19p13.2</td><td align="left" valign="bottom"><bold>FEV<sub>1</sub> and FVC</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>CECR5</italic></td><td align="char" char="." valign="bottom">22q11.1</td><td align="left" valign="bottom">Triglycerides, <bold>eosinophil count</bold>, and body height</td><td align="left" valign="bottom">Liu, D.J. et al<italic>.</italic> Exome-wide association study of plasma lipids in &gt;300,000 individuals. <italic>Nat Genet</italic> <bold>49</bold>, 1758–1766 (2017).</td></tr></tbody></table></table-wrap><table-wrap id="app4table2" position="float"><label>Appendix 4—table 2.</label><caption><title>References to previous relevant associated traits for each region/gene identified in early-onset pre-school remitting wheezing.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">Early-onset pre-school remitting wheezing</th><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Gene(s)</th><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">Previous associated trait</th><th align="left" valign="bottom">Reference or source</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>PPP2R5A</italic></td><td align="char" char="." valign="bottom">1q32.3</td><td align="left" valign="bottom"><bold>Waist circumference and obesity</bold></td><td align="left" valign="bottom">Kim, H.J. et al. Combined linkage and association analyses identify a novel locus for obesity near PROX1 in Asians. <italic>Obesity (Silver Spring)</italic> <bold>21</bold>, 2405–12 (2013).</td></tr><tr><td align="left" valign="bottom"><italic>FAM49A or CYRIA</italic></td><td align="char" char="." valign="bottom">2p24.2</td><td align="left" valign="bottom"><bold>Airway repair</bold> in <bold>non-atopic asthma</bold></td><td align="left" valign="bottom">Hoang, T.T. et al<italic>.</italic> Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study. <italic>Eur Respir J</italic> <bold>56</bold> (2020).</td></tr><tr><td align="left" valign="bottom"><italic>NLGN1</italic></td><td align="char" char="." valign="bottom">3q26.31</td><td align="left" valign="bottom"><bold>Smoking</bold></td><td align="left" valign="bottom">Drgon, T. et al<italic>.</italic> Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. <italic>Mol Med</italic> <bold>15</bold>, 21–7 (2009).</td></tr><tr><td align="left" valign="bottom"><italic>NAALADL2</italic></td><td align="char" char="." valign="bottom">3q26.31</td><td align="left" valign="bottom"><italic>Suggestive association with severe asthma exacerbations</italic></td><td align="left" valign="bottom">Herrera-Luis E et al. Genome-wide association study reveals a novel locus for asthma with severe exacerbations in diverse populations. Pediatr Allergy Immunol. 2021;32(1):106–115.</td></tr><tr><td align="left" valign="bottom"><italic>SV2C</italic></td><td align="char" char="." valign="bottom">5q13.3</td><td align="left" valign="bottom"><bold>BMI</bold>, diastolic <bold>blood pressure</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>PDE10A</italic></td><td align="char" char="." valign="bottom">6q27</td><td align="left" valign="bottom">Birth weight, <bold>asthma</bold>, and <bold>BMI</bold></td><td align="left" valign="bottom">Melen, E. et al. Analyses of shared genetic factors between asthma and obesity in children. J Allergy Clin Immunol <bold>126</bold>, 631–7 e1-8 (2010).</td></tr><tr><td align="left" valign="bottom"><italic>MAGI2</italic></td><td align="char" char="." valign="bottom">7q21.11</td><td align="left" valign="bottom"><bold>Allergic diseases and atopy</bold></td><td align="left" valign="bottom">Freidin, M.B. et al. [Genome-wide association study of allergic diseases in Russians of Western Siberia]. Mol Biol (Mosk) <bold>45</bold>, 464–72 (2011).</td></tr><tr><td align="left" valign="bottom"><italic>MAGI2</italic></td><td align="char" char="." valign="bottom">7q21.11</td><td align="left" valign="bottom"><bold>Smoking</bold></td><td align="left" valign="bottom">Quach, B.C. et al<italic>.</italic> Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits. <italic>Nat Commun</italic> <bold>11</bold>, 5562 (2020).</td></tr><tr><td align="left" valign="bottom"><italic>MAGI2</italic></td><td align="char" char="." valign="bottom">7q21.11</td><td align="left" valign="bottom"><bold>BMI</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>MAGI2</italic></td><td align="char" char="." valign="bottom">7q21.11</td><td align="left" valign="bottom"><bold>Airway wall thickness</bold></td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>C9orf24</italic></td><td align="char" char="." valign="bottom">9p13.3</td><td align="left" valign="bottom"><bold>Airway repair</bold></td><td align="left" valign="bottom">Yoshisue, H. et al<italic>.</italic> Characterisation of ciliated bronchial epithelium 1, a ciliated cell-associated gene induced during mucociliary differentiation. <italic>Am J Respir Cell Mol Biol</italic> <bold>31</bold>, 491–500 (2004).</td></tr><tr><td align="left" valign="bottom"><italic>GUCY1A2</italic></td><td align="char" char="." valign="bottom">11q22.3</td><td align="left" valign="bottom">Systolic/diastolic <bold>blood pressure</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>PRR20A/B/C/D/E</italic></td><td align="char" char="." valign="bottom">13q21.1</td><td align="left" valign="bottom">Systolic <bold>blood pressure</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>SEMA6D</italic></td><td align="char" char="." valign="bottom">15q21.1</td><td align="left" valign="bottom"><bold>Smoking</bold></td><td align="left" valign="bottom">Minica, C.C. et al. Pathways to smoking behaviours: biological insights from the Tobacco and Genetics Consortium meta-analysis. Mol Psychiatry 22, 82–88 (2017).</td></tr></tbody></table></table-wrap><table-wrap id="app4table3" position="float"><label>Appendix 4—table 3.</label><caption><title>References to previous relevant associated traits for each region/gene identified in early-onset mid-childhood remitting wheezing.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">Early-onset mid-childhood remitting wheezing</th><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Gene(s)</th><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">Previous associated trait</th><th align="left" valign="bottom">Reference</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>CADM3, FCER1A, MPTX1, OR10J1</italic></td><td align="left" valign="bottom">1q23.2</td><td align="left" valign="bottom"><bold>Neutrophil count</bold>, CRP</td><td align="left" valign="bottom">Barreto, M. et al<italic>.</italic> Duffy phenotyping and FY*B-67T/C genotyping as screening test for benign constitutional neutropenia. <italic>Hematol Transfus Cell Ther</italic> (2020).</td></tr><tr><td align="left" valign="bottom"><italic>MRPL50P1</italic></td><td align="left" valign="bottom">2p22.3</td><td align="left" valign="bottom"><bold>PM 2.5</bold> exposure level and global <bold>DNA methylation</bold> level</td><td align="left" valign="bottom">Liu, J. et al<italic>.</italic> Genetic variants, PM2.5 exposure level and global DNA methylation level: A multi-center population-based study in Chinese. <italic>Toxicol Lett</italic> <bold>269</bold>, 77–82 (2017).</td></tr><tr><td align="left" valign="bottom"><italic>RAD18</italic></td><td align="left" valign="bottom">3p25.3</td><td align="left" valign="bottom"><bold>Atopy/SPT</bold></td><td align="left" valign="bottom">Bouzigon, E. et al. Meta-analysis of 20 genome-wide linkage studies evidenced new regions linked to asthma and atopy. <italic>Eur J Hum Genet</italic> <bold>18</bold>, 700–6 (2010).</td></tr><tr><td align="left" valign="bottom"><italic>MRPL50P1</italic></td><td align="left" valign="bottom">3q29</td><td align="left" valign="bottom"><bold>BMI</bold></td><td align="left" valign="bottom">Kettunen, J. et al<italic>.</italic> Multicenter dizygotic twin cohort study confirms two linkage susceptibility loci for body mass index at 3q29 and 7q36 and identifies three further potential novel loci. <italic>Int J Obes (Lond)</italic> <bold>33</bold>, 1235–42 (2009).</td></tr><tr><td align="left" valign="bottom"><italic>LSG1</italic></td><td align="left" valign="bottom">3q29</td><td align="left" valign="bottom"><bold>BMI, eosinophil, and neutrophil count</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>TMEM44-AS1, TMEM44, ATP13A3</italic></td><td align="left" valign="bottom">3q29</td><td align="left" valign="bottom">Diastolic blood pressure</td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>SLC9B1</italic></td><td align="left" valign="bottom">4q24</td><td align="left" valign="bottom"><bold>Eosinophil count</bold></td><td align="left" valign="bottom">Aschard, H. et al<italic>.</italic> Sex-specific effect of IL9 polymorphisms on lung function and polysensitization. <italic>Genes Immun</italic> <bold>10</bold>, 559–65 (2009).</td></tr><tr><td align="left" valign="bottom"><italic>SLC9B1</italic></td><td align="left" valign="bottom">4q24</td><td align="left" valign="bottom"><bold>Allergic rhinitis</bold></td><td align="left" valign="bottom">Haagerup, A. et al<italic>.</italic> Allergic rhinitis--a total genome-scan for susceptibility genes suggests a locus on chromosome 4q24-q27. <italic>Eur J Hum Genet</italic> <bold>9</bold>, 945–52 (2001).</td></tr><tr><td align="left" valign="bottom"><italic>AP3B1</italic></td><td align="left" valign="bottom">5q14.1</td><td align="left" valign="bottom"><bold>Vital capacity, BMI</bold></td><td align="left" valign="bottom">GeneCards, GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>RNU6-67P, SLITRK1, VENTXP2, UBE2D3P4, MTND4P1</italic></td><td align="left" valign="bottom">13q31.1</td><td align="left" valign="bottom">RNU6-67P/ rs976078: <bold>food allergy</bold></td><td align="left" valign="bottom">Liu, X. et al<italic>.</italic> Genome-wide association study of maternal genetic effects and parent-of-origin effects on food allergy. <italic>Medicine (Baltimore)</italic> <bold>97</bold>, e0043 (2018).</td></tr><tr><td align="left" valign="bottom"><italic>ZFYVE1</italic></td><td align="left" valign="bottom">14q24.2</td><td align="left" valign="bottom">LDL <bold>cholesterol</bold> and systolic blood pressure</td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>PLCB4</italic></td><td align="left" valign="bottom">20p12.3-p12.2</td><td align="left" valign="bottom"><bold>Neutrophil count</bold></td><td align="left" valign="bottom">Okada, Y. et al<italic>.</italic> Common variations in PSMD3-CSF3 and PLCB4 are associated with neutrophil count. <italic>Hum Mol Genet</italic> <bold>19</bold>, 2079–85 (2010).</td></tr></tbody></table></table-wrap><table-wrap id="app4table4" position="float"><label>Appendix 4—table 4.</label><caption><title>References to previous relevant associated traits for each region/gene identified in late-onset wheezing.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2">Late-onset wheezing</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Gene(s)</th><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">Previous associated trait</th><th align="left" valign="bottom">Reference</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>KLHDC7A</italic></td><td align="left" valign="bottom">1p36.13</td><td align="left" valign="bottom">1p36.13: <bold>metabolic syndrome</bold></td><td align="left" valign="bottom">Hoffmann, K. et al<italic>.</italic> A German genome-wide linkage scan for type 2 diabetes supports the existence of a metabolic syndrome locus on chromosome 1p36.13 and a type 2 diabetes locus on chromosome 16p12.2. <italic>Diabetologia</italic> <bold>50</bold>, 1418–22 (2007).</td></tr><tr><td align="left" valign="bottom"><italic>PPAP2B, PRKAA2</italic></td><td align="left" valign="bottom">1p32.2</td><td align="left" valign="bottom">PRKAA2: lymphocyte count and <bold>asthma</bold> susceptibility</td><td align="left" valign="bottom">Cusanovich, D.A. et al<italic>.</italic> The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes. <italic>Hum Mol Genet</italic> <bold>21</bold>, 2111–23 (2012).</td></tr><tr><td align="left" valign="bottom"><italic>HMGB1P18</italic></td><td align="left" valign="bottom">1p31.1</td><td align="left" valign="bottom"><bold>Smoking</bold>, <bold>BMI</bold></td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>ACOXL, BUB1</italic></td><td align="left" valign="bottom">2q13</td><td align="left" valign="bottom">ACOXL: <bold>later onset asthma and obesity</bold></td><td align="left" valign="bottom">Zhu, Z. et al<italic>.</italic> Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. <italic>J Allergy Clin Immunol</italic> <bold>145</bold>, 537–549 (2020).</td></tr><tr><td align="left" valign="bottom"><italic>AMMECR1L</italic></td><td align="left" valign="bottom">2q14.3</td><td align="left" valign="bottom"><bold>Body height</bold>, blood protein, growth, bone, and heart alterations</td><td align="left" valign="bottom">Moyses-Oliveira, M. et al<italic>.</italic> Inactivation of AMMECR1 is associated with growth, bone, and heart alterations. <italic>Hum Mutat</italic> <bold>39</bold>, 281–291 (2018).</td></tr><tr><td align="left" valign="bottom">RARB</td><td align="left" valign="bottom">3p24.2</td><td align="left" valign="bottom"><bold>FEV<sub>1</sub>/FVC</bold>, adult lung function</td><td align="left" valign="bottom">Collins, S.A. et al<italic>.</italic> HHIP, HDAC4, NCR3 and RARB polymorphisms affect fetal, childhood and adult lung function. <italic>Eur Respir J</italic> <bold>41</bold>, 756–7 (2013).</td></tr><tr><td align="left" valign="bottom"><italic>KIAA2018, NAA50, SIDT1, CD200</italic></td><td align="left" valign="bottom">3q13.2</td><td align="left" valign="bottom">SIDT1: <bold>FEV<sub>1</sub>/FVC</bold>, CD200: <bold>adult-onset non-allergic asthma</bold></td><td align="left" valign="bottom">Siroux, V. et al<italic>.</italic> Genetic heterogeneity of asthma phenotypes identified by a clustering approach. <italic>Eur Respir J</italic> <bold>43</bold>, 439–52 (2014).</td></tr><tr><td align="left" valign="bottom"><italic>TFDP2, XRN1</italic></td><td align="left" valign="bottom">3q23</td><td align="left" valign="bottom">XRN1: <bold>eosinophil count</bold>, 3q23: <bold>allergic disease and atopic sensitisation</bold></td><td align="left" valign="bottom">Freidin, M.B. et al<italic>.</italic> [Genome-wide association study of allergic diseases in Russians of Western Siberia]. <italic>Mol Biol (Mosk)</italic> <bold>45</bold>, 464–72 (2011).</td></tr><tr><td align="left" valign="bottom"><italic>SLAIN2, SLC10A4, FRYL</italic></td><td align="left" valign="bottom">4p11</td><td align="left" valign="bottom">FRYL: body height, age at menopause</td><td align="left" valign="bottom">GeneCards</td></tr><tr><td align="left" valign="bottom"><italic>KRBA1, ZNF467</italic></td><td align="left" valign="bottom">7q36.1</td><td align="left" valign="bottom">Systolic blood pressure</td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>GIMAP family, AOC1, LOC105375566</italic></td><td align="left" valign="bottom">7q36.1</td><td align="left" valign="bottom">AOC1: CV disease, <bold>smoking</bold>, GIMAP family: autoimmune diabetes, <bold>asthma and allergy</bold></td><td align="left" valign="bottom">Heinonen, M.T. et al<italic>.</italic> GIMAP GTPase family genes: potential modifiers in autoimmune diabetes, asthma, and allergy. <italic>J Immunol</italic> <bold>194</bold>, 5885–94 (2015).</td></tr><tr><td align="left" valign="bottom"><italic>PTPRN2</italic></td><td align="left" valign="bottom">7q36.3</td><td align="left" valign="bottom"><bold>Eczema</bold></td><td align="left" valign="bottom">Bogari, N.M. et al<italic>.</italic> Whole exome sequencing detects novel variants in Saudi children diagnosed with eczema. <italic>J Infect Public Health</italic> <bold>13</bold>, 27–33 (2020).</td></tr><tr><td align="left" valign="bottom"><italic>LOC105375631</italic></td><td align="left" valign="bottom">8q21.3</td><td align="left" valign="bottom">8q21.3: <bold>type 1 diabetes</bold></td><td align="left" valign="bottom">Mukhopadhyay, N., Noble, J.A., Govil, M., Marazita, M.L. &amp; Greenberg, D.A. Identifying genetic risk loci for diabetic complications and showing evidence for heterogeneity of type 1 diabetes based on complications risk. <italic>PLoS One</italic> <bold>13</bold>, e0192696 (2018).</td></tr><tr><td align="left" valign="bottom"><italic>NFIB, ZDHHC21</italic></td><td align="left" valign="bottom">9p22.3</td><td align="left" valign="bottom">9p22.3: <bold>asthma</bold> (mean age &lt;16 years)</td><td align="left" valign="bottom">Denham, S. et al<italic>.</italic> Meta-analysis of genome-wide linkage studies of asthma and related traits. <italic>Respir Res</italic> <bold>9</bold>, 38 (2008).</td></tr><tr><td align="left" valign="bottom"><italic>SLC16A12, IFIT family, PANK1</italic></td><td align="left" valign="bottom">10q23.31</td><td align="left" valign="bottom">SLC16A12: body height, PANK1: <bold>insulin resistance</bold></td><td align="left" valign="bottom">Yang, L. et al. P53/PANK1/miR-107 signalling pathway spans the gap between metabolic reprogramming and insulin resistance induced by high-fat diet. <italic>J Cell Mol Med</italic> <bold>24</bold>, 3611–3624 (2020).</td></tr><tr><td align="left" valign="bottom"><italic>CBL, CCDC84, MCAM</italic></td><td align="left" valign="bottom">11q23.3</td><td align="left" valign="bottom">CBL: <bold>sex hormone-binding globulin levels</bold>; MCAM: blood protein levels</td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>SPG11, CTDSPL2</italic></td><td align="left" valign="bottom">15q15.3-q21.1</td><td align="left" valign="bottom">CTDSPL2: <bold>alcohol drinking</bold></td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>ADAMTSL3, GOLGA6L4, UBE2Q2P8</italic></td><td align="left" valign="bottom">15q25.2</td><td align="left" valign="bottom">ADAMTSL3: <bold>FEV<sub>1</sub>/FVC</bold>, lean mass</td><td align="left" valign="bottom">Karasik, D. et al<italic>.</italic> Disentangling the genetics of lean mass. <italic>Am J Clin Nutr</italic> <bold>109</bold>, 276–287 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>SSTR5-AS1, CACNA1H</italic></td><td align="left" valign="bottom">16p13.3</td><td align="left" valign="bottom">CACNA1H: <bold>eosinophil count</bold></td><td align="left" valign="bottom">GWAS Catalog</td></tr><tr><td align="left" valign="bottom"><italic>GSG1L</italic></td><td align="left" valign="bottom">16p12.1</td><td align="left" valign="bottom">16p12.1: current <bold>asthma</bold> and rhino-conjunctivitis at 10–15 years</td><td align="left" valign="bottom">Sottile, G. et al<italic>.</italic> An association analysis to identify genetic variants linked to asthma and rhino-conjunctivitis in a cohort of Sicilian children. <italic>Ital J Pediatr</italic> <bold>45</bold>, 16 (2019).</td></tr><tr><td align="left" valign="bottom"><italic>FAM19A5 or TAFA5</italic></td><td align="left" valign="bottom">22q13.32</td><td align="left" valign="bottom"><bold>Obesity and metabolic dysfunction</bold></td><td align="left" valign="bottom">Recinella L. et al. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front Physiol. 2020 Oct 30;11:578966</td></tr></tbody></table></table-wrap></sec></sec></app><app id="appendix-5"><title>Appendix 5</title><sec sec-type="appendix" id="s18"><title>Replication of <italic>ANXA1</italic> top hits in PIAMA cohort</title><sec sec-type="appendix" id="s18-1"><title>PIAMA cohort description</title><p>PIAMA (Prevention and Incidence of Asthma and Mite Allergy) is an ongoing birth cohort study. Details of the study design have been published previously (<xref ref-type="bibr" rid="bib8">Brunekreef et al., 2002</xref>; <xref ref-type="bibr" rid="bib80">Wijga et al., 2014</xref>). In brief, pregnant women were recruited from the general population through antenatal clinics in the north, west, and centre of the Netherlands in 1996–1997. The baseline study population consisted of 3963 newborns. Questionnaires were completed by the parents during pregnancy when the child was 3 months old, and then annually from 1 up to 8 years; at ages 11, 14, and 17 years, questionnaires were completed by the parents as well as the participants themselves.</p></sec><sec sec-type="appendix" id="s18-2"><title>LCA wheezing phenotypes</title><p>A six-class LCA model was identified including 3832 individuals with at least two observations of wheeze between 1 and 11–12 years of age. The identified classes were labelled: never/infrequent (2909, 75.91%), pre-school onset remitting (571, 14.90%), mid-childhood school remitting (108, 2.82%), intermediate onset remitting (106, 2.77%), school-age onset persisting (74, 1.93%), and continuous wheeze (64, 1.67%).</p></sec><sec sec-type="appendix" id="s18-3"><title>Replication analyses</title><p>We analysed associations between SNPs downstream of <italic>ANXA1</italic> (<xref ref-type="table" rid="app5table1">Appendix 5—table 1</xref>, <xref ref-type="fig" rid="app5fig1">Appendix 5—figure 1</xref>) and continuous wheezing in PIAMA, using the never/infrequent wheezing as the baseline category. Analyses were carried out in SPSS using a logistic regression model.</p><table-wrap id="app5table1" position="float"><label>Appendix 5—table 1.</label><caption><title>Single nucleotide polymorphisms (SNPs) near <italic>ANXA1</italic> associated with persistent wheeze.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Chr</th><th align="left" valign="bottom">Rsid</th><th align="left" valign="bottom">Position</th><th align="left" valign="bottom">A1</th><th align="left" valign="bottom">A2</th><th align="left" valign="bottom">freqA2</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Direction(3 GWAS)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs75260654</td><td align="char" char="." valign="bottom">75788108</td><td align="left" valign="bottom">t</td><td align="left" valign="bottom">c</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">0.90</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom">6.66e-09</td><td align="char" char="hyphen" valign="bottom">---</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs116849664</td><td align="char" char="." valign="bottom">75820902</td><td align="left" valign="bottom">t</td><td align="left" valign="bottom">c</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="hyphen" valign="bottom">1.99e-08</td><td align="char" char="hyphen" valign="bottom">---</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">rs78320984</td><td align="char" char="." valign="bottom">75844302</td><td align="left" valign="bottom">t</td><td align="left" valign="bottom">g</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">0.81</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="hyphen" valign="bottom">6.41e-08</td><td align="char" char="hyphen" valign="bottom">---</td></tr></tbody></table><table-wrap-foot><fn><p>A1 is the effect allele, A2 is the reference allele.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app5table2" position="float"><label>Appendix 5—table 2.</label><caption><title>Allele frequencies of <italic>rs75260654</italic> across different wheeze phenotypes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Phenotype</th><th align="left" valign="bottom">CC</th><th align="left" valign="bottom">CT</th><th align="left" valign="bottom">TT</th></tr></thead><tbody><tr><td align="left" valign="bottom">Never/infrequent</td><td align="char" char="." valign="bottom">5641 (97.2)</td><td align="char" char="." valign="bottom">161 (2.8)</td><td align="char" char="." valign="bottom">0 (0)</td></tr><tr><td align="left" valign="bottom">Early-onset pre-school remitting</td><td align="char" char="." valign="bottom">1409 (97.1)</td><td align="char" char="." valign="bottom">42 (2.9)</td><td align="char" char="." valign="bottom">0 (0)</td></tr><tr><td align="left" valign="bottom">Early-onset mid-childhood remitting</td><td align="char" char="." valign="bottom">572 (96.1)</td><td align="char" char="." valign="bottom">23 (3.9)</td><td align="char" char="." valign="bottom">0 (0)</td></tr><tr><td align="left" valign="bottom">Late-onset</td><td align="char" char="." valign="bottom">613 (95.2)</td><td align="char" char="." valign="bottom">31 (4.8)</td><td align="char" char="." valign="bottom">0 (0)</td></tr><tr><td align="left" valign="bottom">Early-onset persistent</td><td align="char" char="." valign="bottom">867 (94.2)</td><td align="char" char="." valign="bottom">51 (5.5)</td><td align="char" char="." valign="bottom">2 (0.2)</td></tr></tbody></table></table-wrap><table-wrap id="app5table3" position="float"><label>Appendix 5—table 3.</label><caption><title>Selected immune eQTLs of rs75260654.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Rsid</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">an</th><th align="left" valign="bottom">Symbol</th><th align="left" valign="bottom">Study</th></tr></thead><tbody><tr><td align="left" valign="bottom">rs75260654</td><td align="char" char="." valign="bottom">0.014</td><td align="char" char="." valign="bottom">–0.65</td><td align="char" char="." valign="bottom">0.26</td><td align="char" char="." valign="bottom">382</td><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="left" valign="bottom">Quach_2016_monocyte_R848</td></tr><tr><td align="left" valign="bottom">rs75260654</td><td align="char" char="." valign="bottom">0.015</td><td align="char" char="." valign="bottom">–1.02</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="." valign="bottom">396</td><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="left" valign="bottom">Quach_2016_monocyte_IAV</td></tr></tbody></table></table-wrap><table-wrap id="app5table4" position="float"><label>Appendix 5—table 4.</label><caption><title>Lung eQTLs of rs75260654.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Rsid</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Beta</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom">an</th><th align="left" valign="bottom">Symbol</th><th align="left" valign="bottom">Study</th></tr></thead><tbody><tr><td align="left" valign="bottom">rs116849664</td><td align="char" char="." valign="bottom">0.0489</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="." valign="bottom">620</td><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="left" valign="bottom">GTEx_exon_lung</td></tr><tr><td align="left" valign="bottom">rs78320984</td><td align="char" char="." valign="bottom">0.0489</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="." valign="bottom">620</td><td align="left" valign="bottom"><italic>ANXA1</italic></td><td align="left" valign="bottom">GTEx_exon_lung</td></tr></tbody></table></table-wrap><table-wrap id="app5table5" position="float"><label>Appendix 5—table 5.</label><caption><title>Functional enrichment for <italic>ANXA1</italic>: top 10 GO terms.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Term name</th><th align="left" valign="bottom">Description</th><th align="left" valign="bottom">FDR value</th></tr></thead><tbody><tr><td align="left" valign="bottom">GO.0007186</td><td align="left" valign="bottom">G protein-coupled receptor signalling pathway</td><td align="char" char="ndash" valign="bottom">3.57×10<sup>–18</sup></td></tr><tr><td align="left" valign="bottom">GO.0006954</td><td align="left" valign="bottom">Inflammatory response</td><td align="char" char="ndash" valign="bottom">1.13×10<sup>–16</sup></td></tr><tr><td align="left" valign="bottom">GO.0006874</td><td align="left" valign="bottom">Cellular calcium ion homeostasis</td><td align="char" char="ndash" valign="bottom">5.55×10<sup>–15</sup></td></tr><tr><td align="left" valign="bottom">GO.0007204</td><td align="left" valign="bottom">Positive regulation of cytosolic calcium ion concentration</td><td align="char" char="ndash" valign="bottom">1.65×10<sup>–14</sup></td></tr><tr><td align="left" valign="bottom">GO.0060326</td><td align="left" valign="bottom">Cell chemotaxis</td><td align="char" char="ndash" valign="bottom">1.95×10<sup>–14</sup></td></tr><tr><td align="left" valign="bottom">GO.0006955</td><td align="left" valign="bottom">Immune response</td><td align="char" char="ndash" valign="bottom">4.23×10<sup>–14</sup></td></tr><tr><td align="left" valign="bottom">GO.0006935</td><td align="left" valign="bottom">Chemotaxis</td><td align="char" char="ndash" valign="bottom">4.93×10<sup>–14</sup></td></tr><tr><td align="left" valign="bottom">GO.0006952</td><td align="left" valign="bottom">Defense response</td><td align="char" char="ndash" valign="bottom">1.68×10<sup>–13</sup></td></tr><tr><td align="left" valign="bottom">GO.0050801</td><td align="left" valign="bottom">Ion homeostasis</td><td align="char" char="ndash" valign="bottom">2.23×10<sup>–13</sup></td></tr><tr><td align="left" valign="bottom">GO.0002376</td><td align="left" valign="bottom">Immune system process</td><td align="char" char="ndash" valign="bottom">2.87×10<sup>–13</sup></td></tr></tbody></table></table-wrap><table-wrap id="app5table6" position="float"><label>Appendix 5—table 6.</label><caption><title>Replication of associations between single nucleotide polymorphisms (SNPs) downstream of <italic>ANXA1</italic> and early-onset persistent wheezing in Prevention and Incidence of Asthma and Mite Allergy (PIAMA).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">CW (40) vs NI (1557)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Rsid</td><td align="left" valign="bottom">chr:position</td><td align="left" valign="bottom">R2</td><td align="left" valign="bottom">A2/freqA2</td><td align="left" valign="bottom">Beta</td><td align="left" valign="bottom">SE</td><td align="left" valign="bottom">p-Value</td></tr><tr><td align="left" valign="bottom">rs75260654</td><td align="char" char="." valign="bottom">9:75788108</td><td align="char" char="." valign="bottom">0.60</td><td align="left" valign="bottom">c/0.02</td><td align="char" char="." valign="bottom">–0.287</td><td align="char" char="." valign="bottom">0.91</td><td align="char" char="." valign="bottom">0.75</td></tr><tr><td align="left" valign="bottom">rs116849664</td><td align="char" char="." valign="bottom">9:75820902</td><td align="char" char="." valign="bottom">0.61</td><td align="left" valign="bottom">c/0.02</td><td align="char" char="." valign="bottom">0.119</td><td align="char" char="." valign="bottom">1.08</td><td align="char" char="." valign="bottom">0.91</td></tr><tr><td align="left" valign="bottom">rs78320984</td><td align="char" char="." valign="bottom">9:75844302</td><td align="char" char="." valign="bottom">0.59</td><td align="left" valign="bottom">g/0.02</td><td align="char" char="." valign="bottom">0.125</td><td align="char" char="." valign="bottom">1.04</td><td align="char" char="." valign="bottom">0.90</td></tr></tbody></table><table-wrap-foot><fn><p>A2 is the reference allele. CW = continuous wheezing, IR = intermediate wheezing derived from LCA 1–12 years in PIAMA.</p></fn></table-wrap-foot></table-wrap><fig id="app5fig1" position="float"><label>Appendix 5—figure 1.</label><caption><title>Linkage disequilibrium between single nucleotide polymorphisms (SNPs) downstream of <italic>ANXA1</italic> that were associated with persistent wheeze.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app5-fig1-v2.tif"/></fig><fig id="app5fig2" position="float"><label>Appendix 5—figure 2.</label><caption><title>ANXA1 interactors.</title><p>Protein-protein interaction of <italic>ANXA1</italic> including <italic>IL-4</italic>, <italic>IL-13,</italic> and <italic>NR3C1.</italic></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84315-app5-fig2-v2.tif"/></fig></sec></sec></app><app id="appendix-6"><title>Appendix 6</title><sec sec-type="appendix" id="s19"><title>Functional mouse experiments</title><sec sec-type="appendix" id="s19-1"><title>Mice</title><p>In accordance with the Animals (scientific procedures) act 1986, all animal experiments were conducted under the approved UK Home Office Project License No: PPL 70/7643, reviewed by Imperial College’s Animal Welfare and Ethical Review body. Female WT BALB/c and annexin A1 knock-out mice were purchased from Charles River (Bicester, UK). Animals aged 6–8 weeks of age received 25 µg intranasal instillation of either HDM (Greer Laboratories, Lenoir, NC, USA; Cat: XPB70D3A25) or PBS 3× a week for 3 weeks. Mice were sacrificed 4 hr post-final HDM challenge. Mice were housed under specific pathogen-free conditions and a 12:12 light:dark cycle. Food and water were supplied ad libitum. All animal experiments were completed twice, with N=4–6 per group.</p></sec><sec sec-type="appendix" id="s19-2"><title>Airway hyperresponsiveness</title><p>Airway hyperreactivity was measured using Flexivent. Lung resistance was measured in response to increasing doses of methacholine (3–100 mg/ml, Sigma, Poole, UK, Cat: <ext-link ext-link-type="uri" xlink:href="https://www.sigmaaldrich.com/GB/en/product/sigma/a2251">A2251</ext-link>) in tracheotomised anaesthetised mice using an EMMS system (Electro-Medical Measurement Systems, UK).</p></sec><sec sec-type="appendix" id="s19-3"><title>Flow cytometry analysis</title><p>Bronchoalveolar lavage (BAL) was collected. BAL cells were restimulated with ionomycin and phorbol 12-myristate 13-acetate in the presence of brefeldin (Sigma), as previously described (<xref ref-type="bibr" rid="bib7">Branchett et al., 2021</xref>). Specific antibodies for T1/ST2 staining were purchased from Morwell Diagnostics (Zurich, Switzerland). Cells were also stained for lineage negative cocktail, Ly6G, CD45, CD11b, CD11c, SiglecF. Labelled cells were acquired on a BD Fortessa (BD Biosciences, Oxford, UK) and analysed using FlowJo software (Treestar, Ashland, OR, USA). Details of antibodies used can be found in <xref ref-type="table" rid="app6table1">Appendix 6—table 1</xref>.</p><table-wrap id="app6table1" position="float"><label>Appendix 6—table 1.</label><caption><title>Antibodies used in the flow cytometry analysis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Molecule</th><th align="left" valign="bottom">Manufacturer</th><th align="left" valign="bottom">Isotype</th><th align="left" valign="bottom">Conjugated dye</th><th align="left" valign="bottom">Clone</th></tr></thead><tbody><tr><td align="left" valign="bottom">T1/ST2</td><td align="left" valign="bottom">Morwell Diagnostics GMBH, Switzerland</td><td align="left" valign="bottom">Rat IgG1</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom"><italic>DJ8</italic></td></tr><tr><td align="left" valign="bottom">CD45</td><td align="left" valign="bottom">e-Bioscience Ltd, Hatfield, UK</td><td align="left" valign="bottom">Rat IgG2b</td><td align="left" valign="bottom">PerCP-CY5.5</td><td align="char" char="hyphen" valign="bottom">30-F11</td></tr><tr><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">BD Biosciences, Oxford, UK</td><td align="left" valign="bottom">Rat IgG2b</td><td align="left" valign="bottom">e450</td><td align="left" valign="bottom">M1/70</td></tr><tr><td align="left" valign="bottom">CD11c</td><td align="left" valign="bottom">e-Bioscience Ltd, Hatfield, UK</td><td align="left" valign="bottom">Hamster IgG1</td><td align="left" valign="bottom">PerCP-CY5.5</td><td align="left" valign="bottom">N418</td></tr><tr><td align="left" valign="bottom">Siglec F</td><td align="left" valign="bottom">BD Biosciences, Oxford, UK</td><td align="left" valign="bottom">Rat IgG2a</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">E50-2440</td></tr></tbody></table></table-wrap></sec><sec sec-type="appendix" id="s19-4"><title>Analysis of cytokines and chemokines</title><p>Murine lung tissue homogenate supernatants were processed as previously described (<xref ref-type="bibr" rid="bib7">Branchett et al., 2021</xref>). Cytokine levels were analysed by ELISA: IL-4, IL-5 (PharMingen, Oxford, UK), IL-13 Ready-Set-Go kits (eBioscience).</p></sec><sec sec-type="appendix" id="s19-5"><title>Real-time PCR</title><p>Total RNA was extracted from murine lung tissue using an RNeasy Mini Kit (QIAGEN). Total RNA (1 μg) was reverse transcribed into cDNA using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies, UK). Real-time PCRs were performed using TaqMan Gene Expression Master Mix and TaqMan Gene Expression probes, annexin A1, and HPRT (Applied Biosystems). Values were normalised to HPRT and gene expression was analysed using the change-in-threshold 2-∆CT method.</p></sec><sec sec-type="appendix" id="s19-6"><title>Annexin A1 immunohistochemistry</title><p>Paraffin-embedded mouse lung sections were stained with annexin A1 (R&amp;D Systems, MAB3770). Annexin A1 primary antibody was followed by a secondary detection antibody (donkey anti-goat 488, Thermo Fisher, A11055). Annexin A1+ cells were quantified by manual counting under microscope and numbers averaged over four fields, from five biological replicates per group.</p></sec><sec sec-type="appendix" id="s19-7"><title>Statistical analysis</title><p>Data are expressed as median±IQR. Statistical differences between groups were calculated using Mann-Whitney U test, unless otherwise specified. p-Values are indicated in figures.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84315.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Agrawal</surname><given-names>Anurag</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j1xr113</institution-id><institution>Ashoka University</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.03.03.23284449" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.03.03.23284449"/></front-stub><body><p>The study uses a novel meta-analysis approach coupled with endotype discovery in GWAS studies of childhood wheezing to identify ANXA1 as a susceptibility locus. Functional data strengthens the conclusions from a relatively small sample size by GWAS standards. This is representative of a way forward for efficient genetic discovery in deeply phenotyped complex diseases, where there is much unrecognised heterogeneity.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84315.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Agrawal</surname><given-names>Anurag</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j1xr113</institution-id><institution>Ashoka University</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Agrawal</surname><given-names>Anurag</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j1xr113</institution-id><institution>Ashoka University</institution></institution-wrap><country>India</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.03.03.23284449">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://medrxiv.org/cgi/content/short/2023.03.03.23284449v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A meta-analysis of genome-wide association studies of childhood wheezing phenotypes identifies ANXA1 as a susceptibility locus for persistent wheezing&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Anurag Agrawal as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Molly Przeworski as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please provide more details on the meta-analysis strategy and rationale</p><p>Consider the other comments for greater clarity of the work</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The work is interesting, novel, and technically rigorous. Some suggestions follow regarding the experimental mouse model part of the manuscript, which needs further editing for clarity and standardisation of terminology.</p><p>1. Figure 4A, font size needs to be increased.</p><p>2. Line 289-291 needs correction. 4E shows methacholine-induced bronchoconstriction, not allergen-induced reduced lung function.</p><p>3. Was baseline resistance (pre-methacholine) different? Any differences in the slope of the curve?</p><p>4. Airway remodelling changes should be described if possible.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Even though the study described by Granell et al. is an impressive piece of work with robust sets of evidence that support the derived conclusions, this reviewer has some suggestions the authors might want to consider:</p><p>1. A more detailed description of the association models applied to test the association with wheezing phenotypes, including the covariates used, is encouraged.</p><p>2. Which approach was used for the meta-analysis? Did you take into account the heterogeneity among studies to choose fixed or random-effect models to be applied?</p><p>3. Could you please provide an explanation of the genomic inflation found for the persistent wheezing phenotype (Figure E1)?</p><p>4. Table E4: Could you please explain the reason for inclusion/exclusion?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Regarding the definition of wheeze phenotypes from infancy to adolescence, were transitions across different phenotypes over time possible? Was time-varying phenotype of concern? Did the authors evaluate the accuracy of phenotyping using metrics such as sensitivity, specificity, and positive and negative predictive values? And how much of the variation in each wheeze phenotype can be explained by genetic profile?</p><p>2. In order to identify primary and secondary independent loci, can the authors perform the conditional analysis? Further, considering the LD structure, credible set analysis, and colocalization analysis can help identify potential causal variants.</p><p>3. Can the authors provide further explanations on the biology using pQTL and TWAS?</p><p>4. Can the authors use DEPICT or other tools to identify relevant tissues/cell types that are highly expressed?</p><p>5. The heterogeneity in the genetic profile for the wheeze phenotypes can be better illustrated, such as by using a scatter plot to show the differences in genetic effect sizes. A heterogeneity p-value can be computed. In addition, what was the genetic correlation between the wheeze phenotypes?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84315.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please provide more details on the meta-analysis strategy and rationale</p></disp-quote><p>Please see Reviewer 2 Q2.</p><disp-quote content-type="editor-comment"><p>Consider the other comments for greater clarity of the work</p><p>Reviewer #1 (Recommendations for the authors):</p><p>The work is interesting, novel, and technically rigorous. Some suggestions follow regarding the experimental mouse model part of the manuscript, which needs further editing for clarity and standardisation of terminology.</p><p>1. Figure 4A, font size needs to be increased.</p></disp-quote><p>Figure 5A (4Ain previous version) has been updated.</p><disp-quote content-type="editor-comment"><p>2. Line 289-291 needs correction. 4E shows methacholine-induced bronchoconstriction, not allergen-induced reduced lung function.</p></disp-quote><p>We have corrected this in line 322 of the Revised Manuscript.</p><disp-quote content-type="editor-comment"><p>3. Was baseline resistance (pre-methacholine) different? Any differences in the slope of the curve?</p></disp-quote><p>No statistically significant difference was observed in resistance at baseline. However, a leftward shift in the curve was observed.</p><disp-quote content-type="editor-comment"><p>4. Airway remodelling changes should be described if possible.</p></disp-quote><p>We did not assess changes in remodelling in these experiments. Here, we utilised a 3-week HDM challenge model, whereas to fully characterise changes in airways remodelling, mice would need to be assessed later than 3 weeks post HDM.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Even though the study described by Granell et al. is an impressive piece of work with robust sets of evidence that support the derived conclusions, this reviewer has some suggestions the authors might want to consider:</p><p>1. A more detailed description of the association models applied to test the association with wheezing phenotypes, including the covariates used, is encouraged.</p></disp-quote><p>We agree with this reviewer’s comment, and we have made this clearer in the Methods section on lines 185-7 Revised Manuscript:</p><p>“We used SNPTEST v2.5.2(26) with a frequentist additive multinomial logistic regression model (-method newml), using the never/infrequent wheeze as the reference and without including any covariates.”</p><disp-quote content-type="editor-comment"><p>2. Which approach was used for the meta-analysis? Did you take into account the heterogeneity among studies to choose fixed or random-effect models to be applied?</p></disp-quote><p>These details were already available in the Supplement, and they can now be found in Appendix 2: GWAS Meta-analysis:</p><p>“We used the option SCHEME STDERR in METAL to implement an effect-size based method weighted by each study-specific standard error in a fixed-effects model.”</p><disp-quote content-type="editor-comment"><p>3. Could you please provide an explanation of the genomic inflation found for the persistent wheezing phenotype (Figure E1)?</p></disp-quote><p>We would interpret Figure 1—figure supplement 1 (previously Figure E1) as an association between SNPs and Persistent wheeze rather than inflation. For instance, we did not observe any deviation in the other phenotypes. We now report the phenotype specific genomic inflation factor for each wheezing phenotype in lines 222-5 Revised Manuscript:</p><p>“We observed slight deflation of the meta-analysis pvalues in our summary statistics. Genomic Inflation Factor (λ) for Early-onset Pre-school Remitting=0.96, Early-onset Mid-childhood Remitting = 0.94, Late-onset=0.96, and Early-onset Persistent wheezing=0.97.”</p><p>And have added this text in Appendix 2: Genetic Control:</p><p>“The genomic inflation factor (λ) was calculated using the scipy.stats.chi2 module in Python. The chi-squared test statistics from the meta-analysis p-values were first obtained. Then the observed median chi-squared statistic from the calculated chi-squared test statistics were calculated. Finally, the genomic inflation factor (λ) was derived by dividing the observed median chi-squared statistic by the expected median chi-squared statistic.”</p><disp-quote content-type="editor-comment"><p>4. Table E4: Could you please explain the reason for inclusion/exclusion?</p></disp-quote><p>Thank you, this was not properly explained in the main text. Individuals with missing genetic data, as well as related and non-European individuals were excluded. We have now made this clear in line 212-4 Revised Manuscript:</p><p>“Individuals with missing genetic data, as well as related and non-European individuals were excluded. Comparison of included vs. excluded individuals across cohorts (per cohort and time point) is shown in Appendix 1 and Appendix 1-Table 4.”</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Regarding the definition of wheeze phenotypes from infancy to adolescence, were transitions across different phenotypes over time possible? Was time-varying phenotype of concern? Did the authors evaluate the accuracy of phenotyping using metrics such as sensitivity, specificity, and positive and negative predictive values?</p></disp-quote><p>No, LCA does not allow transitions across different phenotypes over time.</p><p>Was time-varying phenotype of concern? Did the authors evaluate the accuracy of phenotyping using metrics such as sensitivity, specificity, and positive and negative predictive values?</p><p>We have explored time-varying phenotype in the context of LCA in our recent paper (Haider S et al. Modeling Wheezing Spells Identifies Phenotypes with Different Outcomes and Genetic Associates. Am J Respir Crit Care Med. 2022 Apr 15;205(8):883-893. doi: 10.1164/rccm.202108-1821OC. PMID: 35050846; PMCID: PMC9838626.) where we compared the robustness of LCA and PAM phenotypes. In this paper we show that latent class analysis- and Partition Around Medoids (PAM) clustering of spell-based phenotypes appeared similar, but within-phenotype individual trajectories and phenotype allocation differed substantially. The spell-based approach was much more robust in dealing with missing data, and the derived clusters were more stable and internally homogeneous than those derived by LCA. If anything, any instability of LCA phenotypes over time would reduce the power of the current study, yet we still identified genome-wide significant associations unique to specific wheeze clusters. None-the-less future studies should explore the utilisation of PAM derived phenotypes in genetic analysis of allergic disease.</p><disp-quote content-type="editor-comment"><p>And how much of the variation in each wheeze phenotype can be explained by genetic profile?</p></disp-quote><p>We have not explored this question in this paper, but we will do so in our follow-up paper.</p><disp-quote content-type="editor-comment"><p>2. In order to identify primary and secondary independent loci, can the authors perform the conditional analysis? Further, considering the LD structure, credible set analysis, and colocalization analysis can help identify potential causal variants.</p><p>3. Can the authors provide further explanations on the biology using pQTL and TWAS?</p><p>4. Can the authors use DEPICT or other tools to identify relevant tissues/cell types that are highly expressed?</p></disp-quote><p>The reviewer makes a number of helpful suggestions of additional post-GWAS analyses that could be undertaken on our results. Given the size of the manuscript and the extensive incorporation of mouse model data for the ANAX1 loci, we feel that adding further post GWAS analyses to the supplementary data is beyond the scope of this paper and we are currently working on a new follow-up paper that will focus on fine mapping of these loci.</p><disp-quote content-type="editor-comment"><p>5. The heterogeneity in the genetic profile for the wheeze phenotypes can be better illustrated, such as by using a scatter plot to show the differences in genetic effect sizes. A heterogeneity p-value can be computed.</p></disp-quote><p>We agree with the reviewer’s suggestion and have produced scatter plots to illustrate the heterogeneity in the genetic profile of the wheezing phenotypes. We have added these plots in Figure 2—figure supplement 1 and the following text has been added in lines 230-3 Revised Manuscript:</p><p>“Scatter plots in Figure 2—figure supplement 1 show the heterogeneity in the genetic profile of the wheeze phenotypes. The plots show that all signals were phenotype-specific at p&lt;10-5 and only nominal associations were shared across wheezing phenotypes. More details on how these plots were derived can be found in Appendix 2: Heterogeneity scatter plots.”</p><disp-quote content-type="editor-comment"><p>In addition, what was the genetic correlation between the wheeze phenotypes?</p></disp-quote><p>We identified exclusive subgroups of SNPs associated with each wheezing phenotype, and only two locus were shared with Persistent and Early-onset Mid-childhood Remitting Wheezing (chr17q12 and chr17q21) therefore the genetic correlation between the wheeze phenotypes is likely to be small.</p></body></sub-article></article>